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Summary
The gastrointestinal (GI) tract is exposed continuously to a variety of foreign 
antigens that range from soluble dietary proteins to numerous pathogens and is thus the
'major site of antigenic challenge in the body. Whereas infection with a mucosal 
pathogen results in an active primary immune response followed by memory to
.......
subsequent exposure, oral administration of soluble antigens results in a suppressed 
response to subsequent systemic exposure to the antigen. This phenomenon is termed 
oral tolerance and its physiological role may be to prevent food hypersensitivities. In 
addition it may provide a potent therapy for a variety of autoimmune and inflammatory 
disorders. However, oral tolerance is also a major obstacle to the development of oral 
vaccines.
Although there is a substantial amount of evidence that suggests that 
suppression of autoimmunity by orally administered antigen is a feasible and 
therapeutic option, most existing studies of oral tolerance have explored the 
mechanisms responsible for the ability of fed antigen to prevent subsequent systemic 
immune responses in previously naive animals. Little is known about the mechanisms 
which determine the induction of oral tolerance in the primed immune system.
Thus the aims of my studies were to define feeding regimes for inducing 
optimal oral tolerance in primed mice, to establish the effects of feeding antigen to 
primed mice on a variety of parameters of systemic immunity in vivo and in vitro and 
to investigate the mechanisms of oral tolerance in primed mice. I used a model antigen 
in my studies so that I could exploit experimental systems already developed in the
laboratory for the induction and assessment of oral tolerance to OVA in naive mice. 
Thus I examined a variety of antigen doses administered at different times after 
priming with OVA/CFA and investigated the scope of responses influenced by the 
tolerance. I first confirmed that it is possible to induce tolerance by feeding antigen to 
primed mice, with DTH responses, proliferation and IFNy production being readily 
tolerised. However, the degree and scope of tolerance was less than that found in an
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equivalent dose fed before immunisation. For example, Th 2 cytokine production and 
antibody responses were not as readily tolerised when antigen was fed after .priming 
compared with feeding antigen before priming. In contrast to previous reports, I found 
that only a brief time window was available after priming when mice were susceptible 
to induction of tolerance, which in my hands, was in order of a week. In an attempt to 
enhance tolerance, I fed higher single doses of antigen and increased frequency of 
feeding. Generally this did result in more intense and wider tolerance, although this was 
still less than in mice fed before priming. Together, these results illustrate the difficulty 
in tolerising a primed immune system and in subsequent chapters, I went on to 
examine the reasons why this should be the case and what the mechanisms responsible 
for the tolerance might be.
Previous studies in naive mice found that several parameters of the systemic 
immune responses remained tolerant for up to 17 months after feeding and so I 
investigated how long tolerance persisted after a single feed of 25mg OVA given 7 
days after priming. The results indicated that the oral tolerance induced when antigen is 
fed after immunisation is not as long lasting as that found in naive mice. In vivo 
tolerance was only found early after feeding, when antigen specific DTH responses 
were suppressed compared with controls. DTH responses were normal at later time 
points and antibody responses were not tolerised at any time after feeding, confirming 
my initial findings. Overall, these results suggest that only some aspects of the 
established immune response can be tolerised for any length of time by a single feed of 
antigen. It seems that as in other forms of oral tolerance, IFNy production is 
particularly sensitive to feeding in primed mice, although my results sug^e^that other 
aspects such as IL5 might also be tolerised at different times. Thus oral tolerance is a 
dynamic phenomenon but there is surprisingly little correlation between those aspects 
which can be tolerised at different times. Although this is consistent with previous 
results in the lab in naive mice, it emphasises the unpredictability of tolerance in primed 
animals.
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These experiments showed that it was impossible to tolerise antibody responses 
and in some cases, IL5 production was more difficult to tolerise than IFNy and could
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suggest that T h2 responses ar e unusually resistant to oral tolerance induction in primed 
mice. Thus, I decided to investigate whether Th2 cells were necessary for oral tolerance 
in primed mice by examining the effects of feeding OVA to IL4“/“ mice which had 
been immunised with OVA/CFA. The results confirmed previous findings from our 
laboratory that feeding OVA to naive IL4"/" mice results in oral tolerance. I also 
extended these studies by showing that primed IL4"/“ mice develop a pattern of oral 
tolerance similar to that found in normal animals, with suppression of DTH in vivo and 
antigen-specific proliferation in vitro, as well as some suppression of IFNy and IL5 
production in vitro, but no effects on serum antibodies. Thus the partial effects of oral 
tolerance in primed mice do not depend on the presence of 1L4 dependent Th2 cells,
but could reflect another mechanism such as clonal anergy/deletion or an alternative 
active suppressor mechanism.
An alternative active suppressor mechanism that I studied was TGFp. To do 
this, I made use of the suggestion that TGFP production is downregulated by IL12 and 
IFNy and examined the induction of tolerance in IL12"/~ mice. Certain aspects of 
tolerance were enhanced in IL12~/" mice compared with wild type mice, namely IgGl 
antibody levels. However, other components of tolerance such as total OVA-specific 
IgG antibody levels were normal and tolerance of OVA-specific DTH levels were 
reduced, and no clear pattern emerged. Therefore, it is probably true to conclude that the 
absence of IL12 has no overall effect on the induction of tolerance induced either before 
or after immunisation, with no reproducible enhancement of tolerance in primed 
animals. These results suggest that it is unlikely that the main mechanism of oral 
tolerance in primed mice is active suppression via TGFp, however, it would be 
important to measure TGFP production directly in such animals.
As oral tolerance in primed mice was not as profound or wide ranging as that 
found when equivalent amounts of antigen aie fed to naive mice, I was interested in 
finding an alternative strategy for enhancing tolerance in primed animals. Recent work
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has shown that administration of Flt3L to mice enhances the induction of oral tolerance 
in naive mice and I decided to test the idea that expansion of DCs by Flt3L might also 
extend tlie scope of oral tolerance in primed mice. The rationale for this effect appears 
to be that Flt3L expands the numbers of resting dendritic cells in the gut which then 
present fed antigen without costimulation to T cells, resulting in more profound anergy 
and/or clonal deletion, and thus function of tolerance. The results showed that 
expanding DCs with Flt3L does not interfere with the induction of oral tolerance in 
primed mice and Flt3L actually enhanced the induction of tolerance in some instances 
and occasionally allowed tolerance of some responses not normally susceptible to 
tolerance, such as antibody production. However, the effects of Flt3L were quite 
variable, probably reflecting the influence that administration of Flt3L had on the level 
and the speed of the systemic immune responses after challenge with OVA/CFA.
Next I attempted to examine the induction of oral tolerance in primed T cells 
using the adoptive transfer of Ag-specific transgenic T cells as I thought this might be 
an appropriate means of studying fate of antigen-specific T cells in primed mice fed 
OVA. In the first experiments, I found that feeding soluble OVA after priming could 
alter the kinetics of T cell expansions, but this only occurred if feeding was delayed 
until 10 days after immunisation. This did not simply appear to be due to re-exposure 
to antigen, as there was no equivalent effect of feeding OVA in an immunogenic 
manner with CT, In addition, the inhibited expansion caused by feeding soluble antigen 
after priming was accompanied by suppressed proliferative responses to OVA. These 
results contrasted with my earUer findings in normal mice, where tolerance could be 
induced early, but not late after priming. To try and investigate why this might be the 
case, I fed a higher dose of OVA, as I thought the increase in numbers of Ag-specific 
T cells in transfer recipients might complicate the system. These experiments again 
showed that tolerance might occur late after priming, but there was still no effect earlier 
and also functional tolerance was variable in that proliferative responses were easier to 
tolerise than cytokines responses.
I then examined some of the possible reasons underlying the resistance of the 
primed immune system to oral tolerance. In the first experiment, I found that feeding 
OVA to mice with a fully established immune response did not improve tolerance. 
Indeed, feeding OVA at this time appeared to stimulate a secondary response for some 
aspects of the systemic immune response. As I thought this long term resistance to oral 
tolerance might reflect the depot effect of this adjuvant, I decided to prime mice with 
OVA and LPS as a means of administering antigen in an adjuvant without long term 
depot effects. I found that feeding OVA early after immunisation with OVA/LPS 
results in a pattern of tolerance similar to that found when mice are primed using CFA 
as the adjuvant. Next, I went on to show that feeding OVA to mice with a fully 
established immune response induced with OVA/LPS did not improve tolerance. 
Thus, I concluded that the difficulty in inducing oral tolerance six weeks after priming 
was not due to a depot of antigen or adjuvant, but was rather due to the presence of an 
established immune response. Therefore, I decided to test the idea that 
activated/memory CD4 T cells were inherently resistant to tolerance induction. In this 
experiment, I found evidence that oral tolerance could be induced when I fed OVA to 
mice that were transferred with antigen experienced "memory" cells. Thus, I concluded 
that activated/memory CD4 T cells are not inherently resistant to orally induced 
tolerance and that their resistance in the intact animal might be due to their being 
exposed to persistent antigen in the context of continual costimulation.
In conclusion, the results presented in this thesis have confirmed and extended 
previous findings on the induction of oral tolerance by feeding antigen after priming. 
However, they have highlighted several important features of the phenomenon 
including the fact that antibody responses are not readily tolerised in primed mice and 
that higher doses of antigen are required to obtain tolerance equivalent to that found in 
naive mice. My study does not allow me to make firm conclusions whether similar 
mechanisms underly the oral tolerance induced by feeding antigen before or after 
systemic immunisation. Although I would propose that anergy and/or clonal deletion is 
the main mechanism of oral tolerance in primed mice, there is need for careful
V I
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approach is to be used therapeutically. These results have implications not only for the 
use of oral tolerance in the treatment of inflammatory diseases, but also for 
understanding the regulation of immune responses to protein antigens in vivo in that 
they highlight the differences in the response of a naive and a primed immune system, 
and therefore subsequent consequences, to antigen given via a tolerogenic route.
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Chapter 1 Introduction
1.1 Oral Tolerance
The gastrointestinal (GI) tract is exposed continuously to a variety of foreign 
antigens that range from soluble dietary proteins to numerous pathogens and is thus the 
major site of antigenic challenge in the body. Although the gut-associated lymphoid 
tissues (GALT) contains a considerable arsenal of effector mechanisms to counter the 
threat of potential pathogens, this armoury is normally not directed against food 
antigens, partly because it would limit their uptake and metabolic usefulness. More 
importantly, it might incur food hypersensitivities such as coeliac disease (1,2). T-cell 
mediated responses to wheat gluten are believed to cause the severe enteropathy found 
in coeliac disease and similar hypersensitivity to harmless intestinal antigens from the 
gut flora may be responsible for inflammatory bowel diseases, such as Crohn's disease 
and ulcerative colitis. However, such diseases are relatively uncommon because the 
intestinal immune system distinguishes between harmless antigens and those of 
pathogenic importance (3-5). Whereas infection with a mucosal pathogen results in an 
active primary immune response followed by memory to subsequent exposure (6), 
oral administration of soluble antigens results in a suppressed response to subsequent 
systemic exposure to the antigen (2-5). This phenomenon is temied oral tolerance and
Î.3its physiological role may be to prevent food hypersensitivities. In addition it may 
provide a potent therapy for a variety of autoimmune and inflammatoiy disorders (7,8). 
However, oral tolerance is also a major obstacle to the development of oral vaccines.
1.2 Anatomy of Mucosal Immune Responses
Mucosal immune responses differ from those in the periphery in many ways 
and it seems probable that these distinctive features may account for some of tlie 
unusual responses to intestinal antigens.
I
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The gut-associated lymphoid tissues (GALT) forms the major part of the 
mucosa-associated lymphoid tissue (MALT) (2) and comprise lymphocytes and other 
cells scattered through the mucosa, as well as the organised tissues of the Peyer's 
patches and mesenteric lymph nodes (MLN). Peyer's patches are organised secondaiy 
lymphoid organs separated from the intestinal lumen by a single epithelial layer. 
Although Peyer's patches have a typical secondary lymphoid structure, they differ from 
other secondary lymphoid organs because they lack afferent lymphatics. However, the
i
dome area of the Peyer's patch is covered by a unique epithelium enriched for 
specialised antigen-sampling cells, known as microfold (M) cells (9). The luminal 
surface of M cells may function to transfer antigen directly from the intestinal lumen to 
underlying macrophages and dendritic cells. M cells do not express class II MHC 
antigens and thus primarily perform a transport function (9). Antigens transported by 
M cells may also pass down through the basal lamina into the lymphoid follicles before 
being carried into the MLN via draining lymphatics. This route provides one way in 
which an antigen from the intestinal lumen can gain access to the systemic circulation 
(7). Also, M cells may transport antigens to the T and B cells in the dome and 
underlying follicles.
Peyer's patches are believed to be the primary area of the GALT where 
specific immune responses are generated. Their germinal centres are the major source 
of IgA producing B cells (10) and the parafolliouldrregion is rich in mature a[3 T cells 
of both CD4+ and CD8+ phenotype. CD4+ cells of both Tpjl and Th 2 phenotype are
found in the dome region (7). Thus, the Peyer's patch contains all the components 
required for the initiation of immune responses to antigens encountered in the lumen of 
the small intestine. Furthermore, Peyer's patches have been shown to be sites where 
regulatoi-y cells which can suppress immune responses to dietary antigens can be 
generated (11-13). Draining the Peyer's patches via the lymphatics are the MLN which 
are identical in overall stmcture to other peripheral lymph nodes (9) and may function 
as a cross-over point between the peripheral and mucosal immune systems.
a;;In addition to the organised tissues of the Peyer's patches and the MLN, the
villus/crypt units of the intestine contain large numbers of scattered lymphocytes, both 
in the epithelium itself and in the deeper layer of the lamina propria. In contrast to the
Peyer's patches and the MLN, which probably act as inductive sites, these scattered 
lamina propria and intraepithélial lymphocytes (lEL) are the effector arm of the local
response, providing a means for generating disseminated immunity throughout the 
length of the intestine (2). The epithelium and lamina propria represent highly distinct 
compartments of the immune system, despite being sepai'ated by only a thin layer of 
basement membrane.
The lamina propria contains most components of the immune system, with 
large numbers of B cells, plasma cells, macrophages, dendritic cells and T cells of both 
the CD4+ and CD8+ subsets. Mucosal inflammatory cells such as eosinophils and 
mast cells are also present (2).
Intraepithélial lymphocytes are adjacent to the columnar epithelial layer of small
‘intestinal villi and are one of the largest populations of lymphocytes in the body (14). 
Virtually all are T cells and 80% or more are CD8+ expressing a unique integrin 
molecule, anP?. Ligation of aEp7 by its counterstmcture, E-cadherin, on enterocytes
is generally considerd to be crucial for tethering EEL within the epithelial layer (2). A 
further unusual feature of EEL in many species is that they are relatively enriched for 
yô TCR expressing T cells, although ap  TCR lEL are also abundant (15). All yô TCR 
expressing EEL and around 50% of aP TCR expressing lEL express the CD8 a  chain 
without the p chain (ie they are CD8 aa+ ). Despite this knowledge, the function of 
EEL is largely unknown though they may constitute a primitive population specialised 
for immune surveillance of epithelial surfaces (14). The TCRs expressed on lEL
appear* to be polyclonal, based on junctional sequences, ap  TCR EELs also appear* to
:express a restricted set of V regions preferentially. However, skewing toward particular 
V region usage appears to be the result of oligoclonal expansion of certain EEL clones, 
perhaps in response to a limited array of antigens. EELs have also been shown to be 
activated and cytolytic, but they proliferate poorly. One possibility is that EEL may play
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a role in cellular immune defense of the intestinal epithelial barrier via their production 
of a variety of cytokines, including IL2, IFNy, IL5 and TGFp (16,17).
Recirculation of lymphoid cells into and within mucosal tissues is also 
controlled by unique mechanisms and by the unusual anatomy of the GALT. T and B 
lymphocytes encountering the appropriate antigen in the Peyer's patch or lamina 
propria, exit via the lymphatic network in the mucosal wall and drain to the MLN and 
thence via the efferent lymphatics and connecting thoracic duct to the bloodstream, 
before recirculating back to the effector sites of mucosal tissues (2,18,19). These 
recirculation properties of mucosal lymphocytes reflect the fact that, after activation in 
the GALT, lymphocytes decrease their expression of L-selectin, the adhesion molecule 
which allows them to interact with high endothelial venules (HEV) in peripheral lymph 
nodes, and up-regulate tlie aqp7 integrin whose ligand, mucosal addressin cell
adhesion molecule (MAdCAM-1) is expressed by blood vessels in mucosal tissues (2, 
20-22). This recirculation pathway differs from the route taken by lymphocytes 
activated in peripheral organs, which do not enter the mucosae as they do not express 
a4p7-
The most obvious feature of the mucosal immune system is the predominance 
of IgA as the major class of antibody present in secretions. This IgA is derived from 
plasma cells present in the lamina propria, which themselves are derived from IgA- 
producing B cells in the Peyer's Patches. The overall function of secretory IgA remains 
somewhat uncleai*, but it is important for neutralization of viruses (23) and toxins (24). 
In addition, IgA helps prevent bacterial colonisation of the mucosa by binding to the 
mucus layer overlying the epithelia and inhibiting the adherence of microorganisms 
(25), or promoting their entrapment in the mucus (26) and subsequent agglutination 
(27). This function is known as immune exclusion and a similar mechanism may also 
reduce the absoiption of dietary and respiratory antigens (28), possibly accounting for 
the increased absorption of food antigens (29) and increased susceptibility to food 
hypersensitivity (20) found in patients with selective IgA deficiency. However, most 
patients with this common immune deficiency have no symptoms. It is important to
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note that there is no coixelation between immune exclusion and oral tolerance in 
experimental studies (21), while the absence of IgA antibodies against food antigens in 
normal individuals indicates that local IgA production does not coiTelate with systemic 
unresponsiveness induced by a fed antigen.
Both the organised and diffuse compartments of the GALT contain 
conventional APC of many kinds, including dendritic cells, activated B cells and 
macrophages. The relative roles of these different APC types are unknown, but it 
seems increasingly possible that each may be involved in different aspects of the local 
immune response, such as determining whether active immunity or tolerance is
■■V
induced. The small surface area of M cells suggests that not all antigen can be taken up 
in this way and it seems likely that soluble antigens also enter the mucosa by being 
endocytosed across the absoiptive gut epithelium via conventional enterocytes, either 
by paracellulai' routes or via the enterocytes themselves (2). The antigens may then be 
processed and presented by local MHC class Il-expressing cells of the underlying 
lamina propria, such as macrophages, B cells and dendritic cells, MHC class II 
molecules ai*e also present on the basolateral membrane of enterocytes and may allow 
these cells to play a role in processing and presenting antigen to T cells of the lamina 
propria or to lEL within the epithelium itself (30). Although supported by in vitro 
studies which have demonstrated that isolated enterocytes from rat and human small 
intestine can present antigens to appropriately primed T cells (31-34) it is not known if 
this functions in vivo. Some antigens entering the mucosa via this route also gain access 
to the systemic circulation and hence are likely to enter peripheral lymphoid tissues.
I
1.3 Regulation of Immune Responses to Dietary Antigens in Oral Tolerance
3:3.1.3.1 History
The first evidence that fed antigens could suppress systemic immune responses 
was an anecdotal report in 1829 by Dakin, who described how South American 
Indians ate poison ivy in an attempt to prevent what we now understand to be contact
I"
hypersensitivity to the plant (35). The author and scientist H.G.Wells in 1911, was the 
first to conduct formal studies of the phenomenon of oral tolerance and showed that 
anaphylactic reactions to OVA and other proteins in guinea pigs were prevented by 
prior feeding with hen egg proteins (36). The immunological nature of the 
phenomenon was first established by the later experiments of Chase in 1946 (37) and 
studies of oral tolerance during the 1970's and 1980’s established that all aspects of the 
immune response could be tolerised by feeding antigen. Since then, the protocols of 
inducing oral tolerance and the mechanisms involved have attracted considerable 
attention, not only from mucosal immunologists, but also from individuals interested 
in using this system as a model of immunoregulation or as a therapy for 
immunopathology.
1.3.2 Scope & Longevity of Oral Tolerance
The induction of oral tolerance has been documented widely in many species, 
including man (38,39). However, species differences do occur and oral tolerance is not 
induced at all in ruminants (40). Most work has examined responses to proteins, but 
oral tolerance can be induced to a wide range of other types of antigen, including 
peptides (41), contact sensitizing agents (42), heterolejouj red blood cells (43), 
allogeneic leukocytes (44) and inactivated viruses (45) or bacteria (46).
Feeding antigen can toleiise almost all aspects of the immune response. These 
include IgM, all IgG isotypes and IgE antibody responses (47-52), as well as cell 
mediated immune (CMI) responses measured by delayed-type hypersensitivity (DTH) 
or contact sensitivity in vivo (53-55) and lymphocyte proliferation (56,57), cytokine 
production (57,58) and CD8 cytotoxic T-cell responses in vitro (59). One exception 
may be the production of IgA in the gut, which has been reported to be primed (60), 
tolerized (11), or unaffected (61) by different regimes of oral tolerance. Although 
antibody responses to soluble antigens are generally more difficult to suppress than 
CMI, IgE responses seem to deviate from this rule, being remarkably susceptible to 
induction of oral tolerance (62-63). This highlights the important biological role of oral
1.4 Clinical and Practical Relevance of Oral Tolerance
1.4.1 Physiological Prevention of Intestinal Hypersensitivity
A number of important chronic diseases of intestinal mucosal surfaces appear 
to have an immunopathological basis. This idea is consistent with observations of 
mucosal pathology when oral tolerance is prevented experimentally by administering 
cyclophosphamide, by activating the reticuloendothelial system, by feeding veiy low 
doses of antigen or by using animals during the neonatal or weaning period (65-68). In 
each case, the features of disease induced are similar to those found in naturally 
occurring food sensitive enteropathies (FSE) (69,70). One example is coeliac disease 
where patients have T cell mediated hypersensitivity to the dietary antigen gluten from 
wheat perhaps reflecting a breakdown in oral tolerance. Recent studies of transgenic
7
tolerance, as it is interesting to note that both IgE and CMI responses are frequently 
associated with pathological food hypersensitivity disease.
Systemic tolerance can be demonstrated if animals are challenged within 1 to 2 
days of a single feed of antigen (60) and is at its maximum during the first few weeks 
after feeding. Oral tolerance has been shown to last for 18 months in laboratoiy mice, 
although the longevity of tolerance varies for the different facets of the immune 
response (64). Tolerance of T cell functions is very long lasting, whereas tolerance of 
IgG responses may wane within 6 months (64). In view of the fact that the average 
life-span of a laboratory mouse is little more than 2 years, these findings highlight the 
potency and stability of this immunoregulatory phenomenon. In addition, these data are 
further evidence that systemic T-cell responses are affected more readily by feeding 
antigen than humoral immunity. Although the longevity of oral tolerance has not been 
addressed formally in humans, food hypersensitivities rarely begin in adulthood, 
indicating the likely persistence of long-term functional unresponsiveness once it has 
been established (5). 'Ï
-3
and knockout rodents suggest that a similar defect in immunoregulation within the
intestine can result in pathological hypersensitivity to gut flora, with the development of 
inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis. 
Examples of the different models of IBD are HLA-B27-transgenic rats (71), human 
CD3e chain transgenic mice reconstituted with normal bone marrow (72) and mice 
with genetically deteimined knockouts of a number of immunologically relevant genes, 
including IL2 (73), ILIO (74), a  chains of the TCR (75), or G i2a (76), an inhibitor of 
G proteins. The induction of IBD in all the models requires intestinal flora, as it does 
not occur in animals bred in germ-free conditions or given gut sterilising antibiotics. 
These models indicate that inflammatory T cells capable of being activated by 
endogenous antigens are present in the normal mucosal immune system and are 
usually held in check by regulatory cells (see below). Therefore, it is generally 
concluded that suppression of the immune response to ubiquitous luminal bacteria may 
be critical for maintaining mucosal homeostasis and thus preventing enteropathy.
1.4.2 Immunotherapy
The oral route offers a convenient and highly acceptable means of administering 
therapeutic agents and several studies have demonstrated the effectiveness of orally 
administered antigen in rat and mouse models of autoimmune disease (77,78). This 
work has stimulated trials of oral tolerance as an immunotherapy for human disease 
(79-81) and a number of such studies are currently underway. Although early reports 
were encouraging, more-recent studies have highlighted difficulties. In one study of 
rheumatoid arthritis, clinical effects and a reduction in collagen type II antibodies were 
associated with a high collagen intake (82), whereas the original study by Weiner and 
colleagues suggested positive responses in patients who had received a low dose. In a 
multiple sclerosis study, clinical response was associated with an increase of myelin- 
specific TGFp-secreting regulatory T cells (83). There are also clinical trials being 
conducted in patients with insulin-dependent diabetes mellitus, myaesthenia gravis and 
uveitis, but no published data are available yet. Clearly more needs to be understood of
1.5 Factors Influencing Immune Responses to Fed Antigen
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the regulatory mechanisms involved in oral tolerance if widely applicable effective 
regimes are to be developed utilising this approach.
1.5.1 Nature and Dose of Antigen
A wide range of antigens are capable of inducing oral tolerance. Tolerance can 
probably be induced to all thymus-dependent soluble antigens (84,85), but particulate 
or replicating antigens (ie pathogens) often induce active immunity instead of tolerance. 
This could reflect preferential uptake by M cells overlying the Peyer's patches, resulting 
in more efficient antigen processing (86). In addition, the provision of an inflammatory 
stimulus also prevents the induction of tolerance, and when antigens such as OVA are 
coupled to immune stimulating complexes (ISCOMs) or to bacterial toxins (87), local 
and systemic immunity are likely (88).
A wide range of doses and regimens of single and multiple feeds of antigen can 
induce systemic unresponsiveness. However, there may be dose-dependent differences 
in the extent to which individual systemic responses are tolerized. There is some 
evidence that single administration of high doses of antigen induces suppression of 
virtually all responses by direct inactivation of T cells (57,58,89,90), whereas multiple 
low doses are more likely to generate regulatory cells (91,92), with more variable 
effects on individual responses. Continuous exposure of antigen in the drinking weater, 
which is the most physiological route, may lead to more-profound tolerance, even 
when corrected for the administered total antigen dose (93,94). However, it should be 
noted that very low doses given orally have been shown to prime the animal for 
subsequent systemic and local immune responses (95). Although, these conclusions 
have been drawn from studies in rodents, similar findings have been made in man and 
a recent report has shown that the duration of feeding alters the mechanisms of 
tolerance induced by soluble protein antigens (96).
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1.5.2 Host Factors
Several host factors influence oral tolerance induction, including genetic 
background, host age, intestinal flora, intestinal absorption and antigen uptake and 
presentation.
Most mouse strains are tolerizable to a large number of antigens and, although 
tliere are some exceptions, there are no clear linkages to major histocompatibility 
complex (MHC) haplotype, IgE responder status or differences in antigen uptake via 
the gut. However, the rate of antigen clearance from the circulation is influenced by 
genetic differences and can affect the degiee of tolerance induction (21).
Food hypersensitivities are most common in infants, particularly at or near the 
time of weaning, suggesting that oral tolerance is defective during these periods. 
Intragastric antigen administration to neonatal rodents during the first 7-10 days of life 
does not suppress systemic immunity and may prime for later systemic immunity and 
autoimmune responses (97,98). It seems that this inability to induce tolerance is not 
merely a result of the immaturity of the digestive system or antigen-handling capacity 
of the neonatal gut (99), but is more likely to be due to an as-yet-uncharacterized 
regulatory imbalance that can be partially restored with adult spleen cells. An analogous 
deviation from tolerance induction occurs during weaning (100,101). At the other end 
of the age spectmm, ageing mice have been reported to become increasingly resistant to 
the induction of oral tolerance by feeding OVA (102).
The extent and nature of intestinal colonization by bacterial flora can effect the 
outcome of oral administration of antigen. Although lipopolysaccharide (LPS)-
unresponsive mice have defective oral tolerance to sheep red blood cells (SRBCs), 
tolerance to proteins is normal. Indeed, if given at the time of feeding, EPS may 
enhance the induction of T-cell tolerance in noimal mice fed OVA (103). However, 
further indirect support for the idea that EPS may play a modulatory role in regulating 
immunity to dietary antigens comes from the observations that tolerance to OVA may 
be relatively short-lived in germ-free mice (104).
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1.5.3 Antigen Uptake and Processing
Antigen handling and processing have important roles in oral tolerance 
induction. Aberrant presentation of antigen by APCs lacking a full range of 
costimulatory molecules is thought to be the cause of clonal anergy of T cells in many 
other forms of tolerance (105). The fact that stimulation of the RES can prevent the 
induction of oral tolerance (66,67,106) indicates that antigen presentation may also be 
important in regulating responses to a fed antigen.
The site and nature of the relevant APC involved in the induction of oral 
tolerance remain to be identified. There are a number of possibilities. If oral tolerance is 
induced entirely at local sites in the gut, this might imply a role for MHC class 11+ 
epithelial cells or non-professional APC either in the Peyer’s patches or lamina propria 
(31). The enterocytes that make up the lining epithelium of the intestine express MHC 
class II and can present antigen to primed T cells in vitro (31,107,108). However, 
enterocytes do not express ICAM-1 or B7-1 (105) and so presentation of antigen by 
these cells would be expected to lead to anergy of naive CD4+ T cells. B cells are 
numerous in the gut and antigen presentation by resting B cells has been shown to be a 
potent inducer of T cell tolerance in vitro. However, peripheral T-cell tolerance can be 
induced in B-cell-knockout mice (109) which may suggest that B cells aie not major 
players in oral tolerance. Dendritic cells (DCs) are abundant in the gut and have been 
shown to migrate to the MLN from the gut after intra-luminal or intra-gastric challenge 
(110,111). Potent presenters of soluble protein, dendritic cells (DC) are normally 
associated with T cell activation (112). However, recent work suggests that dendritic 
cells can present antigen in a tolerogenic fashion (113) and it has been shown recently 
that administration of the DC growth factor Flt3L to mice expands the number of DCs 
in the intestine and other lymphoid organs, and increases the susceptibility to induction 
of tolerance by feeding OVA (114). DCs recruited in the intestine by administration of 
the growth factor Flt3L express only low levels of B7-1 or CD40 costimulatory 
molecules, supporting the view that intestinal DCs may normally be in a resting state in 
situ without the ability to prime T cells (114). Thus, it could be proposed that DCs aie
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one of the major gatekeepers of the mucosal immune system, sustaining the induction 
of T cell tolerance to soluble proteins or noninvasive microorganisms, and generating 
active immunity only when confronted by potentially harmful antigens in the context of 
appropriate secretion of cytokines or other inflammatory signals.
One problem raised by the idea that oral tolerance occurs after entirely local 
presentation of antigen by DCs or epithelial cells is that T cells tolerised in the intestine 
should recirculate preferentially back to mucosal sites. Thus it would be difficult to 
explain the systemic nature of the immune unresponsiveness and this may mean that 
presentation of fed antigen must also occur in the periphery (19). This could be 
achieved if mucosally situated APC acquired antigen in the gut and then dispersed to 
the periphery to present antigen in a tolerogenic manner. Alternatively, fed antigen 
absorbed into the blood might associate with non-professional APCs in the periphery 
(115-117). In support of this, oral tolerance is associated with the presence of 
tolerogenic antigen which appears in the circulation from 15-60 minutes after feeding
,v ; ,and which can suppress systemic delayed-type hypersensitivity when transfered in to 
naive recipients (55,89,118,119). As the amount of fed antigen absorbed intact varies 
widely, between 0.001% and 1% of the administered dose, it seems likely that 
differences in absorption could influence oral tolerance. Whether this is influenced by 
intralumenal digestion is controversial. Attempts to analyse the requirements for 
intralumenal digestion by oral administration of serine protease inhibitors prior to feeds 
have been inconclusive (119-121). However, it is possible to induce systemic tolerance 
by colonic antigen administration (122), suggesting a single filtration mechanism may 
be invloved.
1.5.4 Immunological Status of Host
There is a substantial amount of evidence that suggests that suppression of 
autoimmunity by orally administered antigen is a feasible and therapeutic option. 
However, most existing studies of oral tolerance have explored the mechanisms 
responsible for the ability of fed antigen to prevent subsequent systemic immune
1 2
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responses in previously naive animals and little is known about the mechanisms which 
detennine the induction of oral tolerance in the primed immune system. If treatment of 
humans is to become a therapeutic reality, it will be necessary to re-establish tolerance 
in a previously sensitized host.
It is well known that it is difficult to induce systemic tolerance in animals that
have been previously primed to the antigen (123). Despite this, several investigators
-,have shown that oral tolerance can be induced in paienterally primed mice (124,125) 
and the ability of oral tolerance to abrogate ongoing immunity extends to several 
experimental models of immunologically mediated disease, including EAE (7), 
collagen-induced arthritis (126), experimental autoimmune uveoretinitis (127), immune 
complex-mediated glomemlonephritis (128), insulin-dependent diabetes (129), and 
allograft rejection (130). The few studies conducted with model antigens in primed 
mice suggest that larger or more frequent doses may be required to induce oral 
tolerance in primed animals than in naive animals, and that this may only be possible 
for a limited period after systemic immunization. Higher doses of antigen were 
required to be fed to primed mice compared with naive mice in order to sufficiently 
suppress systemic delayed-type hypersensitivity (DTH) responses. Suppression of 
DTH responses was greatest when antigen was fed soon after immunization, and 
became less pronounced as the time inteiwal between feeding and immunization 
increased over 7 days (124). As in naive animals, oral tolerance of established immune 
responses affects T cell immunity more than humoral responses and it has been 
reported that serum IgG antibody responses can be suppressed only by multiple feeds 
of high dose OVA given in the first 5 days after priming. In contrast DTH responses 
were suppressed by single feeds of high or medium doses of OVA given at the same 
time (124).
A recent study on the suppression of established murine chronic relapsing EAE 
by the oral administration of MBP has confirmed that oral tolerance in primed mice is 
induced better by high doses of antigen given sooner after immunisation and that 
multiple high doses were best. Thus, multiple oral doses of MBP given early after
i
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1.6 Mechanisms of Orai Tolerance
1.6.1 Mechanisms of Peripheral Tolerance
Oral tolerance is one form of peripheral T cell tolerance in which mature 
lymphocytes in the peripheral tissues become unresponsive after contact with antigen. 
The mechanisms of peripheral tolerance to parenterally administered antigens has been 
investigated in great detail and can be organised generally as clonal ignorance, anergy, 
deletion and active regulation.
Naive T lymphocytes that come into contact with their specific antigen can 
effectively ignore the antigen thus rendering the animal phenotypically unresponsive.
1
immunisation were required to achieve suppression of clinical signs of disease (131). 
However, conflicting results were obtained using proteolipid protein peptide (PLP) 
orally to down-regulate ongoing EAE (132). Here neither feeding single nor multiple 
doses of PLP could down-regulate ongoing disease, inhibit the progression of relapsing 
EAE or reduce antigen-specific proliferation or cytokine (IL2, IL4 and IFNy) 
production. Thus, the specific effects of feeding antigen to primed animals remain 
unclear* and much remains to be learnt of the best protocols for inducing this form of 
oral tolerance, as well as of the mechanisms involved. To date there have been no 
formal studies in which wide ranges of single or multiple doses of antigen have been 
given at many different times after immunisation. In addition, the effects of such 
regimes in a full range of effector immune responses in vivo and in vitro have not been 
determined. Experiments of this nature are now feasible due to the great expansion in 
our knowledge of the equivalent events which occur in oral tolerance in naive animals.
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Evidence for this comes from transgenic models which show that peptides may be
presented in the context of MHC Class I on cells which are unable to trigger any 
response from T cells with the appropriate TCR because they lack expression of the 
costimulatory or accessory molecules required to enhance T cell avidity (133-135). In 
many cases, extrathymically expressed antigens also appear to be ignored by CD4 T
14
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cells and this may be because parenchymal tissues normally express relatively few 
MHC Class II molecules and therefore may not be surveyed efficiently by naive T cells 
(136,137). Although this prevents primary responses to tissue antigens, it is cleai* that 
the relevant T cells will remain present in the animals and will respond normally if the 
appropriate antigen is later presented by a professional APC or in the context of 
inflammation (137-140). This is unlikely to account for oral tolerance, as orally 
tolerised T cells do not respond normally when antigen is presented by professional 
APCs and in the context of inflammation due to systemic challenge with antigen in 
adjuvant.
An alternative means of T cell tolerance is direct T cell inactivation either by 
clonal deletion or functional anergy. Clonal deletion of self reactive T and B 
lymphocytes occurs predominantly in the thymus and bone marrow respectively and is 
required for central tolerance to self antigens (141). Clonal deletion of T cells may also 
occur extrathymically when peripheral tolerance is induced by exogenous superantigens 
(142) or after parenteral administration of conventional antigens to TCR transgenic 
animals (143). However, this is probably rare in normal animals, where clonal anergy 
is likely to be more frequent.
Anergy has been operationally defined as the state in which a lymphocyte may
recognize its specific antigen but does not respond to subsequent stimulation by
■proliferation or generation of effector functions (144). Several investigators have 
suggested that induction of anergy in their systems is due at least in part to the lack of 
IL2 production by T cells upon TCR ligation.thus preventing autocrine IL2-mediated 
proliferation (145). Anergy can be reversed either by the addition of IL2 (146), or by 
resting the anergic cells in the absence of antigen (147). This unresponsive state is 
associated primarily with CD4 T cells and can occur under a number of circumstances, 
although one common feature is the presentation of antigen by APC that fail to prime T 
cells adequately. This can occur when antigen is presented by APC that do not provide 
costimulation, or when supraoptimal levels of antigen are used or when T cells are 
stimulated with altered peptide ligands (148). A number of costimulatory molecules are
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important in the activation of T cells and avoidance of anergy. Although a key 
interaction of this kind is that between CD28 on T cells and B7-1 on APC, others 
include LFA-l/ICAM-1, VLA-4/VCAM-1, CD2/LFA-3, CD40L/CD40 or ILL An 
alternative possibility is that distinctive costimulatory interactions are involved in the 
induction of anergy or activation. This is suggested by the recent report that the 
induction of tolerance by paienteral antigen specifically requires interaction between 
CTLA4 and B7, whereas immunity requires interaction between CD28 and B7 
(149,150). It has been shown recently that CTLA4 may also be required for the 
induction of high dose oral tolerance (151).
The cardinal feature of T cell anergy is a lack of proliferation and production of 
IL2 and it has been shown that anergic T cells may have preseiwed production of 
certain cytokines, including IFNy, EL3, ILIO and granulocyte macrophage colony 
stimulating factor (GMCSF) upon restimulation (152-155). The regulatory activity 
associated with some of these cytokines might explain why anergic cells from tolerised 
mice can act as suppressor T cells when adoptively transferred into athymic and SCID 
mice (152,156). This could also reflect the ability of IL2RF anergic T cells to compete 
with naive cells for available IL2 or for antigen-MHC complexes on APC (157).
Tolerance mediated by the regulation of one lymphocyte population by another 
is known as active suppression. This mechanism of tolerance has been known for 
some time and was initially demonstrated in adoptive transfer studies where 
lymphocytes from tolerised animals could transfer hyporesponsiveness to naive 
animals. This was often associated with CD8 T cells, although this idea has 
subsequently fallen into disrepute (158). Active suppression has been described in 
various forms of extrathymic tolerance (159) and is also believed to play an important 
role in the regulation of normal immune responses (160). Frequently the suppression is 
induced in an antigen-specific manner, but exerts its effects through a variety of antigen 
non-specific soluble factors (161,162), including glucocorticoids elicited during a stress 
response (163) and cytokines, such as IL6 (164), ILIO (165), IFNy (166) and TGFp 
(167). One possibility is that active suppression reflects cross-regulation of the T y l
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(173,174). Bystander suppression is therefore the basis for most therapeutic uses of
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and Th 2 subsets of CD4+ T helper cells. The Th I subset secretes IL2 and IFNy
production, promotes inflammation and assists B cell production of IgM and IgG2a, 
whereas Th 2 cells secrete EL4, IL5, IL6 and ELIO and promote B cell production of
antibodies, especially IgE and IgGl. They aie thus important in immune responses to 
allergens and helminth paiasite infections (168). Th I-dependent IFNy downregulates 
production of lymphokines by Th 2 cells, which in turn can inhibit T jjl cell activity via
EL4 and ILIO production (169). Recently it has been suggested that there may be an 
additional susbset of regulatory Th 3 or Tr I cells that can secrete inhibitory cytokines
such as TGFp and/or ILIO (170-172).
It is important to consider that these groups of mechanisms need not be 
mutually exclusive and that their relative importance may depend on the individual 
circumstances.
1.6.2 Mechanisms of Oral Tolerance
1.6.2.1 Introduction
As with peripheral tolerance, the mechanisms that have been implicated in oral 
tolerance can be divided into active modulation and direct inactivation of responding 
lymphocytes. Although these individual mechanisms may not be mutually exclusive, 
the applicability of oral tolerance in the treatment of autoimmune diseases may be 
critically dependent on which mechanism is triggered.
An active suppressor mechanism would imply that tolerance is mediated by the 
regulation of one lymphocyte subpopulation by another and that suppression of 
responses to an unrelated "bystander" antigen may be feasible if the regulatory 
mechanism was mediated by antigen non-specific factors such as cytokines. 
"Bystander suppression" occurs when an orally tolerised animal is challenged both 
with the original antigen and an unrelated antigen and it is believed to be mediated by 
antigen-non-specific cytokines, such as TGF-p, released by regulatoiy T cells
■t
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oral tolerance, which employ antigens that are not normally the original antigen 
inducing the immunopathology. Although the presence of bystander suppression and 
other mechanisms of active regulation have not yet been examined directly in oral 
tolerance in primed mice it has been reported that TGF-p production is not enhanced in 
mice tolerised by feeding myelin basic protein after priming (131). A disadvatage of 
bystander suppression would be that this mechanism of tolerance might not be stable 
and could suppress the immune response to a harmful antigen at the site where active 
suppression was being induced. In contrast, antigen induced inactivation of potentially 
reactive lymphocytes due to deletion or functional anergy might imply a more stable, 
long-lasting tolerance that is less susceptible to modification by other immune 
responses, although anergy could be reversed by IL2 production released e.g. during 
inflammation or an infection. In addition, practical exploitation of this mechanism 
would require that the disease-inducing antigen was known. Interestingly, which 
mechanism that dominates in individual circumstances may be determined by the dose 
of antigen that is fed.
1.6.2.2 Direct Inactivation of Ag-specific Lymphocytes
Clonal deletion has not been described during oral tolerance induction in normal 
animals. Studies using TCR transgenic mice have shown that high doses of OVA or 
the immunodominant epitope of myelin basic protein can induce Ag-specific deletion 
of T cells in the spleen and gut-associated lymphoid tissue (GALT) of Ag-fed mice 
(175,176). However, 'unphysiologically' large doses of antigen were required to 
demonstrate such effects and it is difficult to detect functional tolerance in vivo in these 
fully transgenic animals. Circumstantial evidence that deletion may occur during oral 
tolerance under physiological conditions has been provided by the observation that 
orally tolerized lymphocytes die by apoptosis when cultured in vitro after an in vivo 
challenge (177). However, apoptosis of antigen specific lymphocytes has never been 
demonstrated in vivo in tolerised normal mice. Furthermore, the apoptosis in vitro only 
occurred if the animals had been challenged systemically with antigen in adjuvant. Oral
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tolerance can also be induced normally in Ipr mice arguing against a role for fas- 
dependent deletion in the intact animal (178). Overall, these results suggest that 
elimination of tolerant lymphocytes by classical mechanisms of clonal deletion may not 
normally occur after the induction of oral tolerance in vivo. Rather, the apoptosis of 
tolerised lymphocytes observed in vitro may refleet abnormal susceptibility of anergic 
cells to die when restimulated in vivo and removed to culture in vitro. However, it is 
possible that apoptosis in normal animals occurs at such a low frequency in vivo as to 
be undetectable.
Clonal anergy is therefore considered to be a more important mechanism of 
oral tolerance to peripheral antigens, especially when tolerance has been induced by 
feeding high doses of antigen. There ai’e several experimental models of oral tolerance 
in which there was no evidence of active suppression and in which functional antigen-
1 9
reactive lymphocytes appeared to be absent (58,89,90). Under these circumstances, the
impaired ability of cells to respond to antigen in vitro was restored by a period of 
culture with exogenous IL2 indicating the continued presence of antigen-reactive T cells 
(89). More recently, it has been shown by using mice adoptively transferred with 
OVA-reactive transgenic T cells, that Ag-specific T cells persist after feeding 
tolerogenic doses of OVA, but aie unresponsive to restimulation with Ag in vitro 
(114,179,180). This is direct evidence that anergy rather than deletion is one of the 
major mechanisms underlying oral tolerance. These findings have been extended by a 
recent report in which cytochrome c was fed to mice transgenic for the (3 chain of a 
cytochrome c-specific TCR. Using cyt c/I-E^ tetramer staining reagent to detect Ag- 
specific T cells, it was shown that multiple feedings of Cyt c decreased the number of 
antigen specific T cells in the periphery and reduced T cell responses (181). The results 
in this report are consistent with clonal anergy and perhaps some deletion. Interestingly, 
no evidence was found for skewed T cell cytokine production.
If anergy is the mechanism induced by oral administration of antigen then this 
makes it difficult to understand the functional tolerance which maintains the 
unresponsiveness throughout the animal, especially if naive cells repopulate from the
E
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thymus. One possibility is that anergic cells might be able to mediate suppressor 
phenomena, as has been suggested by studies showing that anergic T cells may transfer 
tolerance into naive animals (156). In this study, in which they transferred orally 
tolerised CD4+ T eelis mixed with naive CD4+ T cells to nude mice and investigated 
antibody production in response to immunisation, they found that the suppressive 
activity of the anergic CD4+ T cells from tolerant mice might not be cytokine mediated 
but cell mediated. This was because suppressive eytokines, including IFNy, TGF|3 and 
ILIO from CD4+ T cells were not observed. Their findings ai*e consistent with the 
findings of Lombardi et al (182) who demonstrated that anergic T cells suppressed the 
proliferative response of normal T cells, and that suppression was not mediated by 
ILIO or TGFp.
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1.6.2.3 Active Suppression
There is substantial evidence that active suppressor mechanisms may play a 
role in oral tolerance (7,95). T cells with suppressive activity have been identified in the 
intestinal mucosa, mesenteric lymph nodes and spleen (11,125,173,183-185) and 
antigen fed mice, and many transfer experiments have demonstrated that systemic 
suppression can be transferred by orally tolerized spleen, MLN and Peyer's patch cells 
(118,186,187). Oral tolerance can be prevented with agents that were believed to be 
suppressor-cell specific toxins. These suppressor cells were believed to be induced in 
the Peyer's patches and migrate to the systemic immune system and were originally 
shown to be CD8+ T cells (170,188-191). However, more recent studies have 
suggested that CD8+ cells are not necessaiy for oral tolerance (57,59,192), as it can be 
induced in CD8-knockout mice (193) and in mice depleted of CDS T cells using 
monoclonal antibodies (59,188). All of these studies have indicated that CD4 T cells 
rather than CDS T cells are required for oral tolerance induction, even when the effector 
response is entirely CDS dependent (192). In agreement, other recent work has shown 
that CD4 T cells can transfer oral tolerance in vivo (194). Nevertheless, some evidence 
persists that CDS cells may play a role in oral tolerance, as it has been shown that there
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may be a lack of local suppression in orally tolerant CD8-deficient mice, despite full 
tolerance in the periphery (193).
T cells expressing the yô TCR have more recently been suggested as playing a 
role in mucosally induced systemic tolerance (195,196). In vivo treatment with 
antibodies specific for the yô TCR inhibited induction of oral tolerance in OVA-fed 
mice and yô TCR knock-out mice have defects in oral tolerance (197,198). 
Conversely, unconfirmed work has shown that yô T cells from the gut epithelium may 
abrogate oral tolerance (199). Thus, more work is required to define the regulatory role 
of yô T cells in oral tolerance and to examine if tliese cells ar*e intraepithélial 
lymphocytes or other, systemic populations of yô T cells.
As noted above, recent evidence suggests that one of the primary mechanisms 
of active suppression may be via the secretion of suppressive cytokines such as IL4, 
ILIO, and transforming growth factor g (TGPP) following Ag-specific triggering (200- 
205). Thus it has been proposed that the induction of oral tolerance may reflect a 
preferential activation of T helper 2 (Th2) cells with down-regulation of T hI- 
dependent DTH and IFNy responses by Tfj2 cytokines such as IL4, DL5 and ILIO 
This idea is compatible with the fact that it is easier to induce and maintain oral 
tolerance of CMI responses in comparison with humoral responses. Indeed, a recent 
report has shown that treatment with an anti-IL4 monoclonal antibody blocks 
suppression of collagen-induced arthritis in mice induced by oral administration of type 
II collagen. However, it must be noted that TH2-type responses in vivo (e.g. I n ­
dependent IgE production) can also be suppressed by feeding antigen. Furthermore, 
oral tolerance can still be induced in IL4 knockout mice (57,206) and a concomitant 
helminth-induced mucosal Th2 response prevents oral tolerance of Th2, but not T hT
responses to OVA (207).
ILIO appeared to be an attractive candidate as a mediator of oral tolerance since 
it is a Th 2 cytokine (208) which suppresses Th I cell activity via downregulation of
macrophage IL12 production (203). Also, its absence in ILIO knock-out mice allows 
the development of intestinal pathology due to hyperreactivity to components of the
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normal gut flora (209). Initial reports suggested that the production of ILIO was 
enhanced in oral tolerance and some reports showed that ILlO-producing T cell clones 
could be isolated from animals tolerised by feeding MBP (170). Indeed ILIO has 
recently been shown to be a growth factor for regulatory T cells, termed Trl cells, that 
prevent colitis and may thus be involved in oral tolerance (171,172). However, other 
groups have found marked suppression of ILIO in OVA fed mice (57), and normal 
tolerance occurs in mice depleted of ILIO (204), indicating that this cytokine is not a 
central mediator of oral tolerance.
TGFp is the mediator receiving most current attention and is abundantly 
produced in the normal intestine by cells of both haematopoietic and epithelial origin. It 
is important in regulating epithelial homeostasis, IgA switching and may also be 
involved in the homing of cells to high endothelial venules (210,211). It has also been 
recently demonstrated that antigen-specific TGFp production is preserved in orally 
tolerised TCR transgenic animals (175), although the source of this cytokine following 
the clonal deletion of antigen-specific T cells that occurs in these animals is unclear. The 
prevention of EAE by oral administration of MBP is associated with upregulation of 
TGFp in the brain (212), and TGFP-secreting T cell clones can be produced from 
animals tolerised in this way (213). Furthermore, protection from EAE can be 
transferred with CD8+ T cells or clones that produce TGFp, and bystander suppressor 
effects exerted by these cells in vitro can be prevented with anti-TGFp. Oral tolerance 
can be enhanced by anti-IL12 antibodies and this is associated with inhibition of T y l
responses and high TGFP production (214,215). Another more recent study has 
shown that TGFp induced by oral tolerance ameliorates experimental tracheal 
eosinophilia (216). Although these findings are consistent with an important role for 
TGFp, the biological significance of the levels of TGFp measured in vitro is uncertain 
and very few studies have addressed directly the role of this cytokine in oral tolerance 
in vivo using appropiate depleting antibodies. A recent report on the induction of oral 
tolerance in TGFpl Null mice has shown that mice fed high doses of OVA still 
exhibited highly significant suppression compared with controls, showing that
I
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suppression via TGFp is not the only mechanism of oral tolerance in high dose fed 
mice (217). However, a weaker, but still significant, suppression was observed in 
lymphocytes from the majority of TGFpl Null mice fed low doses of OVA 
suggesting that suppression via TGFp may be a more important mechanism of oral 
tolerance in low dose fed mice.
It has been reported that TGFp may be produced by both CD4 and CDS 
GALT-derived regulatory T cells (170,189,190,200). Recently it has been suggested 
that there may be a unique subset of CD4 helper T cells that primarily produce TGFp 
or ILIO. These have been termed Th3 or Trl cells (170-172,189,190). To generate the 
regulatory Th3 cells, MLN of mice that had been fed MBP and immunised with 
MBP/CFA were cultured in vitro with MBP and the CD4 T cells from these cultures 
were cloned. The cytokine profile of each of the clones after activation with MBP or 
anti-CD3 was determined and most of the clones produced mainly TGFp and these 
clones were termed Th3 cells (170). Transfer of these Th3 cells to mice prior to
immunization with MBP suppressed EAE, as measured by disease incidence, day of 
onset, maximum disease score and fatality. An analogous population of in vitro 
generated antigen-specific IL 10-dependent regulatory cells (Trl) that also produce 
TGFp has recently been shown to be capable of down-regulating a murine model of 
inflammatory bowel disease, further highlighting a possible role for this cytokine in 
mucosal immune regulation (171,172). To generate Trl cells, naive OVA-TCR Tg 
CD4 cells from D O ll.lO  transgenic mice were repeatedly stimulated in vitro with 
splenic APCs and OVA peptide in the presence of ILIO. Then they transfened OVA- 
specific Trl cells into SCID mice and observed that they were able to prevent IBD 
induced by pathogenic CD4+CD45RBhi splenic T cells only upon stimulation in vivo 
by feeding the mice with OVA.
Priming of antigen-specific IFNy secretion in Peyer's patches and peripheral 
tissues has been demonstrated in mice transgenic for a myelin basic protein (MBP)- 
specific TCR or OVA-specific TCR (214,215), suggesting that priming of Th I
responses may occur before oral tolerance is established. Indeed, nasal tolerance
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appears to depend on IFNy (218,219). This is because adoptive transfer of small 
numbers of IFNy-producing y§ T cells from nasally tolerised mice to recipients that 
were subsequently immunised with OVA selectively suppressed TH2-dependent IgE
antibody production without affecting parallel IgG responses (218). Further, nasally 
induced tolerance to OVA in rats involves active suppression of IgE responses by 
IFNy-producing CD8+ T cells (219). However, studies using mice depleted of IFNy 
have produced conflicting results, as although it has been reported that IFNy KO mice 
have a defect in oral tolerance (220), others find normal oral tolerance in IFNyR KO 
mice (221). In addition, most workers find that the production of IFNy is highly 
susceptible to the suppressive effects of feeding antigen (57,90).
1.6.2.4 Influence of Ag Pose on Mechanisms of Oral Tolerance
It is important to note once again that it is likely that many of the mechanisms 
may not be mutually exclusive. However, whether active regulation or direct T cell 
inactivation predominates as a mechanism of oral tolerance may depend on the 
circumstances of antigen exposure and, in particular, may be influenced by the dose 
and frequency of antigen administration. Clonal anergy or deletion of antigen-specific T 
cells seems to occur in oral tolerance induced by high doses (ie greater than 25mg) of 
antigen in the context of high affinity T cells (175,214). In contrast, feeding lower 
doses of antigen on multiple occasions is associated with active regulatory mechanisms 
and bystander suppression. However, it is difficult to extrapolate doses from antigen to 
antigen and animal to animal thus making it hard to make firm conclusions or 
predictions as to the mechanism of oral tolerance induced by a certain dose of antigen.
Two previously mentioned recent studies which highlight the influence that the 
dose of antigen has on the mechanisms of oral tolerance and the difficulty in making 
firm conclusions as to the mechanism of oral tolerance induced by a certain dose of 
antigen. For example, the first of these studies used cyt c tetramer staining reagents 
and concluded that multiple low doses of cyt c fed to mice down-regulates the systemic 
immune response which can be correlated with a reduction of antigen-specific T cells
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via anergy and/or deletion and not with immune deviation (181). The second study, in 
TGpp KG mice, revealed that active suppression, as mediated by TGPP, is not the 
mechanism of tolerance induced by feeding a high dose of antigen. The same study 
also concluded that while feeding a low dose of antigen may result in some active 
suppression via TGpp, it is not the exclusive mechanism (217).
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1.7 Aims of this Study
The clinical application of oral tolerance will be to treat established disease, but 
most existing studies of oral tolerance have concentrated on the ability of feeding 
antigen to prevent subsequent systemic immune responses to specific antigen in 
previously naive animals. Therefore the aims of my studies were to define feeding 
regimes for inducing optimal oral tolerance in primed mice, to establish the effects of 
feeding antigen to primed mice on a variety of parameters of systemic immunity and to 
investigate the mechanisms of oral tolerance in primed mice. I decided to use a model 
antigen in my studies as many previous studies have used disease models which are
complex. In addition, this allowed me to exploit experimental systems already
developed in the laboratoiy for the induction and assessment of oral tolerance to OVA 
.in naive mice.
In Chapter 3 I describe the experiments designed to establish optimal protocols 
for inducing tolerance in primed mice fed antigen by using antigen-specific in vivo and 
in vitro assays to investigate the scope of responses influenced by the tolerance. The 
longevity of these effects is examined in Chapter 4 since oral tolerance is currently 
under evaluation as a potential immunotherapy. In an attempt to understand more fully 
the mechanisms of oral tolerance that are induced in mice fed after priming I employed 
several new strategies including the use of knockout mice, TCR-specific transgenic 
mice and a DC growth factor. In Chapter 5 I investigated the role of the cytokines, IL4 
and IL12, by examining tolerance in knockout mice with targetted lesions in the 
appropriate genes in order to investigate the roles of Th2 cells and TGFp respectively
in oral tolerance in primed mice. In Chapter 6, a novel dendritic cell inducer, the growth
I
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factor Flt3L, was used to examine if it was possible to increase the scope of oral 
tolerance by expanding the numbers of dendritic cells in vivo. The work described in 
Chapter 7 then employed mice transgenic for the T cell receptor specific for the MHC 
Class II restricted immunodminant peptide of OVA to analyse directly the effects of 
feeding antigen on primed T cells at the clonal level. Finally, in Chapter 8, I explored 
why oral tolerance was haider to induce in primed mice compaied with naive mice, by 
investigating the influence of persistence of antigen and the susceptibility of memory T 
cells to oral tolerance.
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Chapter 2 Materials and Methods
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2.1 Mice
BALB/c (H-2<i) mice were obtained from Harlan Olac (Bicester, Oxon, U.K.) 
or were bred in house (Central Research Facility, CRF, University of Glasgow) and 
maintained in the CRF. IL4~/" (129Sv x C57B1/6)F2 (H-2^ >) mice (222) were obtained
originally from Dr. H. Bluethmann, F. Hoffman-La Roche AG, Basel, Switzerland and 
maintained in CRF. p40 IL12 deficient (IL12"/") BALB/c mice (223) were obtained 
from Dr. J. Magram, Roche Pharmaceuticals, Piscataway, NJ and maintained in CRF. 
Mice transgenic for the OVA323-339 and I-A^-specific DO 11.10 TCR on a BALB/c
genetic background (224) were obtained from Dr. Nils Lycke, Goteborg, Sweden and 
maintained in the CRF.
Mice were specified pathogen free and were maintained under standard animal 
house conditions with free access to both water and standard rodent pellets, containing 
no ovalbumin, until use at 6-8 weeks of age. In most experiments, female mice were 
used. s
2.2 Antigens and Mlitogens
Ovalbumin (OVA, Fraction V), lipopolysaccharide (LPS, from Salmonella 
enteritidis), cholera toxin (CT) and concanavalin A (Con A) were obtained from 
Sigma, while purified protein derivative (PPD) from M. tuberculosis was obtained 
from Central Veterinary Laboratory, New Haw, Addlestone, Surrey, U.K. and 
prepared according to the manufacturer's instructions.
Heat-aggregated OVA (HAO) was prepared by heating a 2% (w/v) solution of 
OVA in saline (Baxter Healthcare Ltd. Thetford, Norfolk) at 70“C for 60 minutes in a 
water bath (Grant Instruments Ltd., Barrington, Cambridge, U.K.). The resulting 
suspension was centrifuged at 450g for 5 minutes and the precipitated OVA washed 
further by resuspending in ice cold saline and centrifuging at 450g for 10 minutes. 
After discarding the supernatant, the HAO was resuspended at 20mg/ml in saline and
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stored at -20°C until required. Before use, the HAO was diluted to 2mg/ml in saline 
and sonicated in a glass bijoux for 20 minutes to produce a colloidal suspension (50).
2.3 Oral Administration of OVA
Mice were fasted for 18 hours prior to being fed OVA dissolved in 0.2ml 
saline and administered via a stainless steel gavage needle (1.5 by 20 gauge. 
International Market Supply, Dane Mill, Broadhurst Lane, Chesire, U.K.) without 
anaesthetic. Control animals were fed 0.2ml saline alone.
2.4 Systemic Immunisation Procedures
Systemic immune responses were induced by immunising mice s.c. with an 
emulsion of lOOpg OVA in saline prepared at a ratio of 1:1 with complete Freund's 
adjuvant (CFA; Sigma).
In most experiments, subcutaneous (s.c.) immunisations were performed by
2 8
:#
,.VJinjection of a total volume of 50pl into one rear footpad under light anaesthetic using 
5% halothane (Zeneca, U.K.). In other experiments, s.c. immunisations were 
performed by injection of a total volume of 0.2ml distributed between three sites on the 
back under light anaesthetic.
:
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2.5 Collection of Serum for Antibody Measurements
Mice under halothane anaesthesia were bled from the retro-orbital plexus using 
heparinised capillary tubes (Hawksley & Sons Ltd. Lancing, Sussex, U.K.). A 
maximum of 200p,l was collected and serum was separated by centrifugation for 20 
minutes at 450g and stored at -20°C until use.
2.6 Assessment of Antigen-specific Delaved Type Hypersensitivity (DTHl 
Responses in vivo
OVA-specific DTH responses were assessed as decribed in detail elsewhere 
(51). 20 days after immunisation with OVA/CFA, mice were anaesthetised with
halothane and the thickness of the unimmunised rear* footpad measured using skinfold 
calipers (0-10mm in 0.1mm; Ki’oeplinn Langenmesstecknik, Kingston-on-Thames, 
Surrey, U.K.). The footpads were then injected intradermally (i.d.) with lOOpg HAO 
in 50pl saline and after a further 24 hours, the increases in individual footpad thickness 
were measured. The mean increment of each group was calculated and the OVA-
specific DTH responses obtained by subtracting the increment found in CFA 
unimmunised mice challenged with HAO.
2.7 Measurement of Antigen-specific Serum IgG Responses
Enhanced protein binding, 96-well ELISA plates (Immulon-4; Dynatech, 
Billingshurst, Sussex, U.K.) were coated overnight at 4^0 with lOOpl of a lOpg/ml 
solution of OVA in O.IM carbonate buffer (pH 9.3: Appendix I). After three washes 
with 150pl/well PBS/0.05% Tween 20 (Sigma), lOOpI aliquots of doubling dilutions
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of (NH4)2S04 -purified anti-OVA hyperimmune serum IgG standard, diluted 1:400 in
PBS/0.05% Tween 20/1 %FCS (Gibco Life Technologies, Paisley, U.K.), were added 
to the plates. lOOpl aliquots of serum samples diluted 1:400 in PBS/Tween 20, were 
added in triplicate to the plates. After incubation at room temperature for 2.5 hours, the 
plates were washed as before, and incubated for a further 3 hours at room temperature 
with lOOpl/well alkaline phosphatase-conjugated goat anti-mouse IgG (Sigma) diluted 
1:500 in PBS/Tween 20. After a final wash step, 120pl/weil of phosphatase substrate 
(1 mg/ml in 10% diethanolamine, DBA, dissolved in distilled water; both from Sigma) 
was added and 5-10 minutes later, the plates read at 405nm (reference filter 510nm) 
using a MR5000 automatic microplate reader (Dynatech). The anti-OVA IgG 
concentration of test supernatants was determined with reference to a standard curve 
constructed using serial dilutions of the hyperimmune anti-OVA standard.
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2.8 Measurement of Antigen-specific Serum IgG Isotvoe Antibodies
Enhanced protein binding, 96-well ELISA plates (Immnlon-4) were coated 
overnight at 4®C with 50pl of a lOpg/ml solution of OVA in 0.05M carbonate buffer. 
After three washes with PBS/0.05% Tween 20, non-specific protein-binding sites were 
blocked with lOOpl/well of a 3% solution of bovine serum albumin (BSA; Sigma) in 
PBS/Tween 20 for 1 hour at room temperature. After three washes with PBS/Tween 
20, 50pl aliquots of test sera in doubling dilutions (beginning at 1:400 for IgGl or 1:20 
for IgG2a assays) in PBS/Tween 20 were added to the plate, as were doubling dilutions 
of the (NH4)2S04 -purified anti-OVA IgG hyperimmune serum standard diluted
1:400 in PBS/Tween 20, and incubated at room temperature for 1.5 hours. After three 
further washes, biotinylated rat anti-murine IgGl (Serotec), diluted 1:16000, or 
biotinylated rat anti-murine IgG2a (both AMS Biotechnology, Witney, Oxon, U.K.) 
diluted 1:500 in PBS/Tween 20 was added at 75pl/well and incubated at room 
temperature for 1 hour. The plates were then washed three times and 75pl/well 
extravidin-peroxidase (Sigma) diluted 1:1000 in PBS/Tween 20 was added. After a 
final incubation for 1 hour at room temperature, the plates were washed six times 
before lOOpl of 3,3',5,5'-tetramethylbenzidine peroxidase (TMB) substrate (Dynatech) 
was added to each well. The plates were read at 630nm (reference filter 405nm) using 
a MR5000 automatic reader. Concentrations of anti-OVA antibody isotypes in test 
supernatants were determined with reference to a standard curve constmcted using 
serial dilutions of the hyperimmune anti-OVA standard.
2.9 Preparation of Lvmpboid Cells
Single-cell suspensions of popliteal lymph nodes (PLN) were prepared in 
RPMI-1640 by rubbing gently over Nitex mesh (gauge 100p.m, Cadisch & Sons, 
London, U.K.) using a syringe plunger and passed through Nitex mesh to remove any 
clumps. After washing the cells twice in RPMÏ 1640 by centrifugation at 4°C for 8 
minutes at 450g and resuspending in 10ml RPMI 1640, viable cells were counted by
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phase contrast microscopy (Nikon Labophot microscope, x40 objective) using a 
haemocytometer (Neubauer). Cells were finally resuspended in complete medium ■2,1.
(RPMI 1640 containing 10% PCS, lOOU/ml penicillin, 100|Lig/ml streptomycin.
50pg/ml fungizone, 2mM L-glutamine (all Gibco BRL), 25mM Hepes (Sigma) and
50p.M 2-mercaptoethanol (Sigma) ).
2.10 Measurement of T Cell Proliferation in vitro
200|il aliquots of lymphoid cells resuspended at lO^/ml in complete medium 
were added to quadruplicate wells of flat-bottomed 96-well tissue culture plates 
(Costar, Northumbria Biologicals, Cramlington, Northumberland), either alone or in 
the presence of OVA, PPD or Con A, at concentrations previously shown to be 
optimal (1 mg/ml, 50|ig/ml and lOpg/ml, respectively). The plates were covered with 
plate sealers (FLOW ICN Biomedicals Inc., Costa Mesa, CA, U.S.A.) and incubated 
in a 5% CO2 humidified incubator (Heraeus Instmments, U.K.) at 37®C. Proliferation
was assessed at various times by addition of lp,Ci/well [^H] thymidine (West of 
Scotland Radionucleotide Dispensary, Western Infirmary, Glasgow) for the last 24 
hours of culture. Cell bound DNA was harvested onto glass fibre filter mats and [^H] 
thymidine incorporation measured on a 1205 Betaplate scintillation counter (both 
Wallac Oy, Turku, Finland).
2.11 Measurement of Cytokine Production in vitro
or Con A at the concentrations described above. The plates were covered with plate 
sealers and incubated in a 5% CO2 humidified incubator at 37^C. Supernatants were
harvested at various times of culture, centrifuged at 13000rpm for 5 minutes to remove 
non-adherent cells and stored at -20°C until assayed for cytokine content.
Cytokine production was quantified using sandwich ELISA techniques, for 
which optimal conditions had previously been established in the laboratory. Enhanced
3 1
Lymphoid cells resuspended at 10^/ml in complete medium were added in 
400p.l aliquots to 24-well tissue culture plates (Costar), either alone or with OVA, PPD
'1
protein-binding 96-well plates (Immulon 4; Dynatech) were coated overnight at 4®C 
with 50|Lil of monoclonal anti-cytokine antibody (Table 1) in O.IM NaHCOg buffer
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(pH8.2, Appendix 1). The plates were then washed twice with PBS/0.05% Tween 20, 
before non-specific binding was blocked by incubation with 200ftl of PBS/IO%FCS 
for 1 hour at 37<^ C. After two washes, 50p,l/well of neat culture supernatant was added 
to quadmplicate wells, while doubling dilutions of standard recombinant murine 
cytokine (Table 2) in PBS/10% FCS, was added to duplicate wells. The plates were 
then incubated for 3 hours at 37^C and washed four times before 50p,l/well 
biotinylated anti-murine cytokine antibody (Table 1) diluted in PBS/10% FCS was 
added. After incubation for 1 hour at 37^C, the plates were then washed six times and 
100|il/well extravidin-peroxidase (Sigma) diluted 1:1000 in PBS/10% FCS was added. 
After further incubation for 1 hour at 37^C, the plates were washed eight times before 
addition of 100p.l/well of TMB substrate. The plates were read at 630nm (reference 
filter 405nm) using a MR5000 automatic microplate reader. Cytokine concentrations 
in test supernatants were determined with reference to a standard curve, constructed 
using serial dilutions of the standard cytokines and analysed using Mikrotek software 
(Dynatech).
2.12 Phenotypic Analysis of Lymphocytes bv Flow Cvtometrv
10^ lymphoid cells freshly prepared in a single cell suspension were 
resuspended in plastic conical tubes (Falcon, Cowley Oxford, U.K.) in 50pl staining 
buffer (SB, Appendix 1) and stained with the antibodies shown in Table 3. Biotinylated
antibodies were detected using FITC-SAV or PE-SAV and all staining reactions were 
performed for 20 minutes on ice. Between steps, cells were washed once in 2ml FACS 
Buffer (Appendix 1) by centrifugation for 5 minutes at 1200rpm. After staining, cells 
were washed twice in FACS Buffer and any red blood cells present were lysed by 
resuspending in 1ml FACSLyse (diluted 1:10 in distilled water; Becton Dickson, San 
Jose, CA, U.S.A.) at room temperature for 10 minutes. After a final wash in 1ml 
PBS, cells were resuspended in 0.5ml of ice cold FACSFlow (Becton Dickson) and
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analysed using a FACS can IV flow cytometer (Becton Dickson). A 488nm argon ion 
laser was used to detect green and red fluorescence, while dead cells were excluded 
from analysis by gating on forward and side light scatter properties. The data were 
analysed using Lysis II softwai'e (Becton Dickinson). In all experiments, negative 
control samples were cells incubated with FITC-Streptavidin or PE-Streptavidin in the 
absence of any primary antibody.
2.13 Adoptive Transfer of OVA specific Transgenic T Cells
BALB/c mice were adoptively transferred with D O ll.lO  TCR transgenic T 
cells as described by Kearney et al (143) A single cell suspension of TCR transgenic 
lymph node and spleen cells from D O ll.lO  mice was made as described above, the 
percentage of KJl-26'^ cells present calculated by flow cytometry and mice were 
injected with 3 x 10^ KJ1-26+CD4+ cells intravenously in a volume of 0.3ml saline. 
Recipient mice in any given experiment were age- and sex- matched.
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2.14 Statistical Analysis
Results ai'c represented as the mean ±  1 SEM where indicated and were 
analysed using Student's t-test.
IgG isotypes were not normally distributed and were compared using
Wilcoxon's Rank test.
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Table 1: Monoclonal Antibodies used in Cytokine Sandwich ELIS As 
(i) Capture Antibodies
All of the above monoclonal antibodies were purchased from PharMingen, San Diego, 
U.S.A.
Specificitv Clone Isotvpe Cone. tp.g/mn 'l!■ÿ,
Murine IL2 JES6-1A12 Rat IgG2a 2 1
Murine IL3 MP2-8F8 Rat IgGl 2 j
Murine JLA BVD4-1D11 Rat IgG2b 2
v3..;
Murine EL5 TRFK5 Rat IgGl 4 ;iaMurine ELIO JES5-2A5 Rat IgGl 4 1Murine IFNy R4-6A2
(ii) Biotinylated Detecting Antibodies
Rat IgGl 2 «:V
:
2.Specificitv Clone Isotvpe Cone, tpg/mn
Murine EL2 IES6-5H4 Rat IgG2b 1
Murine EL3 MP2-43D11 Rat IgG2a 1
Murine EL4 BVD6-24G2 Rat IgGl 1 Î
Murine EL5 TRFK4 Rat IgG2a 4
....1
Murine ELIO SXC-1 Rat IgM 2 ■Î
IÎ.3-Muirne IFNy XMG1.2 Rat IgGl 1
34 I
Table 3: Primary Antibodies used In Flow Cytometric Analysis
Specificity Clone Isotype
Anti-CD4 was obtained from Pharmingen and anti-KJl-26 was obtained from Marc 
Jenkins, Minneapolis, U.S.A. and both were used at 1:25 dilutions in staining buffer.
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Table 2: Recombinant Murine Cytokine Standards used in Sandwich ELIS As
Cytokine Source
DL2 Pharmingen
DL3 Genzyme, West Mailing, Kent.
IL4 Genzyme
IL5 Genzyme
.ILIO and IFNy Both gifts from Prof. F.Y. Liew,
Department of Immunology, University of 
Glasgow.
PE-antLmurine CD4 (L3T4) GK1.5 RatIgG2a
biotinylated-anti-murine KJ1-26 KJl-26 Mouse IgG2a
#
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Coating Buffer 
O.lMNaHCOs
Add 8.4g NaHCOs to 11 ddH20 and allow to dissolve, then pH to 8.2
0.05M Carbonate Buffer
1.6g Na2C03
2.95g NaHCOs
Add to 11 ddH20 and pH to 9.3
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Appendix 1: Buffers
Phosphate Buffered Saline TPBSl 
80.0g NaCl 
11.6g Na2HP04 
2.0g KH2PO4
2.0g KCl
Initially add to 7 litres distilled water (ddH20: Purite Prestige Analyst HP water 
purifier, Purite Ltd., Bandet Way, Thame, Oxon). Stir and allow to dissolve, then pH 
to 7.0 and make up to a final volume of 10 litres.
■IO.IM Carbonate Buffer 
3.2g Na2C03 
5.9g NaHC03
Add to 11 ddH20 and pH to 9.3
.1
'33%
PBS containing:
10% foetal bovine serum (GibcoBRL), 
0.05% (w/v) sodium azide (Sigma)
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Staining Buffer 
PBS containing:
10%normal goat serum (Sigma),
:
lOpg/ml purified anti-mouse CD 16/32 (Fcylll/II Receptor) monoclonal 
antibody (clone 2.4G2, rat IgG2b,K) (Pharmingen),
0.05% (w/v) sodium azide (Sigma)
FACS buffer
‘
I
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3.2 Experimental Protocol
BALB/c mice were immunised s.c. with OVA/CFA on dO and oral tolerance 
was induced by feeding mice OVA at various times thereafter. As controls, sepai’ate 
groups were fed 25mg OVA 10 days before immunisation, in a standard oral tolerance 
protocol. Control mice were fed saline. Systemic immune responsiveness was 
assessed by measuring antigen specific proliferation and production of IFNy and EL4 
and 5 in the draining popliteal lymph nodes 14 days after the original immunisation and
3 8
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Chapter3 Oral Tolerance in Primed Mice
3.1 Introduction
Despite the success of oral tolerance in several models of autoimmune disease, 
most experimental studies on the induction of oral tolerance have used naive animals 
and little is known about the immunoregulatory mechanisms induced when antigen is 
fed to primed animals. The limited work that has been done found that feeding OVA to 
systemically primed mice suppressed subsequent DTH responses better than humoral 
immunity and indicated that tolerance was induced better by high doses of antigen 
given soon after immunisation (124,125). Also, recent work on oral tolerance in 
established experimental acute encephalomyelitits (EAE) concluded that the frequency 
of feeding, rather than the dose of antigen was the most important factor in determining 
the efficacy of the tolerising regime (131). However, the mechanisms have not been 
explored in any detail and only a limited scope of responses has been examined. The 
aim of my thesis was to apply recent insights into the mechanisms of oral tolerance in 
naive mice to investigate the equivalent phenomena in primed animals.
The experiments described in this chapter were designed to establish a model 
for inducing oral tolerance to OVA in mice with an established systemic immune 
response to OVA. Thus I examined a variety of antigen doses administered at different 
times after priming with OVA/CFA and investigated the scope of responses influenced 
by the tolerance. .
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3.3 Results
'M
I
by assessing serum antibody levels and OVA-specific DTH responses 20 days after 
immuniscïtfofl-
3.3.1 Effects of Feeding OVA Before or After Priming on Subsequent Effector 
Functions
■I
3.3.1.1 In Vivo Responses
As expected from previous studies, the OVA-specific DTH responses of mice 
fed 25mg OVA 10 days prior to priming were significantly lower than those of 
immunised controls. Mice fed the same dose of OVA 7 days after priming also had 
DTH responses lower than those of controls, but this was not statistically significant 
(Fig 3.1).
The OVA-specific total IgG serum antibody levels of mice fed 25mg OVA 
before or after priming were not significantly lower than those of immunised controls 
(Fig 3.2a). OVA-specific IgG serotype levels, IgGl and IgG2a, were also measured 
but no significant tolerance was found in either of the OVA fed groups (Fig 3.2b and c
.respectively).
3.3.1.2 In Vitro Responses
Cell-mediated immunity in vitro was measured by OVA-specific proliferation 
and cytokine production of PLN cells.
The OVA specific proliferative responses of PLN cells taken from mice fed 
OVA before immunisation were significantly lower than those of control mice (Fig 
3.3). These mice also had suppressed production of IFNy, IL4 and IL5 (Fig 3.4a,b and 
c). These results confirm previous studies in the lab and demonstrate that this regime of 
oral tolerance affects both Th I and Th 2 responses in naive animals. IFNy production
!
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3.3.2 Effect of Feeding Time on Oral Tolerance in Primed Mice
In the first experiments, I examined whether primed mice could be tolerised 
more readily if the interval between immunisation and feeding was altered. Therefore, I 
fed 25mg OVA 2, 4 or 8 days after immunisation on dO with OVA/CFA.
3.3.2.1 In Vivo Responses
The OVA-specific DTH responses of mice fed 25mg OVA 2 days after 
priming were significantly lower than those of immunised controls. Significant OVA- 
specific DTH tolerance was not found in mice fed 25mg OVA 4 or 8 days after 
priming, although these responses were both somewhat lower than those of controls 
(Fig 3.5). There appeared to be a high variability in these groups, with some mice being 
profoundly tolerant and others showing normal responses (data not shown).
The OVA-specific total IgG antibody levels of mice fed 25mg OVA 2, 4 or 8 
days after priming were not significantly lower than those of immunised controls (Fig 
3.6a). OVA-specific IgGl and IgG2a antibody responses were also not reduced in 
mice fed OVA at any time after immunisation, except the IgGl response of mice fed 
on d2 (Fig 3.6b and Fig 3.6c respectively).
3.3.2.2 In Vitro Responses
OVA specific proliferative responses of PLN cells taken from mice fed OVA 2 
or 4 days after immunisation were significantly lower than those of control mice, but.
4 0
was also significantly tolerised in mice fed OVA after immunisation, but IL4 or IL5 
production was not (Fig 3.4a, b and c).
The results of this preliminary experiment indic£«ted that it might be possible to 
induce oral tolerance in previously primed mice but that this was not as profound as 
that found when antigen is fed to naive mice and affects a narrower range of systemic 
responses. I therefore went on to examine if I could improve this tolerance by 
modifying the dose of fed antigen or the time of feeding. %
'f
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mice fed 8 days after priming no longer had significant tolerance of their proliferative 
responses (Fig 3.7), OVA specific IFNy and IL5 production by PLN cells taken from 
mice fed OVA 2 or 4 days after immunisation was also significantly lower than that of 
control mice but mice fed 8 days after priming only had significantly reduced IL5 
production (Fig 3,8). OVA specific IL4 production was measured but no tolerance was 
ever found and therefore the data is not shown subsequently.
Thus, oral tolerance of both in vivo and in vitro responses is induced more 
readily when antigen is fed soon after priming.
3.3.3 The Role of Antigen Dose and Feeding Frequency in Oral Tolerance in
i
J-
Primed Mice.
Previous studies in which antigen was fed after priming suggested that oral 
tolerance was more profound when higher doses of antigen or multiple feeds of antigen 
were used. I therefore examined a number of protocols of tolerance induction in which 
I fed a variety of single doses of OVA (2, 25, 200, 400mg) 7 days after priming, or in 
which I administered five feeds of 5mg or 25mg starting 7 days after priming.
;.v
.
3.3.3.1.1 In Vivo Responses
In the first study, the effects of feeding 2-200mg OVA 7 days after priming 
were compared with 25mg fed 10 days before as a control. In a separate experiment, I 
examined a single feed of 400mg given on d+7.
All groups of OVA fed mice had significantly suppressed DTH responses 
compared with controls with the exception of those fed 2mg 7 days after priming. This 
tolerance was greatest in mice fed before immunisation, but there was a dose dependent 
increase in tolerance in mice fed increasing doses of OVA after priming, with 400mg 
having almost as much effect as 25mg before priming (Fig 3.9a and b).
A similar pattern was seen when antibody responses were examined. Total IgG 
antibody levels as well as OVA-specific IgGl and IgG2a antibodies were significantly 
suppressed in mice fed 25mg OVA 10 days before priming (FigS.lOa, Fig3.11a and
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Fig 3.12a respectively) and mice fed 400mg after priming had significantly suppressed 
total IgG antibody levels (Fig3.10b, FigS.llb and Fig 3.12b). Consistent with the 
previous results in this chapter, no OVA-specific antibody tolerance was found with 
any other feeding regime, although there was some evidence that total IgG responses 
were decreasing at higher doses of OVA (Fig3.10, Fig3.11 and Fig 3.12).
1
3.3.3.1.2 In Vitro Responses
All doses of fed OVA given before or after priming significantly suppressed 
subsequent OVA specific proliferative responses and there was little evidence of a clear 
dose response in the mice fed 2-400mg OVA after priming (Fig 3.13a,b). As expected, ■
OVA specific IFNy and IL5 production were significantly reduced in mice fed OVA 
10 days before immunisation (Fig 3.14a and Fig 3.15a). OVA specific IFNy 
production was also significantly reduced in all groups of mice fed OVA after 
immunisation, with the exception of those fed 25mg 7 days after priming. OVA 
specific IL5 production was also significantly lower than that of control mice in all 
these groups except for mice fed 400mg (Fig 3.15b).
Thus, increasing the dose of fed antigen given after immunisation enhances the 
degree and scope of oral tolerance, although there is not always a clear dose response 
and certain aspects of the immune response, such as humoral immunity, remain 
relatively resistant. I therefore proceeded to investigate whether more frequent feeding 
of antigen would increase tolerance.
3.3.3.2.1 In Vivo Responses
In the first experiment I administered five feeds of 5 mg starting 7 days after 
priming and in the second experiment I administered five feeds of 25mg starting 7 
days after priming.
In both experiments, OVA fed mice had significantly suppressed DTH 
responses compared with controls, although this appeai'ed to be more marked in mice 
fed 5 X 25mg OVA. Consistent with the previous results in this chapter, no OVA-
4 2
specific antibody tolerance was found with either of the feeding regimes (Fig3.17, 
Fig3.18and Fig 3.19).
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3.3.3.2.2 In Vitro Responses
Both doses of OVA given after priming significantly suppressed subsequent 
OVA specific proliferative responses and again this was more marked when mice were 
fed 5 X 25mg rather than 5mg (Fig 3.20a,b). OVA specific IFNy and IL5 production 
was also significantly reduced in both groups of mice fed OVA after immunisation 
(Fig 3.21 and 3.22). Mice fed 5mg appeared to have more suppressed IFNy responses 
when compared with mice fed 25mg, however, mice fed 25mg appeared to have more 
suppressed EL5 responses when compared with mice fed 5mg.
Thus, multiple feeding of antigen given after immunisation does not enhance 
the degree and scope of oral tolerance induced when compared to feeding a single dose 
of antigen, although multiple feeding of high doses of antigen did however, seem to 
cause slightly better suppression, on the whole, than that of low doses.
s3.3.4 Time Course of OVA-Specific IgG Production in Mice Primed with 
OVA/CFA.
To investigate whether the reduction of tolerance in mice fed 7 days after 
priming compared with feeding eaiiier after priming coincided with the appearance of 
OVA-specific antibody in the semm I immunised mice w ith  OVA/CFA and assessed 
the serum levels of TctdL OVA-specific IgG (Figure 3.23). Here it is shown that 
antibody does appear in the semm 7 days after priming.
3.4 Conclusions
Here I have confirmed that it is possible to induce tolerance by feeding antigen 
to primed mice, with DTH responses, proliferation and IFNy production being readily 
tolerised. However, the degree and scope of tolerance were less than that found in 
equivalent dose fed before immunisation. For example, Tiq2 cytokine production and
■if
antibody responses were not as tolerisable when antigen is fed after priming compared 
with antigen fed before priming. In contrast to previous reports, I also found that only a 
brief time window was available after priming when mice were susceptible to induction 
of tolerance, which in my hands, was in order of a week. In an attempt to enhance 
tolerance, I fed higher single doses of antigen and increased frequency of feeding. 
Generally this did result in more intense and wider tolerance, although this was still less 
than in mice fed before priming. Together, these results illustrate the difficulty in 
tolerising a primed immune system and in subsequent chapters, I went on to examine 
the reasons why this should be the case and what the mechanisms responsible for the 
tolerance might be.
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Figure 3.1 Induction of Oral Tolerance by Feeding Antigen Before or After 
Immunisation.
Systemic DTH responses in mice given a single feed of 25mg OVA 10 days 
before immunisation or 7 days after subcutaneous immunisation with OVA/CFA, and 
in saline fed controls measured 21 days after immunisation. The results shown are 
mean specific increments in footpad thickness ± 1 SD for 5 mice per group. (*p<0.05 
versus controls)
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Figure 3.2 Induction of Oral Tolerance by Feeding Antigen Before or After 
Immunisation.
(a) OVA-specific total serum IgG antibody responses in mice given a single 
feed of 25mg OVA 10 days before immunisation or 7 days after subcutaneous 
immunisation with OVA7CFA, and in saline fed controls measured 21 days after 
immunisation. The results shown are mean % of purified IgG standard ± 1 SD for 
individual sera from 5 mice per group, (b) OVA-specific serum IgGl and (c) XgG2a 
antibody responses in control and OVA fed mice. The results shown are the reciprocal 
dilutions which give an OD equal to 5% of that given by a standard serum from 
hyperimmunised control mice for 5 mice per group.
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Figure 3.3 Induction of Oral Tolerance by Feeding Antigen Before or After 
Immunisation.
OVA-specific proliferative responses in draining lymph nodes of mice given a 
single feed of 25mg OVA 10 days before immunisation or 7 days after subcutaneous 
immunisation with OVA7CFA, and saline fed controls. The results shown are mean 
uptake of ^H-TdR ± 1 SD for quadruplicate cultures of lymph node cells pooled from 
3 mice per group. (*p<0.005 versus controls)
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Figure 3.4 Induction of Oral Tolerance by Feeding Antigen Before or After 
Immunisation.
Antigen specific IFN-y (a), IL4 (b) and IL5 (c) production by draining 
popliteal lymph node cells of mice given a single feed of 25mg OVA 10 days before 
immunisation or 7 days after subcutaneous immunisation with OVA/CFA, and saline 
fed controls. The results shown are mean cytokine levels (U/ml) ± 1 SD of triplicate 
samples from supernatants of cells pooled from 3 mice per group cultured in vitro for 
2-4 days. There was little or no production of cytokines from cells cultured in the 
absence of antigen. (*p<0.01 versus controls, **p<0.005 versus controls)
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Figure 3.5 Effects of Feeding Antigen at Different Times After Immunisation on 
Systemic Immune Responses.
Systemic DTK responses in mice given a single feed of 25mg OVA 2, 4 or 8 
days after subcutaneous immunisation with OVA/CFA, and in saline fed controls 
measured 21 days after immunisation. The results shown aie mean specific 
increments in footpad thickness ± 1 SD for 5 mice per group. (*p<0.005 versus 
controls)
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Figure 3.6 Effects of Feeding Antigen at Different Times After Immunisation on 
Systemic Immune Responses.
(a) OVA-specific total serum IgG antibody responses in mice given a single 
feed of 25mg OVA 2, 4 or 8 days after subcutaneous immunisation with OVA/CFA, 
and saline fed controls measured 21 days after immunisation. The results shown are 
mean % of purified IgG standard ± 1 SD for individual sera from 5 mice per group,
(b) OVA-specific serum IgGl and (c) IgG2a antibody responses in control and OVA 
fed mice. The results shown are the reciprocal dilutions which give an OD equal to 5% 
of that given by a standard serum from hyperimmunised control mice for 5 mice per 
group (*p<0.05 versus controls)
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Figure 3.7 Effects of Feeding Antigen at Different Times After Immunisation on 
Systemic Immune Responses.
OVA-specific proliferative responses in draining lymph nodes of mice given a 
single feed of 25mg OVA 2, 4 or 8 days after subcutaneous immunisation with 
OVA/CFA, and saline fed controls. The results shown are mean uptake of ^H-TdR ± 1 
SD for quadruplicate cultures of lymph node cells pooled from 3 mice per group. 
(*p<0.005 versus controls)
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Figure 3.8 Effects of Feeding Antigen at Different Times After Immunisation on 
Systemic Immune Responses.
Antigen specific IFN-y and IL5 production by draining popliteal lymph node 
ceils of mice given a single feed of 25mg OVA 2, 4 or 8 days after subcutaneous 
immunisation with OVA/CFA, and saline fed controls. The results shown are mean 
cytokine levels (U/ml) ± 1 SD of triplicate samples from supernatants of cells pooled 
from 3 mice per group cultured in vitro for 2-4 days. There was little or no production 
of cytokines from cells cultured in the absence of antigen. (*p<0.05 versus controls, 
**p<0.01 versus controls, ***p<0.005 versus controls)
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Figure 3.9 Effects of Feeding Different Doses of Antigen After Immunisation on 
Systemic DTH Responses.
Systemic DTH responses in mice given a single feed of 2, 25 or 200mg OVA 
(a) or 400mg OVA (b) 7 days after subcutaneous immunisation with OVA/CFA, and 
in saline fed controls measured 21 days after immunisation. The results shown are 
mean specific increments in footpad thickness ± 1 SD for 5 mice per group. (*p<0.05 
versus controls, **p<0.005 versus controls)
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Figure 3.10 Effects of Feeding Different Doses of Antigen After Immunisation on
Total OVA-Specific IgG Production.
Total primary OVA-specific serum IgG responses in mice given a single feed
of 2, 25 or 200mg OVA (a) or 400mg OVA (b) 7 days after subcutaneous 
immunisation with OVA/CFA, and in saline fed controls measured 21 days after 
immunisation. The results shown are mean % of purified IgG standard ± 1 SD for 
individual sera from 5 mice per group. (*p<0.02 versus controls, **p<0.005 versus 
controls)
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Figure 3.11 Effects of Feeding Different Doses of Antigen After Immunisation on
OVA-Specific IgGl Production.
OVA-specific serum IgGl responses in mice given a single feed of 2, 25 or 
200mg OVA (a) or 400mg OVA (b) 7 days after subcutaneous immunisation with 
OVA/CFA, and in saline fed controls measured 21 days after immunisation. The 
results shown are the reciprocal dilutions which give an OD equal to 5% of that given 
by a standard serum from hyperimmunised control mice for 5 mice per group and the 
reciprocal dilutions were done in duplicate. (*p<0.05 versus controls)
5  8
I
I
"'33I
:;r
=4:3;:
9
£3Vn0)(0
Q
s?
U )
il
a<5O)
cücoü
£3V-0W
(/)
ô?
LO
II
(0
CMO
D )
C
Ucoü
100001 (a)
1000 :
100:
10 I ■ I  • " I ..■ I • j —~
Control 2 5 m g d -1 0  2m g d+7 25m g d+7 200m g d+7
1 0 0 0 0 ]
1000:
100
(b )
Control Fed After:d7 400m gOVA
Figure 3.12 Effects of Feeding Different Doses of Antigen After Immunisation on
OVA-Specific IgG2a Production.
OVA-specific serum IgG2a responses in mice given a single feed of 2, 25 or 
200mg OVA (a) or 400mg OVA (b) 7 days after subcutaneous immunisation with 
OVA/CFA, and in saline fed controls measured 21 days after immunisation. The 
results shown are the reciprocal dilutions which give an OD equal to 5% of that given 
by a standard serum from hyperimmunised control mice for 5 mice per group and the 
reciprocal dilutions were done in duplicate. (*p<0.05 versus controls)
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Figure 3.13 Effects of Feeding Different Doses of Antigen After Immunisation on
OVA-Specific Proliferation.
OVA-specific proliferative responses in draining lymph nodes of mice given a 
single feed of 2, 25 or 200mg OVA (a) or 400mg OVA (b) 7 days after subcutaneous 
immunisation with OVA/CFA, and saline fed controls. The results shown are mean 
uptake of ^H-TdR ± 1 SD for the last 24 hours of culture in quadmplicate cultures 
from lymph node cells pooled from 3 mice per group. (*p<0.02 versus controls, 
**p<0.005 versus controls)
'1
I:
6 0
it
I
O)c
40 ~
Controld-10 25mg OVA 
d+7 2mg OVA d+7 25mg OVA 
d+7 200mg OVA
3 0 -
20"
10 -
5040 60 70 80 9 0 100
Time In Culture (Hours)
30 1
20 -
C3Î
C
10"
(b )
Controld+7 400mg OVA
40 50 60 70 80 90 1 00
Time in Culture (hours)
Figure 3.14 Effects of Feeding Different Doses of Antigen After Immunisation on 
OVA-Specific IFNy Production.
Antigen specific IFNy production by draining lymph nodes of mice given a 
single feed of 2, 25 or 200mg OVA (a) or 400mg OVA (b) 7 days after subcutaneous 
immunisation with OVA/CFA, and saline fed controls. The results shown are mean 
cytokine levels (ng/ml) ± 1 SD of triplicate samples from supernatants of cells pooled 
from 3 mice per group cultured in vitro for 2-4 days. There was little or no production 
of IFNy from cells cultured in the absence of antigen. (*p<0.05 versus controls, 
**p<0.005 versus controls)
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Figure 3.15 Effects of Feeding Different Doses of Antigen After Immunisation on
OVA-Specific IL5 Production.
Antigen specific IL5 production by draining lymph nodes of mice given a
single feed of 2, 25 or 200mg OVA (a) or 400mg OVA (b) 7 days after subcutaneous 
immunisation with OVA/CFA, and saline fed controls. The results shown are mean 
cytokine levels (U/ml) ± 1 SD of triplicate samples from supernatants of cells pooled 
from 3 mice per group cultured in vitro for 2-4 days. There was little or no production 
of IL5 from cells cultured in the absence of antigen. (*p<0.001 versus controls)
6 2
f
(a)
0 .4
S 0 .3  i  E 0)o c
•aC3a+-»ooLL
O
0.2-
0.1 -
o0)aW 0.0
C ontrol: S a lin e  
F ed  After: 5x5m gO V A
Group
x>
(QQ .
OOU .
ÜEü0)aw
0 .3 0 -
0.20-
0.10-
0.00
C ontrol: S a lin e
F ed  After: 5x25m gO V A
Group
Figure 3.16 Effects of Different Antigen Feeding Regimes on Systemic DTH 
Responses in Primed Mice.
Systemic DTH responses in mice given 5 single feeds of 5mg OVA (a) or 
25mg OVA (b) starting 7 days after subcutaneous immunisation with OVA/CFA, and 
in saline fed controls measured 21 days after immunisation. The results shown aie 
mean specific increments in footpad thickness ± 1 SD for 5 mice per group. (^=p<0.005 
versus controls)
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Figure 3.17 Effects of Different Antigen Feeding Regimes on Total OVA-Specific
IgG Production in Primed Mice.
Total primary OVA-specific serum IgG responses in mice given 5 single feeds
of 5mg OVA (a) or 25mg OVA (b) starting 7 days after subcutaneous immunisation 
with OVA/CFA, and in saline fed controls measured 21 days after immunisation. The 
results shown are mean % of purified IgG standard ± 1 SD for individual sera from 5 
mice per group.
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Figure 3.18 Effects of Different Antigen Feeding Regimes on OVA-Specific IgG l
Production in Primed Mice.
OVA-specific serum IgGl responses in mice given 5 single feeds of 5mg 
OVA (a) or 25mg OVA (b) starting 7 days after subcutaneous immunisation with 
OVA/CFA, and in saline fed controls measured 21 days after immunisation. The 
results shown are the reciprocal dilutions which give an OD equal to 5% of that given 
by a standard serum from hyperimmunised control mice for 5 mice per group and the 
reciprocal dilutions were done in duplicate.
65
-VS
E3
(D«
QKCO
10000 1 (a)
I
U )
(Q
Cg
'■M(Qk.■+-'
C0)ocoü
Ë3la0)woI—CO
10
II
(0CMC5
D)
cucoü
1000 -
100
loooon
Control Fed After:5x5mgOVA 
Group
1000
(b)
I
Control Fed After:5x25mgOVA 
Group
Figure 3.19 Effects of Different Antigen Feeding Regimes on OVA-SpeciDc
IgG2a Production in Primed Mice.
OVA-specific serum IgG2a responses in mice given 5 single feeds of 5mg 
OVA (a) or 25mg OVA (b) starting 7 days after subcutaneous immunisation with 
OVA/CFA, and in saline fed controls measured 21 days after immunisation. The 
results shown are the reciprocal dilutions which give an OD equal to 5% of that given 
by a standard serum from hyperimmunised control mice for 5 mice per group and the 
reciprocal dilutions were done in duplicate.
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Figure 3.20 Effects of Different Antigen Feeding Regimes on OVA-Specific
Proliferation in Primed Mice.
OVA-specific proliferative responses in draining lymph nodes of mice given 5
single feeds of 5mg OVA (a) or 25mg OVA (b) starting 7 days after subcutaneous 
immunisation with OVA/CFA, and in saline fed controls. The results shown aie mean
uptake of ^H-TdR ± 1 SD for the last 24 hours of culture in quadruplicate cultures 
from lymph node cells pooled from 3 mice per group. (*p<0.02 versus controls, 
"^*=p<0.005 versus controls, **"*^p<0.001 versus controls)
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Figure 3.21 Effects of Different Antigen Feeding Regimes on OVA-Specific IFNy
Production in Primed Mice.
Antigen specific IFNy production by draining lymph nodes of mice given 5
single feeds of 5mg OVA (a) or 25mg OVA (b) starting 7 days after subcutaneous 
immunisation with OVA/CFA, and in saline fed controls. The results shown are mean 
cytokine levels (ng/ml) ± 1 SD of triplicate samples from supernatants of cells pooled 
from 3 mice per group cultured in vitro for 2-4 days. There was little or no production 
of IFNy from cells cultured in the absence of antigen. (*p<0.005 versus controls, 
**p<0.001 versus controls)
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Figure 3.22 Effects of Different Antigen Feeding Regimes on OVA-Specific IL5 
Production in Primed Mice.
Antigen specific IL5 production by draining lymph nodes of mice given 5 
single feeds of 5mg OVA (a) or 25mg OVA (b) staiting 7 days after subcutaneous 
immunisation with OVA/CFA, and in saline fed controls. The results shown are mean 
cytokine levels (U/ml) ± 1 SD of triplicate samples from supernatants of cells pooled 
from 3 mice per group cultured in vitro for 2-4 days. There was little or no production 
of IL5 from cells cultured in the absence of antigen. (*p<0.05 versus controls, 
**p<0.02 versus controls, ***p<0.01 versus controls)
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Figure 3.23 Time Course of OVA-Specific IgG Production in Mice Primed with 
OVA/CFA.
Total primary OVA-specific serum IgG responses in mice over 3 weeks after 
subcutaneous immunisation with OVA/CFA. The results shown are mean % of 
purified IgG standard for individual sera from 5 mice per time point.
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Chapter4 Longevity of Oral Tolerance In Mice Fed Antigen After Systemic 
Priming
4.1 Introduction
The experiments in the previous chapter show that feeding after systemic 
priming results in tolerance of some in vivo and in vitro immune responses. If oral
J:"tolerance is to be used as a therapy, the antigen specific suppressive effects will need to 
be long lasting. Previous studies in naive mice found that several parameters of the
systemic immune responses remained tolerant for up to 17 months after feeding (178) 
and, in this chapter, I investigated how long tolerance persisted after a single feed of 
25mg OVA given 7 days after priming.
4.2 Experimental Protocol
BALB/c mice were immunised s.c. with OVA/CFA on dO and oral tolerance 
was induced by feeding mice 25mg OVA on d+7. Control mice were fed saline after 
immunisation. 7 days after feeding, PLN were taken and Ag specific proliferation and 
cytokine production was assessed. 14 days after feeding, mice were bled for 
assessment of serum antibody levels. Three separate groups of mice were then used. 
The first group were challenged immediately with HAO in the opposite footpad for 
measurement of DTH responses. Two further groups were given a secondary 
immunisation 6 and 12 months later with OVA/CFA in the base of the tail and their 
PLN taken 7 days later for in vitro assessment. Serum antibodies and systemic DTH 
were measured 14 days after the secondary immunisation,
4.3 Results
4.3.1 Persistence of Oral Tolerance in vivo
OVA-specific DTH responses were significantly reduced in mice fed OVA 
when examined 14 days after feeding confirming the results in Chapter 3 (Fig 4.1a).
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4.3.2.2 Cytokine Production
In contrast to my previous findings, OVA-specific IFNy production was not 
significantly reduced in mice examined 14 days after feeding compared with controls
7 2
%
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However, by 6 and 12 months after immunisation, there was no tolerance of specific 
DTH responses in OVA fed mice (Fig4.1b+c).
At the first time point examined, the serum levels of total OVA-specific IgG, 
IgGl and XgG2a antibodies were not significantly reduced by feeding 25mg OVA after 
immunisation, confirming my previous results (Figs 4.2a, 4.3a, and 4.4a). As might 
be expected from this finding, none of the antibody responses were tolerant in mice 
examined 6 months (Figs 4.2b, 4.3b, and 4.4b) or 12 months (Figs 4.2c, 4.3c, and 
4.4c) after feeding.
4.3.2 Persistence of Oral Tolerance in vitro
Cell-mediated immunity in vitro was measured by OVA-specific proliferation 
and cytokine production of PLN cells.
4.3.2.1 Proliferative Responses
As expected from my previous findings, OVA-specific proliferation was 
significantly tolerised in the OVA fed mice examined 14 days after feeding (Fig 4.5a). 
By 6 months, this tolerance was no longer present (Fig 4.5b) and at 12 months, the 
proliferative response of the OVA fed group was significantly increased compared 
with unfed controls (Fig 4.5c). This priming of the proliferative response in OVA fed 
mice was confirmed by the fact that OVA-specific proliferation was still present in 
PLN cells taken from mice in which DTH responses had been measured, whereas 
responses in immunised control mice had disappeared by this time (Fig 4.5d). Thus 
proliferative tolerance is lost by six months after feeding.
, 1
•is
ï(Fig. 4,6a). However, at 6 months and 12 months after feeding, IFNy production was 
significantly suppressed in OVA fed mice.
OVA-specific IL5 production was significantly primed in OVA fed mice 
examined at 14 days (Fig. 4.7a). However, IL5 production was significantly reduced in 
mice examined at 6 months (Fig. 4.7b) before returning to control levels at 12 months.
4.4 Conclusions
The results presented in this chapter indicate that the oral tolerance induced 
when antigen is fed after immunisation is not as long lasting as that found in naive 
mice, where several parameters remained tolerised for up to 17 months./n vivo 
tolerance was only found early after feeding, when antigen specific DTH responses 
were suppressed with controls. DTH responses were normal at later time points and 
antibody responses were not tolerised at any time after feeding, confirming my initial 
findings in Chapter 3.
Some aspects of the in vitro response showed longer lasting tolerance however. 
Thus IFNy production remained tolerant in OVA fed mice for 12 months after 
feeding, although the inteipretation of these findings is complicated by the fact this 
function was not inhibited at the earliest time as I would have expected. The reason for 
this discrepancy is unknown and time did not permit me to repeat the experiment. 
Similarly, the experiment in the current chapter indicated that IL5 production was 
primed early after feeding, whereas it had been unaffected in my first experiments. This 
underlines the possible resistance of Th2 responses to feeding antigen but it should be
noted that IL5 production was tolerised at 6 months, before returning to normal at 12 
months. OVA-specific proliferation was found to be tolerised at the first time point but 
then returned to. conW levels by 6 month time point. Surprisingly, the proliferative 
response was enhanced in the group fed OVA at the 12 month time point.
Overall, these results suggest that only some aspects of the established immune 
response can be tolerised for any length of time by a single feed of antigen. It seems 
that as in other forms of oral tolerance, IFNy production is particularly sensitive to
7 3
.feeding in primed mice, although my results sugge^ that other aspects such as IL5 
might also be tolerised at different times. Thus oral tolerance is a dynamic phenomenon 
but there is surprisingly little correlation between those aspects which can be tolerised at 
different times. Although this is consistent with previous results in the lab in naive 
mice, it emphasises the unpredictability of tolerance in primed animals.
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Figure 4.1 Time Course of Oral Tolerance in Primed Mice.
Systemice DTH responses in mice given a single feed of 25mg OVA 7 days 
after primary immunisation with OVA/CFA assessed 21 days, 6 months or 12 months 
after primary immunisation. Mice examined at 6 or 12 months received a secondary 
immunisation 21 days before DTH response was assessed. The results shown are 
mean specific increments in footpad thickness ± 1 SD for 5 mice per group. (*p<0.001 
versus controls)
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Figure 4.2 Time Course of Oral Tolerance in Primed Mice.
Total primary OVA-specific serum IgG responses in mice given a single feed 
of 25mg OVA 7 days after primary immunisation with OVA/CFA assessed 21 days, 
6 months or 12 months after primaiy immunisation. Mice examined at 6 or 12 months 
received a secondary immunisation 21 days before semm IgG response was assessed. 
The results shown are mean % of purified IgG standard ± 1 SD for individual sera 
from 5 mice per group. I
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Figure 4.3 Time Course of Oral Tolerance in Primed Mice.
OVA-specific semm IgGl responses in mice given a single feed of 25mg 
OVA 7 days after primary immunisation with OVA/CFA assessed 21 days, 6 months 
or 12 months after primary immunisation. Mice examined at 6 or 12 months received a 
secondary immunisation 21 days before the serum IgGl response was assessed. The 
results shown are the reciprocal dilutions which give an OD equal to 5% of that given 
by a standard serum from hyperimmunised control mice for 5 mice per group and the 
reciprocal dilutions were done in duplicate.
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Figure 4.4 Time Course of Oral Tolerance in Primed Mice.
OVA-specific semm IgG2a responses in mice given a single feed of 25mg 
OVA 7 days after primary immunisation with OVA/CFA assessed 21 days, 6 months 
or 12 months after primary immunisation. Mice examined at 6 or 12 months received a 
secondary immunisation 21 days before the serum IgG2a response was assessed. The 
results shown are the reciprocal dilutions which give an OD equal to 5% of that given 
by a standard serum from hyperimmunised control mice for 5 mice per group and the 
reciprocal dilutions were done in duplicate.
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Figure 4.5 Time Course of Oral Tolerance in Primed Mice.
OVA-specific proliferative responses in mice given a single feed of 25mg 
OVA 7 days after primary immunisation with OVA/CFA assessed 14 days, 6 months 
or 12 months after primary immunisation. Mice examined at 6 or 12 months received a 
secondary immunisation 14 days before proliferation response was assessed. The 
results shown are mean uptake of ^H-TdR ± 1 SD for the last 24 hours of culture in 
quadmplicate cultures from lymph node cells pooled from 3 mice per group. (*p<0.05 
versus controls, **p<0.02 versus controls, ***p<0.005 versus controls)
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Figure 4.6 Time Course of Oral Tolerance in Primed Mice.
Antigen specific IFNy responses in mice given a single feed of 25mg OVA 7 
days after primary immunisation with OVA/CFA assessed 14 days, 6 months or 12 
months after primary immunisation. Mice examined at 6 or 12 months received a 
secondary immunisation 14 days before IFNy response was assessed. The results 
shown are mean cytokine levels (U/ml) + 1 SD of triplicate samples from supernatants 
of cells pooled from 3 mice per group cultured in vitro for 2-4 days. There was little or 
no production of IFN-yfrom cells cultured in the absence of antigen. (*p<0.05 versus 
controls)
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Figure 4.7 Time Course of Oral Tolerance in Primed Mice.
Antigen specific IL5 responses in mice given a single feed of 25mg OVA 7 
days after primary immunisation with OVA/CFA assessed 14 days, 6 months or 12 
months after primary immunisation. Mice examined at 6 or 12 months received a 
secondary immunisation 21 days before IL5 response was assessed. The results shown 
are mean cytokine levels (U/ml) ± 1 SD of triplicate samples from supernatants of cells 
pooled from 3 mice per group eultured in vitro for 2-4 days. There was little or no 
production of IL-5 from cells cultured in the absence of antigen. (*p<0.05 versus 
controls, **p<0.001 versus controls)
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Chapters The Role of IL4 and IL12 in Oral Tolerance in Primed Mice
p.
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I5.1 Introduction
The experiments in chapters 3 and 4 showed that feeding antigen after systemic 
priming results in in vivo and in vitro tolerance of several aspects of the systemic 
immune response. In these experiments it was impossible to tolerise antibody 
responses and in some cases, IL5 production was more difficult to tolerise than IFNy. 
This contrasts with the findings in naive mice from our laboratory (57) and could 
suggest that Th2 responses are unusually resistant to oral tolerance induction in primed 
mice. Some workers have reported that Th2 dependent responses may also be
relatively preserved in orally tolerised naive mice and have suggested that IL4 
dependent Th 2 cells may act as active suppressor cells under their conditions 
(188,200). Thus, I decided to investigate whether Th 2 cells were necessary for oral 
tolerance in primed mice by examining the effects of feeding OVA to EL4~/" mice 
which had been immunised with OVA/CFA.
A further active regulatory mechanism which has been implicated in oral 
tolerance is the release of TGFp by a discrete subset of T cells. This is proposed to 
operate primarily when oral tolerance has been induced when multiple low doses of 
antigen are administered to mice (170,190,200,205) and it has been suggested that 
TGFp and IFNy play opposing roles in the regulation of mucosal immune responses 
(214,215). This idea is supported by the fact that IFNy dependent gut inflammation 
caused by TNBS or CD45RBhiCD4+ T cells in scid mice can be prevented by TGFP- 
secreting T cells (171,172) and by the ability of anti-IL12 to enhance oral tolerance. I 
therefore decided to investigate if I could exploit this proposed regulatoiy axis to 
improve oral tolerance in primed mice, by feeding antigen to mice lacking IL12 (IL12" 
/-). As these mice have deficient production of IFNy, it would be predicted that this 
would allow the development of enhanced TGFP responses and might increase 
susceptibility to oral tolerance compared with wild type mice. I therefore examined oral
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tolerance in naive IL12~/" mice using protocols which might be likely to involve TGFp- 
dependent mechanisms.
5.3 Results
5.3.1 Effects of Feeding OVA Before or After Priming on Subsequent Effector 
Functions in IL4~^ " mice
5.3.1.1 In vivo Responses
As I found previously in BALB/c mice (Chapter 3), OVA-specific DTH 
responses of YLA~^ ~ mice fed OVA before or after priming were significantly lower 
than those of immunised controls and there was no difference between the different 
doses of OVA fed after priming (Fig 5.1).
OVA-specific total IgG and IgG2a antibody levels were reduced by feeding 
25mg OVA before immunisation of IL4"/" mice but not by any of the doses of OVA 
fed after priming, except in mice fed 200mg OVA, where there was a significant
9 0
5.2 Experimental Protocol
EL4"/" mice were challenged s.c. with OVA/CFA on dO and oral tolerance was 
induced by feeding mice either 25mg OVA 10 days prior to immunisation or by 
feeding 2, 25 or 200mg OVA 7 days after immunisation. Control IL4"/" mice were fed 
saline after immunisation. p40 IL12"/“ BALB/c mice and wild type BALB/c mice were 
challenged s.c. with OVA/CFA on dO and oral tolerance was induced by feeding mice 
either a single dose of 2mg OVA 10 days prior to immunisation, or five feeds of Img 
OVA starting 10 days prior to immunisation or by feeding 25mg OVA 7 days after 
immunisation. In all experiments, OVA specific proliferation and cytokine production 
was assessed 14 days after immunisation, while antibody was assessed 20 days after 
immunisation. On the same day, mice were given HAO in the other rear footpad and 
24 hours later OVA-specific DTH responses were measured.
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ireduction in total IgG production (Figs 5.2 and 5.3). As expected, IL4'/' mice did not 
make any IgGl antibodies (data not shown). Thus, primed IL4"/" mice show similar 
patterns of oral tolerance in vivo to that found in normal animals.
:
5.3.1.2 In vitro Responses
PLN cells from IL4~/" mice fed 25mg OVA before immunisation had 
significant tolerance of OVA-specific proliferation and there was dose dependent 
suppression of these responses in TLA~f~ mice fed 2-200mg OVA after systemic 
immunisation (Fig 5.4), again confirming my findings in normal BALB/c mice.
As expected, PLN cells from unfed IL4"^“ mice made substantial levels of 
OVA-specific IFNy when restimulated in vitro, but produced only low amounts of 
IL5. As I found in BALB/c mice, IL4"/" mice fed before immunisation had suppressed 
IFNy and IL5 responses (Fig 5,5 and 5.6 respectively). However, in primed IL4“/" 
mice, significant suppression of IFNy responses was found only after feeding 200mg 
OVA and not with lower doses (Fig 5.5). Furthermore, in primed IL4“/~ mice, 
significant suppression of the already low IL5 responses was found only after feeding 
200mg OVA, but not with lower doses (Fig 5.6). Indeed, mice fed 2 and 25mg OVA 
had increased IL5 production compared with saline fed controls. Thus the defective 
Th2 cytokine production in IL4“/~ mice is relatively resistant to induction of oral -
tolerance in primed animals.
Together these results suggest that the pattern of tolerance in primed 1L4“/" mice 
is generally similar to that in normal animals, although some small differences may 
exist.
9 1
9 2
5.3.2 Effects of Feeding OVA Before or After Priming on Subsequent Effector 
Functions in IL12"/~ mice
1
5.3.2.1 In vivo Responses
Wild type BALB/c mice fed either a single low dose of 2mg OVA or 5x1 mg 
OVA before priming had significant tolerance of OVA-specific DTH responses, as did 
mice fed 25mg OVA after priming, confirming my previous results in Chapter 3 (Fig
5.7). Saline fed IL12“/" mice made good DTH responses and these were tolerised in 
mice fed 2rag OVA once or 5x1 mg OVA before priming. In contrast, IL12-/" mice 
fed 25mg OVA after priming did not have significant tolerance of DTH responses 
compared with saline fed controls, although their responses were somewhat lower (Fig
5.7).
Wild type BALB/c mice fed either a single low dose of 2mg OVA or 5xlmg 
OVA before priming had significant tolerance of OVA-specific total IgG responses, 
but mice fed 25mg OVA after priming did not (Fig 5.8). Saline fed IL12"/" mice made 
good OVA-specific total IgG responses and these were tolerised in mice fed 2mg 
OVA once or 5x1 mg OVA before priming. In contrast, IL12" '^' mice fed 25mg OVA 
after priming did not have significant tolerance of OVA-specific total IgG responses 
compared with saline fed controls (Fig 5.8).
Wild type BALB/c mice fed 5xlmg OVA before priming had significant 
tolerance of OVA-specific IgGl responses, but mice fed either a single low dose of 
2mg OVA before priming or 25mg OVA after priming did not (Fig 5.9). Saline fed 
IL12"/" mice made good OVA-specific IgGl responses and these were tolerised in 
mice fed 2mg OVA once or 5x1 mg OVA before priming, as well as in mice fed 25mg 
OVA after priming (Fig 5.9).
Wild type BALB/c mice fed 5x1 mg OVA before priming had significant 
tolerance of OVA-specificIgG2a responses, but mice fed either a single low dose of 
2mg OVA before priming or 25mg OVA after priming did not (Fig 5.10). Saline fed 
IL12“/“ mice made good OVA-specific IgG2a responses and these were tolerised in
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mice fed 2mg OVA. In contrast, IL12"^" mice fed 5x1 mg OVA before priming or 
25mg OVA after priming did not have significant tolerance of OVA-specific IgG2a 
responses compared with saline fed controls (Fig 5.10).
S.3.2.2 In vitro Responses
Wild type BALB/c mice fed either a single low dose of 2mg OVA or 5xlmg 
OVA before priming had significant tolerance of OVA-specific proliferative responses. 
However, in contrast to my previous results, mice fed 25mg OVA after priming did 
not have significant tolerance (Fig 5.11). Saline fed IL12"/" mice made good OVA- 
specific proliferation responses and these were tolerised in mice fed 5x1 mg OVA 
before priming and in mice fed 25mg OVA after priming. In contrast, IL12“^ " mice fed 
a single low dose of 2mg OVA before priming did not have significant tolerance of 
OVA-specific proliferation responses compared with saline fed controls (Fig 5.11).
In contrast to my previous results, wild type mice did not have tolerance of 
IFNy production after any regime of feeding OVA before or after priming (Fig 5.12). 
However, IL5 production was markedly suppressed in mice fed 2mg OVA once or 
5xlmg OVA before immmunisation and was also significantly reduced in mice fed 
after priming (Fig 5.13).
As expected, IL12"'^ " mice made no OVA-specific IFNy (Fig 5.12), but had 
higher EL5 levels than wild type mice (Fig 5.13). These IL5 levels were very markedly 
suppressed in mice fed before immunisation and were also significantly tolerant in 
mice fed after priming.
Together, these findings indicate that oral tolerance in naive and primed IL12~/" 
mice, despite some individual discrepancies, is generally similar to that in equivalent 
wild type mice.
5.4 Conclusions
The results presented in this chapter confirm previous findings from our 
laboratory that feeding OVA to naive IL4"/" mice results in oral tolerance. I have also
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extended these studies by showing that primed IL4“/" mice develop a pattern of oral 
tolerance similar to that found in normal animals, with suppression of DTH in vivo and 
antigen-specific proliferation in vitro, as well as some suppression of IFNy and IL5 
production in vitro, but no effects on serum antibodies. Thus the partial effects of oral 
tolerance in primed mice do not depend on the presence of IL4 dependent Th2 ceils,
but could reflect another mechanism such as clonal anergy/deletion or an alternative 
active suppressor mechanism.
An alternative active suppressor mechanism that I studied in this chapter was 
TGFp. To do this, I made use of the suggestion that TGFp production is 
downregulated by IL12 and IFNy and examined the induction of tolerance in IL12“/" 
mice. Certain aspects of tolerance were enhanced in IL12“/“ mice compared with wild 
type mice, namely IgGl antibody levels. However, other components of tolerance 
such as total OVA-specific IgG antibody levels were normal and tolerance of OVA- 
specific DTH levels were reduced, and no clear pattern emerged. Therefore, it is 
probably tme to conclude that the absence of IL12 has no overall effect on the induction 
of tolerance induced either before or after immunisation, with no reprodcible 
enhancement of tolerance in primed animals. However, these experiments need to be 
repeated.
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Figure 5.1 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL4"^ " Mice.
OVA-specific DTH responses in mice given a single feed of 25mg OVA 10 
days prior to immunisation or of 2-200mg OVA 7 days after immunisation with 
OVA/CFA. The results shown aie mean specific increments in footpad thickness ± 1 
SD for 5 mice per group. (*p<0.002 versus controls)
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Figure 5.2 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL4“/“ Mice.
Total semm IgG antibody levels in mice given a single feed of 25mg OVA 10 
days prior to immunisation or of 2-200mg OVA 7 days after immunisation with 
OVA/CFA. The results shown are mean % of purified IgG standard ± 1 SD for 
individual sera from 5 mice per group. (*p<0.05 versus controls, "'''*p<0.02 versus 
controls)
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Figure 5.3 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL4"/" Mice.
Total serum IgG2a antibody levels in mice given a single feed of 25mg OVA 
10 days prior to immunisation or of 2-200mg OVA 7 days after immunisation with 
OVA/CFA. The results shown are the reciprocal dilutions which give an OD equal to 
5% of that given by a standard serum from hyperimmunised control mice for 5 mice 
per group and the reciprocal dilutions were done in duplicate. (*p<0.05 versus controls)
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Figure 5.4 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL4"^ " Mice.
OVA-specific proliferation response in mice given a single feed of 25mg 
OVAIO days prior to immunisation or of 2-200mg OVA 7 days after immunisation 
with OVA/CFA. The results shown are mean uptake of ^H-TdR ± 1 SD for the last 24 
hours of culture in quadruplicate cultures from lymph node cells pooled from 3 mice 
per group. (*p<0.002 versus controls,**p<0.001 versus controls)
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Figure 5.5 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL4“^ “ Mice.
OVA-specific IFNy production in mice given a single feed of 25mg OVA 10 
days prior to immunisation or of 2-200mg OVA 7 days after immunisation with 
OVA/CFA. The results shown are mean IFNy level (OD value) ± 1 SD of triplicate 
samples from supernatants of cells pooled from 3 mice per group cultured in vitro for 
4 days. (*p<0.05 versus controls,**p<0.01 versus controls)
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Figure 5.6 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL4"^ " Mice.
OVA-specific IL5 production in mice given a single feed of 25mg OVA 10 
days prior to immunisation or of 2-200mg OVA 7 days after immunisation with 
OVA/CFA. The results shown are mean IL5 level (U/ml) ± 1 SD of triplicate samples 
from supernatants of cells pooled from 3 mice per group cultured in vitro for 3 days. 
(*p<0.05 versus controls, **p<0.002 versus controls)
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Figure 5.7 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL12“^ “ Mice.
OVA-specific DTH responses in wild type and IL12"^“ BALB/c mice fed either 
a single dose of 2mg OVA 10 days prior to immunisation, or five feeds of Img OVA 
starting 10 days prior to immunisation or fed 25mg OVA 7 days after immunisation 
with OVA/CFA. Control mice were fed saline after immunisation. The results shown 
are mean specific increments in footpad thickness ± 1 SD for 5 mice per group. 
(*p<0.01 versus respective saline fed control, **p<0.005 versus respective saline fed 
control, ***p<0.001 versus respective saline fed control)
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Figure 5.8 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL12"/’ Mice.
Total semm IgG antibody levels in wild type and XL 12“^ " BALB/c mice fed 
either a single dose of 2mg OVA 10 days prior to immunisation, or five feeds of Img 
OVA starting 10 days prior to immunisation or fed 25mg OVA 7 days after 
immunisation with OVA/CFA. Control mice were fed saline after immunisation. The 
results shown are mean % of purified IgG standard ± 1 SD for individual sera from 5 
mice per group. (*p<0.05 versus respective saline fed control, **p<0.01 versus 
respective saline fed control, ***p<0.002 versus respective saline fed control)
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Figure 5,9 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL12“^“ Mice.
Total serum IgGl antibody levels in wild type and XL 12"/" BALB/c mice fed 
either a single dose of 2mg OVA 10 days prior to immunisation, or five feeds of Img 
OVA starting 10 days prior to immunisation or fed 25mg OVA 7 days after 
immunisation with OVA/CFA. Control mice were fed saline after immunisation. The 
results shown are the reciprocal dilutions which give an OD equal to 5% of that given 
by a standard serum from hyperimmunised control mice for 5 mice per group and the 
reciprocal dilutions were done in duplicate. (*p<0.05 versus respective saline fed 
control, **p<0.01 versus respective saline fed control)
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Figure 5.10 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL12"/" Mice.
Total semm IgG2a antibody levels in wild type and IL12"/~ BALB/c mice fed 
either a single dose of 2mg OVA 10 days prior to immunisation, or five feeds of Img 
OVA starting 10 days prior to immunisation or fed 25mg OVA 7 days after 
immunisation with OVA/CFA. Control mice were fed saline after immunisation. The 
results shown aie the reciprocal dilutions which give an OD equal to 5% of that given 
by a standard serum from hyperimmunised control mice for 5 mice per group and the 
reciprocal dilutions were done in duplicate. (*p<0.05 versus respective saline fed 
control, **p<0.01 versus respective saline fed control)
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Figure 5.11 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL12"/' Mice.
OVA-specific proliferative responses in wild type and XL 12"'^ " BALB/c mice 
fed either a single dose of 2mg OVA 10 days prior to immunisation, or five feeds of 
Img OVA starting 10 days prior to immunisation or fed 25mg OVA 7 days after 
immunisation with OVA/CFA. Control mice were fed saline after immunisation. The 
results shown are mean uptake of ^H-TdR ± 1 SD for the last 24 hours of culture in 
quadmplicate cultures from lymph node cells pooled from 3 mice per group. (*p<0,05 
versus respective saline fed control,**p<0.01 versus respective saline fed control, 
***p<0.005 versus respective saline fed control)
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Figure 5.12 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL12"^ " Mice.
OVA-specific IFNy production in wild type and DL12"/" BALB/c mice fed 
either a single dose of 2mg OVA 10 days prior to immunisation, or five feeds of Img 
OVA starting 10 days prior to immunisation or fed 25mg OVA 7 days after 
immunisation with OVA/CFA. Control mice were fed saline after immunisation. The 
results shown are mean IFNy level (OD value) ± 1 SD of triplicate samples from 
supernatants of cells pooled from 3 mice per group cultured in vitro for 4 days.
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Figure 5.13 Induction of Oral Tolerance by Feeding Ovalbumin Before or After 
Immunisation in IL12"/" Mice.
OVA-specific IL5 production in wild type and IL12“'^ " BALB/c mice fed either 
a single dose of 2mg OVA 10 days prior to immunisation, or five feeds of Img OVA 
starting 10 days prior to immunisation or fed 25mg OVA 7 days after immunisation 
with OVA/CFA. Control mice were fed saline after immunisation. The results shown 
are mean 1L5 level (U/ml) ± 1 SD of triplicate samples from supernatants of cells 
pooled from 3 mice per group cultured in vitro for 3 days. (*p<0.02 versus respective 
saline fed control, **p<0.002 versus respective saline fed control, ***p<0.001 versus 
respective saline fed control)
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Chapter 6 Effect of F113L in Oral Tolerance in Primed Mice 
6.1 Introduction
My experiments thus far have shown that feeding OVA to systemically primed 
mice results in in vivo and in vitro tolerance. However, the oral tolerance in primed 
mice is not as profound or wide ranging as that found when equivalent amounts of 
antigen are fed to naive mice. This is particularly manifested in the antibody response 
which I have found to be generally resistant to tolerance induction. In Chapter 5, I 
showed that this pattern of tolerance was not influenced by the absence of IL4 or 
upregulation of TGpp in the absence of IL12 and therefore I was interested in finding 
an alternative strategy for enhancing tolerance in primed animals.
The haemopoetic growth factor Flt3ligand (FLT3L) increases the numbers of 
dendritic cells when it is given in vivo and recent work has shown that administration of 
Flt3L to mice enhances the induction of oral tolerance in naive mice (114). This 
affected all aspects of the immune responses and allowed normally non-tolerogenic 
doses of OVA to induce significant tolerance. The rationale for this effect appears to be 
that Flt3L expands the numbers of resting dendiitic cells in the gut which then present 
fed antigen without costimulation to T cells, resulting in more profound anergy and/or 
clonal deletion, and thus function of tolerance. Thus, I decided to test the idea that 
expansion of DCs by Flt3L might also extend the scope of oral tolerance in primed 
mice.
6.2 Experimental Protocol
In the first experiment, BALB/c mice mice were challenged s.c. with 
OVA/CFA on dO and oral tolerance was induced by feeding mice 25mg OVA 8 days 
after immunisation. Control mice were fed saline after immunisation. lOpg Flt3L 
saline was administered i.p. from dl until d9 with saline being injected daily as a 
control. 14 days after immunisation PLN were taken and Ag specific proliferation and 
cytokine production was assessed. 20 days after immunisation mice were bled and
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semm assessed for antibody levels. On the same day mice were given HAO in the 
other rear footpad and 24 hours later OVA-specific DTH responses were measured.
In separate experiments, BALB/c mice mice were challenged s.c. with 
OVA/CFA on dO and oral tolerance was induced by feeding mice 25mg OVA 5 days 
after immunisation with lOjLtg Flt3L being administered from d-2 until d6. PLN were 
taken from d-1 to day 15, while DTH and serum antibodies were assessed as usual.
6.3 Results
6.3.1 Effects of Flt3L on Oral Tolerance in Primed mice
6.3.1.1 In Vivo Responses
OVA-specific DTH responses of mice given saline 
ip and fed OVA 8 days after priming were significantly lower than those of equivalent 
saline fed controls (Fig 6.1). DTH responses in Flt3L treated mice were difficult to
l!
I
:l
interpret due to the fact that saline fed mice given Flt3L had very low DTH responses 
compared with equivalent saline treated controls. OVA fed, Flt3L treated mice had 
DTH responses that were not significantly different.
There was no tolerance of total IgG, IgGl or IgG2a antibodies in 
saline treated mice fed OVA, cons istent with my previous results. Administration of 
FIt3L revealed significant tolerance of total IgG production in OVA fed mice. 
However, there was still no tolerance of either IgGl or IgG2a in Flt3L treated OVA fed 
mice. No effect of Flt3L on humoral immunity reap in saline fed mice >
The total serum levels of OVA-specific IgG were only significantly reduced by 
feeding 25mg OVA after immunisation in the Flt3L treated mice (Fig 6.2). However, 
the OVA-specific IgGl and IgG2a responses of mice fed OVA in the Flt3L treated 
groups were not reduced (Fig 6.3 and 6.4 respectively). In keeping with previous 
results in BALB/c mice, the antibody responses of mice fed after priming in the i.p. 
saline treated groups were not tolerised.
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6.3.2 Effects of FU3L on Early Induction of Oral Tolerance in Primed Mice.
In these experiments, mice were fed OVA 5 days after immunisation and given 
FltSL or saline ip from d-2 to d+6.
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6.3.1.2 In Vitro Responses
As before, saline treated mice fed 25mg OVA after immunisation had 
significant tolerance of proliferative responses in vitro (Fig 6.5). There was also 
significant tolerance of proliferative responses in OVA fed, FltSL treated mice 
compared witli the appropriate controls^  despite the fact that FltSL markedly suppressed 
the response in saline fed controls.
Saline treated mice fed OVA after immunisation had no tolerance of IFNy 
responses compared with controls, supporting my previous findings when primed 
mice were fed OVA 8 days after immunisation (Fig6.6). FltSL had no significant effect 
on IFNy responses in saline fed mice and did not reveal tolerance after feeding OVA. 
Significant tolerance of IL5 production in both saline treated mice fed OVA, while both 
groups of FltSL treated mice had very low IL5 production inespective of whether they 
were fed OVA or noi(Fij CT)>
The fact that FltSL appeared to suppress systemic immune responses to 
OVA/CFA meant that it was difficult to determine the influence of this treatment on 
tolerance. Such effects of FltSL have not been described previously and somewhat 
surprisingly given the fact that FltSL expands dendritic cells, a procedure which one 
might anticipate would increase immunity. One possible explanation for my findings 
was that the systemic immune responses peaked more rapidly in FltSL treated mice 
and to test this idea, I decided to reduce the length of the experiment by feeding mice 
sooner after immunisation. In addition, I assessed the time course of the developing 
immune response in OVA fed and control mice given FltSL.
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6.3.2.1 In Vivo Responses
As I had found previously, OVA-specific DTH responses of mice given saline 
ip and fed OVA 5 days after priming were significantly lower than those of equivalent 
saline fed controls (Fig 6,8). Unlike the previous experiment, DTH responses in FltSL 
treated mice were okay to interpret due to the fact that saline fed mice given FltSL had 
DTH responses compaiable with equivalent saline treated controls. OVA fed, FltSL 
treated mice had DTH responses that were not significantly reduced compared to  
their saline fed controls.
As for the DTH responses, the total semm levels of OVA-specific IgG were 
significantly reduced by feeding 25mg OVA after immunisation in both the saline and 
the FltSL treated mice (Fig 6.9). A significant reduction in serum IgG caused by 
feeding OVA to saline te ted  mice was surprising since I do not normally find that 
feeding 25mgOVA 5 days after priming significantly reduces serum IgG. 
Administration of FltSL slightly enhanced the OVA-specific IgG tolerance at this time- 
point. Consistent with my previous findings, feeding OVA Sdaje after priming to 
saline treated mice did not significantly reduce IgGl or IgG2a production compared 
with stfLine fed controls. However, OVA-specific IgG2a, but not IgGl, responses of 
mice fed OVA in the FltSL treated groups were significantly reduced (Fig 6.10 and 
6.11 respectively). These results do suggest that administration of FltSL in this 
experiment did enhance oral tolerance induction compared with saline treated controls.
6.5.2.2 In Vitro Responses
Saline treated mice fed OVA after priming had significant tolerance of OVA- 
specific proliferation responses compared with controls when examined at both 8 (Fig 
6.12a) and 14 days after immunisation, when the systemic response was at its peak 
(Fig 6.12b). FltSL treated mice fed saline had normal proliferative responses 8 days 
after immunisation, but by 14 days, the responses of these animals were significantly 
reduced compared with saline treated controls. On day 8, OVA fed RtSL treated mice
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had much higher proliferative responses compared with saline fed mice, On. day 14, the 
two groups had identical responses.
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Saline treated mice fed OVA after priming had significant tolerance of OVA-
specific IFNy production compared with controls when examined 14 (Fig 6.13b) but 
not 8 days after immunisation (Fig 6.13a). Saline treated mice that were fed saline 
produced equivalent levels of IFNy when compared with mice that were Flt3L treated 
and fed saline at both 8 and 14 days after immunistion. The production of IFNy 
appealed to be slightly greater 8 days compared with 14 days after immunisation thus
suggesting that the peak of the IFNy production was 8 days after immunisation no
matter whether mice were treated with saline or Flt3L. Flt3L treated mice fed OVA had 
significant tolerance of OVA-specific IFNy production both 8 and 14 days after 
immunisation. This suggeststhat treatment with Flt3L enhanced IFNy tolerance.
Saline treated mice fed OVA after priming did not have significant tolerance of 
OVA-specific IL5 production compared with controls when examined at both 8 (Fig 
6.14a) and 14 days after immunisation (Fig 6.14b) which is in keeping with previous 
findings that IFNy responses are easier to tolerise than IL5 responses. Saline treated 
mice that were fed saline produced much reduced levels of IL5 when compared with 
mice that were Flt3L treated and fed saline at both 8 and 14 days after immunistion. As 
was found for IFNy production in the Flt3L treated mice, IL5 production was greater 8 
days compared with 14 days after immunisation suggesting that the peak of the IL5
production was 8 days after immunisation. Flt3L treated mice fed OVA had significant
-tolerance of OVA-specific BL5 production both 8 and 14 days after immunisation. As 
was found with IFNy production, this suggests that treatment with Flt3L enhanced ÎL5 
tolerance.
These results show that administration of FltSL to mice can enhance oral 
tolerance induced in mice fed OVA after immunisation compared with mice treated 
with saline, in terms of IFNy and IL5 production. In view of this significant tolerance 
observed in Flt3L treated mice fed OVA it is somewhat surprising that these mice had 
very high proliferative responses 8 days after immunisation even when compared with
Î
saline treated mice that were fed saline. This may, however, suggest that these cells
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from mice fed OVA and treated with FltSL are undergoing some form of activation 
and expansion before being deleted in a manner similar to that described for AICD. 
This might imply that FltSL may enhance oral tolerance induced when antigen is fed 
after immunisation.
6.3.3 Kinetics of Oral Tolerance Development in Flt3L Treated Primed Mice
%
As the results of the previous experiments suggested that the effects of FltSL 
might depend on the time immune responsiveness was assessed, I carried out a more 
detailed time course of proliferative responses in primed mice fed OVA and treated 
with FltSL or saline. In this experiment, mice were treated with saline or FltSL ip from 
d-2 until d+6. Mice were fed saline or OVA on d+5 and lymph nodes were removed 4,
6,8, IS and 20 days after immunisation. s
Four days after immunisation (1 day before feeding saline) both saline fed mice 
treated with saline or FltSL had similar OVA-specific proliferation responses (Fig 
6.15). Six days after immunisation, mice treated with saline and fed saline or OVA 
both had similar proliferative responses. However, eight days after immunisation
which appeared to be the peak of the response, mice fed OVA and treated with saline 
had significantly reduced proliferation responses when compared with the equivalent 
mice fed saline. Thirteen days after immunisation mice fed OVA and treated with 
saline had more significantly reduced proliferation responses, compared to that found 
eight days after immunisation, than the appropriate mice fed saline . The level of 
suppression at this timepoint was the same as found in previous experiments. Twenty 
days after immunisation mice fed OVA and treated with saline only had slightly 
suppressed proliferation responses when compared to saline fed mice treated with 
saline. At all the time points looked at it did not appear that FltSL increased or reduced 
proliferation responses when the responses of mice fed saline were compared.
l i s
6.4 Conclusions
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Six days after immunisation there was a significant increase in the proliferation 
response of cells taken from mice fed OVA and treated with FltSL when compared 
with cells from mice fed saline and treated with FltSL. This appeared to be the peak of 
the proliferation response of cells from both groups of mice. As this is two days earlier 
than those cells taken from mice treated with saline these results further suggest that 
FltSL increases the kinetics of the immune response to immunisation with OVA/CFA. 
By eight days after immunisation the proliferation response of cells taken from mice 
fed saline or OVA and treated with FltSL were exactly the same. However, IS days 
after immunisation, the proliferation response of cells taken from mice fed OVA were 
significantly reduced when compared with mice fed saline and also treated with FltSL. 
This tolerance was shortlived however, as by 20 days after immunisation the 
proliferation response of mice fed OVA were not significantly different when 
compared with appropriate mice fed saline.
These results confirm the results of the previous experiment in this chapter in 
that treating mice with FltSL slightly alters the kinetics of the response compared with 
saline treated controls. This is because it would appear that the peak of the proliferation 
response of FltSL treated mice is achieved slightly more quickly than saline treated 
mice. Further, this experiment shows that feeding OVA to FltSL treated mice results in 
a burst of proliferation eaiiy after feeding which then results in a significantly reduced 
proliferation response later after immunisation when compared with saline fed, FltSL 
treated control mice. This was also found in the previous experiment. $
Results show that expanding DCs with FltSL does not interfere with the 
induction of oral tolerance in primed mice, confirming previous results in naive 
animals. FltSL actually enhanced the induction of tolerance in some instances and 
occasionally allowed tolerance of some responses not normally susceptible to 
tolerance, such as antibody production. However, the effects of FltSL were quite
variable, probably reflecting the influence that administration of FltSL had on the level 
and the speed of the systemic immune responses after challenge with OVA/CFA. It 
proved difficult to determine precisely the best time course and protocol for examining 
the effects of FltSL on oral tolerance in primed mice and I did not have time to extend 
these studies to obtain definitive results.
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Figure 6.1 Effects of F113L on the Induction of Oral Tolerance in Primed Mice.
Systemic DTH responses in mice given a single feed of 25mg OVA 8 days 
after subcutaneous immunisation with OVA/CFA, and in saline fed controls measured 
21 days after immunisation. Mice were treated with saline or lOpg Flt3L daily from dl 
until d9. The results shown are mean specific increments in footpad thickness ± 1 SD 
for 5 mice per group. (*p<0.05 versus appropriate saline fed control)
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Figure 6.2 Effects of Fit3L on the Induction of Oral Tolerance in Primed Mice.
OVA-specific total serum IgG antibody responses in mice given a single feed 
of 25mg OVA 8 days after subcutaneous immunisation with OV/V/CFA, and in saline 
fed controls measured 21 days after immunisation. Mice were treated with saline or 
lOjig FltSL daily from dl until d9. The results shown are mean % of purified IgG 
standard ± 1 SD for individual sera from 5 mice per group. (*p<0.05 versus 
appropriate saline fed control)
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Figure 6.3 Effects of Flt3L on the Induction of Oral Tolerance in Primed Mice.
OVA-specific serum IgGl antibody responses in mice given a single feed o f 
25mg OVA 8 days after subcutaneous immunisation with OVA/CFA, and in saline 
fed controls measured 21 days after immunisation. Mice were treated with saline or 
lOjig FltSL daily from dl until d9. The results shown are the reciprocal dilutions which 
give an OD equal to 5% of that given by a standard serum from hyperimmunised 
control mice for 5 mice per group.
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Figure 6.4 Effects of FltSL on the Induction of Oral Tolerance in Primed Mice.
OVA-specific serum IgG2a antibody responses in mice given a single feed of 
25mg OVA 8 days after subcutaneous immunisation with OVA/CFA, and in saline 
fed controls measured 21 days after immunisation. Mice were treated with saline or 
lOjag FltSL daily from dl until d9. The results shown are the reciprocal dilutions which 
give an OD equal to 5% of that given by a standard serum from hyperimmunised 
control mice for 5 mice per group.
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Figure 6.5 Effects of FltSL on the Induction of Oral Tolerance in Primed Mice,
OVA-specific proliferative responses in draining lymph nodes of mice given a 
single feed of 25mg OVA 8 days after subcutaneous immunisation with OVA/CFA, 
and in saline fed controls measured 14 days after immunisation. Mice were treated with 
saline or 10|ig FltSL daily from dl until d9. The results shown are mean uptake of ^H- 
TdR ± 1 SD for the last 24 hours of culture in quadmplicate cultures from lymph node 
cells pooled from 3 mice per group. (*p<0.01 versus appropriate saline fed control 
**p<0.005 versus appropriate saline fed control, ***p<0.002 versus appropriate saline 
fed control)
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Figure 6.6 Effects of FltSL on the Induction of Oral Tolerance in Primed Mice.
OVA-specific IFNy production in draining lymph nodes of mice given a single 
feed of 25mg OVA 8 days after subcutaneous immunisation with OVA/CFA, and in 
saline fed controls measured 14 days after immunisation. Mice were treated with saline 
or 10|Xg FltSL daily from dl until d9. The results shown are mean IFNy level (ng/ml) 
± 1 SD of triplicate samples from supernatants of cells pooled from 3 mice per group 
cultured in vitro for 2-4 days. There was little or no production of IFNy from cells 
cultured in the absence of antigen.
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Figure 6.7 Effects of F113L on the Induction of Oral Tolerance in Primed Mice.
OVA-specific IL5 production in draining lymph nodes of mice given a single 
feed of 25mg OVA 8 days after subcutaneous immunisation with OVA/CFA, and in 
saline fed controls measured 14 days after immunisation. Mice were treated with saline 
or lOp-g FltSL daily from dl until d9. The results shown are mean IL5 level (U/ml) ± ! 
SD of triplicate samples from supernatants of cells pooled from 3 mice per group 
cultured in vitro for 2-4 days. There was little or no production of IL5 from cells 
cultured in the absence of antigen. (*p<0.005 versus appropriate saline fed control, 
*p<0.001 versus appropriate saline fed control)
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Figure 6.8 Effects of FltSL on the Induction of Oral Tolerance in Primed Mice.
Systemic DTH responses in mice given a single feed of 25mg OVA 5 days 
after subcutaneous immunisation with OVA/CFA, and in saline fed controls measured 
21 days after immunisation. Mice were treated with saline or lOfig FltSL daily from d- 
2 until d+6. The results shown are mean specific increments in footpad thickness ± 1 
SD for 5 mice per group. (*p<0.005 versus appropriate saline fed control) S'
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Figure 6.9 Effects of Flt3L on the Induction of Oral Tolerance in Primed Mice.
OVA-specific total serum IgG antibody responses in mice given a single feed 
of 25mg OVA 5 days after subcutaneous immunisation with OVA/CFA, and in saline 
fed controls measured 21 days after immunisation. Mice were treated with saline or 
lOjLig FltSL daily from d-2 until d+6. The results shown are mean % of purified IgG 
standard ± 1 SD for individual sera from 5 mice per group. (*p<0.05 versus 
appropriate saline fed control, **p<0.01 versus appropriate saline fed control)
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Figure 6.10 Effects of Flt3L on the Induction of Oral Tolerance in Primed Mice.
OVA-specific serum IgGl antibody responses in mice given a single feed of 
25mg OVA 5 days after subcutaneous immunisation with OVA/CFA, and in saline 
fed controls measured 21 days after immunisation. Mice were treated with saline or 
lOjXg FitBL daily from d-2 until d+6. The results shown are the reciprocal dilutions 
which give an OD equal to 5% of that given by a standard serum from 
hyperimmunised control mice for 5 mice per group.
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Figure 6.11 Effects of FltSL on the Induction of Oral Tolerance in Primed Mice.
OVA-specific serum XgG2a antibody responses in mice given a single feed of 
25mg OVA 5 days after subcutaneous immunisation with OVA/CFA, and in saline 
fed controls measured 21 days after immunisation. Mice were treated with saline or 
lOjtg Flt3L daily from d-2 until d+6. The results shown are the reciprocal dilutions 
which give an OD equal to 5% of that given by a standard serum from 
hyper immunised control mice for 5 mice per group. (*p<0.05 versus appropriate saline 
fed control)
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Figure 6.12 Effects of Flt3L on the Induction of Oral Tolerance in Primed Mice.
OVA-specific proliferative responses in draining lymph nodes of mice given a 
single feed of 25mg OVA 5 days after subcutaneous immunisation with OVA/CFA, 
and in saline fed controls measured 8 (a) and 14 (b) days after immunisation. Mice 
were treated with saline or 10p.g Flt3L daily from d-2 until d+6. The results shown are 
mean uptake of ^H-TdR ± 1 SD for the last 24 hours of culture in quadruplicate 
cultures from lymph node cells pooled from 3 mice per group. (*p<0.05 versus 
appropriate saline fed control, **p<0.01 versus appropriate saline fed control, 
***p<0.005 versus appropriate saline fed control)
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Figure 6.13 Effects of FU3L on the Induction of Oral Tolerance in Primed Mice.
OVA-specific IFNy production in draining lymph nodes of mice given a single 
feed of 25mg OVA 5 days after subcutaneous immunisation with OVA/CFA, and in 
saline fed controls measured 8 (a) and 14 (b) days after immunisation. Mice were 
treated with saline or lOjag FltSL daily from d-2 until d+6. The results shown are mean 
IFNy level (OD value) ± 1 SD of triplicate samples from supernatants of cells pooled 
from 3 mice per group cultured in vitro for 2-4 days. There was little or no production 
of IFNy from cells cultured in the absence of antigen. (*p<0.05 versus appropriate 
saline fed control, **p<0.01 versus appropriate saline fed control)
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Figure 6.14 Effects of FIt3L on the Induction of Oral Tolerance in Primed Mice.
OVA-specific EL5 production in draining lymph nodes of mice given a single 
feed of 25mg OVA 5 days after subcutaneous immunisation with OVA/CFA, and in 
saline fed controls measured 8 (a) and 14 (b) days after immunisation. Mice were 
treated with saline or 10|Lig FltSL daily from d-2 until d+6. The results shown are mean 
IL5 level (U/ml) ± 1 SD of triplicate samples from supernatants of cells pooled from 3 
mice per group cultured in vitro for 2-4 days. There was little or no production of IL5 
from cells cultured in the absence of antigen. (*p<0.01 versus appropriate saline fed 
control, **p<0.001 versus appropriate saline fed control)
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Figure 6.15 Effects of FltSL on the Induction of Oral Tolerance in Primed Mice.
OVA-specific proliferative responses in draining lymph nodes of mice given a 
single feed of 25mg OVA 5 days after subcutaneous immunisation with OVA/CFA, 
and in saline fed controls measured 4, 6 ,8 , 13 and 20 days after immunisation. Mice 
were treated with saline or lOjlg FltSL daily from d-2 until d+6. The results shown are 
mean uptake of ^H-TdR ± 1 SD for the last 24 hours of culture in quadruplicate 
cultures from lymph node cells pooled from 3 mice per group. (*p<0.02 versus 
appropriate saline fed control, **p<0.005 versus appropriate saline fed control, 
***p<0.001 versus appropriate saline fed control)
129
Chapter? Use of the Adoptive Transfer System in Oral Tolerance in Primed 
Mice
1 3 0
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I7.1 Introduction
Recently there have been many advances in techniques and experimental 
systems allowing antigen specific T cell responses to be followed in vivo. This is useful 
for my studies because I wanted to look directly at what happened to an established 
antigen-specific immune response when I fed antigen. One of the most useful 
approaches has been to transfer TCR transgenic T cells into normal mice and follow 
them using a clonotypic antibody. The advantage of this system for my studies was 
that I was able to look directly at the expansion and/or deletion of antigen-specific T 
cells when I fed my model antigen, ovalbumin, to mice to try and induce oral tolerance. 
As previous chapters in my thesis have shown that the time the antigen was fed after 
priming effects the oral tolerance induced, another (io(vantage of this system was that it 
enabled me to investigate more thoroughly the effects that feeding antigen had on 
antigen-specific T cells at various stages of a developing immune response. The first of 
these TCR transgenic T cell transfer systems to be described was that using DO 11.10 
transgenic T cells specific for the OVA323-339 immunodominant peptide and I-A^
which are recognised by KJl-26 antibody (143). This has now been widely used to 
study peripheral immune responses and also more recently oral tolerance in naive mice
i
(114,179,180,225).
I thought this might be an appropriate means of studying fate of antigen- 
specific T cells in primed mice fed OVA and also of assessing directly if primed T 
cells are inherently resistant to the induction of oral tolerance. Therefore, I decided to try 
and establish the adoptive transfer model as a means of explaining my model of oral 
tolerance.
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7.2 Experimental Protocol
Normal sex-matched BALB/c mice were adoptively transferred with systemic 
DOl L 10 TCR transgenic T cells as described by Kearney et al (143) The percentage of 
KJ1-26+CD4+ cells present in suspensions of spleen and lymph node DOl 1.10 cells 
was calculated by flow cytometry and mice were injected with 1-3 x 10^ K Jl- 
26"^CD4'*" cells intravenously. 2 days after the adoptive cell transfer, BALB/c mice 
were immunised s.c. with OVA/CFA (dO) and oral tolerance was induced by feeding 
mice OVA at various times thereafter, Control mice were fed saline, and to assess the -■effects of an immunogenic stimulus, additional mice were fed OVA and lOpg cholera 
toxin (CT). The expansion of Ag-specific T cells was then assessed in the drainihg 
PLN by determining the proportions and absolute numbers of KJ1-26+CD4+ T cells. 
Functional responses were assessed after restimulation of these cell suspensions with 
OVA in vitro by measuring antigen specific proliferation and production of IFNy and 
IL5.
7.3 Results
7.3.1 Effects of Oral Tolerance on Primed Antigen-Specific T cells
Mice were transferred with 3 x 10^ KJ1-26‘^ CD4+ cells and two days later 
were immunised with OVA/CFA sc. 1, 2, 3, 4, 7 or 10 days after immunisation mice 
were fed 0.2ml saline, 50mg OVA / 0.2ml saline or 50mg OVA / lOpg CT / 0.2ml 
saline. It is known that the peak of expansion of antigen-specific T cells occurs around 
5 days after immunisation with OVA/CFA. Thus, Wcis jW. at
various times before, during and after this peak of antigen-specific T cell expansion so 
that I could investigate the effects that feeding antigen had on these antigen-specific T 
cells as they respond to immunisation with OVA/CFA . Mice adoptively transfened 
with transgenic T cells would have a larger number of antigen-specific T cells than an 
untransferred animal and so I chose to feed a higher dose of OVA, 50mg, compared 
with my normal feeding dose of 25mg OVA so that there would be enough antigen
1 3 1
presented to all of the transgenic T cells. 1 and 5 days after feeding the percentage and 
function of the KJ1-26+CD4+ cells in the draining PLN of the mice were assessed.
7.3.1.1 Expansion of Primed T cells in vivo After Feeding OVA
The percentage of KJ1-26+CD4+ cells present in the draining lymph nodes of 
mice was assessed at frequent intervals over a period of 13 days after 
feeding/immunisation. In mice fed saline, OVA-specific T cell expansion was apparent 
at the first time point, day 2 after immunisation. This peaked at 3-6 days, before falling. 
This profile was then used as a basis for examining the effects of feeding antigen on the 
kinetics of the evolving response.
When mice were fed soluble OVA 1,2,3,  4, and 7 days after immunisation, 
there was no obvious effect on the kinetics of the developing systemic immune 
response in terms of percentage (Fig7.1a, b, c, d and e) and numbers (Fig7.2a, b, c, d 
and e) of KJ1-26+CD4+. However, feeding OVA 10 days after immunisation led to a 
small but significant reduction in the proportion (Fig7.1f) and absolute numbers 
(Fig7.2f) of KJ1-26+CD4+ cells in the draining lymph at later time points compared 
with saline fed controls. Feeding OVA + CT had no effect on T cell expansion at any 
time.
7.3.1.2 In Vitro Responses
The function of the KJ1-26+CD4+ cells present in the draining lymph nodes of 
the mice in vitro was measured by OVA-specific proliferation at 24 and 72 hours of 
culture to examine for alterations in the kinetics of responsiveness in vitro.
The OVA specific proliferative responses of PLN cells taken from mice fed 
OVA or OVA + CT 1,2,3,  4, and 7 days after immunisation and harvested after 24 
(Fig7.3a, b, c, d and e) and 72hrs (Fig7.4a, b, c, d and e) in culture were not 
significantly different compared with control saline fed mice. However, feeding OVA 
or OVA/CT 10 days after immunisation significantly reduced the OVA specific 
proliferative responses of PLN cells harvested after 24 (Fig7.3f) and 72hr (Fig7.4f) in
I
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culture compared with saline fed controls, whose response had declined more 
markedly by this time.
Thus it would appear that feeding OVA early after immunisation does not alter 
the kinetics of the response of KJ1-26+CD4+ cells to OVA/CFA, feeding OVA to 
mice 10 days after immunisation did reduce the expansion and proliferative capacity of 
primed OVA-specific T cells.
7.3.2 Effects of Feeding High Doses on Adoptively Transferred Primed T Cells
The apparent ability to tolerise primed transgenic T cells late, but not early after 
immunisation, contrasted with my previous results in noimal mice. As I thought this 
might reflect the greater number of OVA specific T cells present in mice adoptively 
transferred mice, I decided to examine the effects of feeding higher doses of antigen.
In these experiments, mice were transferred with 3 x 10^ KJ1-26+CD4+ cells 
and two days later were immunised with OVA/CFA sc. 5 or 12 days after 
immunisation, the mice were fed saline, 200mg OVA or 200mg OVA + lOpg CT and 
the numbers and proliferation of the KJl-26+CD4’^  cells in the draining PLN assessed 
1-7 days later.
7.3.2.1.1 Expansion of Antigen Specific T cells in vivo After Feeding High Doses ■of OVA Early After Immunisation
In the first experiment, T cell expansion in saline fed controls was at its peak at
:the first time of sacrifice, 6 days after immunisation. T cell expansion was significantly 
higher in mice fed soluble OVA 5 days after immunisation immediately after feeding, 
suggesting that this procedure had restimulated primed T cells in the periphery. 
However, there were no differences between the proportions of OVA-specific T cells at 
later times in OVA fed and control mice (Fig 7.5). In addition, the absolute numbers of 
KJ1-26+CD4+ T cells were not significantly altered at any time in OVA fed mice 
(Fig7.6). However, the proportion and number of OVA-specific T cells was 
significantly higher in mice fed soluble OVA + CT 5 days after immunisation
immediately after feeding, suggesting that this procedure had restimulated primed T 
cells in the periphery. As for OVA fed mice, there were no differences between the 
proportions and numbers of OVA-specific T cells at later times in OVA + CT fed and 
control mice.
i
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7.3.21.2 In Vitro Responses of OVA-specific T cells in Mice Fed High Doses of 
OVA Early After Immunisation
Lymph node cells from mice fed OVA 5 days after immunisation showed 
some increased proliferative activity when assessed 1 day after feeding, consistent with 
the increased expansion of KJl-26+CD4+T cells (Figure 7.7). Therefore, proliferative 
responses were normal until 7 days, when significantly suppressed responses were 
observed. Conversely, mice fed OVA + CT had a significant increase in proliferation at 
this time, although these responses were normal at other times.
Because of the apparent tolerance of proliferating T cells in OVA fed primed 
mice, I also measured the OVA-specific IFNy and IL5 production by cells from these 
mice. However, feeding OVA or OVA + CT did not significantly alter IFNy 
(Figure7.8a) or EL5 (Figure7.8b) production compared with saline fed controls.
■
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7.3.2.2.1 Expansion of Antigen Specific T cells in vivo After Feeding High Doses 
of OVA Late After Immunisation
In the second experiment, where I fed 12 days after priming and analysed 1 and 
5 days after feeding, T cell expansion in all the groups would have past its peak in 
response to immunisation. T cell expansion was reduced, but not significantly, in mice 
fed soluble OVA 12 days after immunisation immediately after feeding, suggesting 
that this procedure had reduced the amount of primed T cells in the periphery (Fig 7.9 
and 7.10). However, there were no differences between the proportions or numbers of 
OVA-specific T cells 5 days after feeding in OVA fed and control mice. Further, there
Îa:
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%ii-were no differences between the proportions or numbers of OVA-specific T cells eaily 
or late after feeding in OVA + CT fed and control mice.
73.2.2.2 In Vitro Responses of OVA-specific T cells in Mice Fed High Doses of 
OVA Late After Immunisation
Lymph node cells from mice fed OVA 12 days after immunisation showed 
signi-ficcjrttly decreased proliferative activity when assessed 1 day after feeding, 
consistent with the apparent decreased expansion of KJ1-26+CD4+ T cells at this time 
(Figure 7.11a). However, as for proportion and numbers of OVA-specific T cells.
proliferative responses were unaltered 5 days after feeding, when compared with saline 
fed controls. Mice fed OVA + CT appealed to have slightly decreased proliferation
responses compared with saline fed controls early after feeding. However, mice fed 
OVA + CT had no significant differences in proliferation 1 and 5 days after feeding 
compared with saline fed controls which was also found for the proportion and 
numbers of OVA-specific T cells.
Because of the apparent tolerance of proliferating T cells in OVA fed primed 
mice, I also measured the OVA-specific IFNy and IL5 production by cells from these 
mice 1 and 5 days after feeding. However, feeding OVA or OVA + CT did not 
significantly alter IFNy (Figure7.l3v) or IL5 (Figure?. |3) production compared with 
saline fed controls.
Thus, feeding OVA later after immunisation may induce some degree of 
tolerance in primed T cells, although this may not be a general effect and was only 
partly reproduced by an immunogenic feeding protocol.
7.4 Conclusions
In this chapter I attempted to examine the induction of oral tolerance in primed 
T cells using the adoptive transfer of Ag-specific transgenic T cells. In the first 
experiments, I found that feeding soluble OVA after priming could alter the kinetics of 
T cell expansions, but that this only occurred if feeding was delayed until 10 days. This
135
did not simply appear to be due to re-exposure to antigen, as there was no equivalent 
effect of feeding OVA in an immunogenic manner with CT. In addition, the inhibited 
expansion caused by feeding soluble antigen after priming was accompanied by 
suppressed proliferation responses to OVA. However, these results contrast to my 
earlier findings in normal mice, where tolerance could be induced early, but not late 
after priming. To try and investigate why this might be the case, I fed a higher dose of 
OVA, as I thought the increase in numbers of Ag-specific T cells in transfer recipients 
might complicate the system. These experiments showed again that tolerance might 
occur late after priming but there was still no effect earlier and also functional tolerance 
was variable in that proliferative responses were easier to tolerise than cytokines 
responses. Also, the effects of multiple exposure to antigen on antigen-specific T cells, 
as revealed by feeding OVA + CT, show that this did not radically alter the kinetics and 
level of the primary response to antigen.
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Figure 7.1 Kinetics of Antigen Specific T Cell Expansion After Feeding Antigen 
to Primed Mice
Percentage of KJl-26+CD4"^ cells in the draining lymph nodes of mice 
adoptively transferred with 3 x 10^ KJ1-26+CD4+ cells and given a single feed of 
50mg OVA or 50mg OVA + CT 1(a), 2(b), 3(c), 4(d), 7(e) or 10(f) days after 
subcutaneous immunisation with OVA/CFA, and in saline fed controls. The results 
shown are the mean percentage of KJ1-26+CD4+ cells ± 1 SD in lymph nodes from 2 
mice per group. (*p<0.01 versus controls)
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Figure 7.2 Kinetics of Antigen Specific T Cell Expansion After Feeding Antigen 
to Primed Mice
Numbers of KJ1-26+CD4+ cells in the draining lymph nodes of mice 
adoptively transferred with 3 x 10  ^ KJ1-26+CD4+ cells and given a single feed of 
50mg OVA or 50mg OVA + CT 1(a), 2(b), 3(c), 4(d), 7(e) or 10(f) days after 
subcutaneous immunisation with OVA/CFA, and in saline fed controls. The results 
shown are the mean absolute numbers of KJ1-26+CD4+ cells ± 1 SD in lymph nodes 
from 2 mice per group. (*p<0.05 versus controls, '^*p<0.01 versus controls)
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Figure 7.3 Kinetics of Antigen Specific T Cell Expansion After Feeding Antigen 
to Primed Mice
OVA-specific proliferative responses in the draining lymph nodes of mice 
adoptively transferred with 3 x 10^ KJ1-26+CD4+ cells given a single feed of 50mg 
OVA or 50mg OVA + CT 1(a ), 2(b), 3(c), 4(d), 7(e) or 1 0 (f)  days after subcutaneous 
immunisation with OVA/CFA, and in saline fed controls. The results shown are the 
mean uptake of ^H-TdR ± 1 SD for quadruplicate cultures of lymph node cells from 2 
mice per group after 24 hours in culture. (*p<0.005 versus controls)
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Figure 7.4 Kinetics of Antigen Specific T Cell Expansion After Feeding Antigen 
to Primed Mice
OVA-specific proliferative responses in the draining lymph nodes of mice 
adoptively transferred with 3 x 10^ KJ1-26+CD4+ cells given a single feed of 50mg 
OVA or 50mg OVA + CT 1(a), 2(b), 3(c), 4(d), 7(e) or 10(f) days after subcutaneous 
immunisation with OVA/CFA, and in saline fed controls. The results shown are the 
mean uptake of ^H-TdR ± 1 SD for quadruplicate cultures of lymph node cells from 2 
mice per group after 72 hours in culture. C^p<0.005 versus controls)
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Figure 7.5 Expansion of Antigen Specific T Cells in Mice Fed a High Dose of 
Antigen 5 Days After Priming
Percentage of KJ1-26+CD4+ cells in the draining lymph nodes of mice 
adoptively transfeired with 3 x 10^ KJ1-26+CD4’*' cells given a single feed of 200mg 
OVA or 200mg OVA + CT 5 days after subcutaneous immunisation with OVA/CFA, 
and in saline fed controls, 1 , 2 ,3  and 7 days after feeding. The results shown are the 
mean percentage of KJ1-26+CD44' cells ± 1 SD in lymph node cells from 2 mice per 
group. (*p<0.05 versus controls)
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Figure 7.6 Expansion of Antigen Specific T cells in Mice Fed a High Dose of 
Antigen 5 Days After Priming
Numbers of KJ1-26+CD4+ cells in the draining lymph nodes of mice 
adoptively transferred with 3 x 10^ KJ1-26+CD4+ cells given a single feed of 200mg 
OVA or 200mg OVA + CT 5 days after subcutaneous immunisation with OVA/CFA, 
and in saline fed controls, 1,2,3 and 7 days after feeding. The results shown aie mean 
absolute numbers of KJ1-26+CD4+ cells ± 1 SD in lymph node cells from 2 mice per 
group. (*p<0.005 versus controls)
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Figure 7.7 Expansion of Antigen Specific T cells in Mice Fed a High Dose of
Antigen 5 Days After Priming
OVA-specific proliferative responses in the draining lymph nodes of mice 
adoptively transferred with 3 x 10^ KJ1-26+CD4+ cells given a single feed of 200mg 
OVA or 200mg OVA + CT 5 days after subcutaneous immunisation with OVA/CFA, 
and in saline fed controls, 1(a), 2(b), 3(c) and 7(d) days after feeding. The results 
shown are the mean uptake of ^H-TdR ± 1 SD for quadruplicate cultures of lymph 
node cells from 2 mice per group after 72 hours in culture. (*p<0.05 versus controls)
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Figure 7.8 Expansion of Antigen Specific T cells in Mice Fed a High Dose of 
Antigen 5 Days After Priming
OVA-specific IFNy (a) and IL5 (b) production in the draining lymph nodes of 
mice adoptively transferred with 3 x 10^ KJ1-26+CD4+ cells given a single feed of 
200mg OVA or 200mg OVA + CT 5 days after subcutaneous immunisation with 
OVA/CFA, and in saline fed controls, 7 days after feeding. The results shown are 
mean cytokine levels (Units/ml) ± 1 SD of triplicate samples from supernatants of cells 
from 2 mice per group cultured in vitro for 2-4 days. There was little or no production 
of IFNy or IL5 from cells cultured in the absence of antigen.
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Figure 7.9 Reduction of Antigen Specific T cells in Mice Fed a High Dose of 
Antigen 12 Days After Priming
Percentage of KJl-26+CD4'^ cells in the draining lymph nodes of mice 
adoptively transferred with 3 x 10^ KJ1-26+CD4+ cells and given a single feed of 
200mg OVA or 200mg OVA + CT 12 days after subcutaneous immunisation with 
OVA/CFA, and in saline fed controls. The results shown are the mean percentage of 
KJ1-26+CD4+ cells ± I SD in lymph node cells from 2 mice per group.
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Figure 7.10 Reduction of Antigen Specific T cells in Mice Fed a High Dose of 
Antigen 12 Days After Priming
Numbers of KJ1-26+CD4+ cells in the draining lymph nodes of mice 
adoptively transferred with 3 x 10^ KJ1-26+CD4+ cells given a single feed of 200mg 
OVA or 200mg OVA+ CT 12 days after subcutaneous immunisation with 
OVA/CFA, and in saline fed controls. The results shown are the mean absolute 
numbers of KJ1-26+CD4+ cells ± 1 SD in lymph node cells from 2 mice per group.
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Figure 7.11 Reduction of Antigen Specific T cells in Mice Fed a High Dose of
Antigen 12 Days After Priming
OVA-specific proliferative responses in the draining lymph nodes of mice 
adoptively transferred with 3 x 10^ KJ1-26'*‘CD4+ cells and given a single feed of 
200mg OVA or 200mg OVA+ CT 12 days after subcutaneous immunisation with 
OVA/CFA, and in saline fed controls, 1(a), and 5(b) days after feeding. The results 
shown are the mean uptake of ^H-TdR ± 1 SD for quadruplicate cultures of lymph 
node cells from 2 mice per group after 72 hours in culture. (*p<0.05 versus controls, 
**p<0.01 versus controls)
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Figure 7.12 Reduction of Antigen Specific T cells in Mice Fed a High Dose of 
Antigen 12 Days After Priming
OVA-specific EFNy production in the draining lymph nodes of mice adoptively 
transferred with 3 x 1Q6 KJ 1-26+CD4+ cells and given a single feed of 200mg OVA 
or 200mg OVA -f CT 12 days after subcutaneous immunisation with OVA/CFA, and 
in saline fed controls, 1(a), and 5(b) days after feeding. The results shown are the mean 
cytokine levels (Units/ml) ± 1 SD of triplicate samples from supernatants of cells from 
2 mice per group cultured in vitro for 2-4 days. There was little or no production of 
IFNy from cells cultured in the absence of antigen. (*p<0.05 versus controls, 
**p<0.005 versus controls)
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Figure 7.13 Reduction of Antigen Specific T cells in Mice Fed a High Dose of 
Antigen 12 Days After Priming
OVA-specific BL.5 production in the draining lymph nodes of mice adoptively 
transferred with 3 x 10^ KJ1-26+CD4+ cells and given a single feed of 200mg OVA 
or 200mg OVA + CT 12 days after subcutaneous immunisation with OVA/CFA, and 
in saline fed controls, 1(a), and 5(b) days after feeding. The results shown are the mean 
cytokine levels (Units/ml) ± 1 SD of triplicate samples from supernatants of cells from 
2 mice per group cultured in vitro for 2-4 days. There was little or no production of IL5 
from cells cultured in the absence of antigen. (*p<0.05 versus controls, "*=*p<0.005 
versus controls)
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Chapter 8 Influence of Antigen Persistence and Memory Response on Oral 
Tolerance in Primed Mice 
8.1 Introduction
The results I have obtained thus far have shown that it is hard&rto induce oral 
tolerance of CMI in primed mice than in naive mice and together these findings raise 
doubts about the general applicability of oral tolerance for therapeutic use and I decided 
to investigate some of the possible reasons underlying the resistance of the primed 
immune system to oral tolerance. The factors I considered were the effects of persisting 
antigen and adjuvant activity after initial priming and the possibilities that actively 
expanding or Ag-specific memory T cells were inherently resistant to tolerance 
induction.
To do this, I first fed antigen six weeks after immunisation with OVA/CFA, by 
which time I considered the immune response would be established and T cell 
expansion would have ceased. Under these conditions, there would still be a depot of 
antigen in an immunogenic form and I therefore repeated this experiment by feeding 
antigen six weeks after immunisation with OVA/LPS, where there would not be the 
same residual depot of antigen and adjuvant. Finally, I also assessed the susceptibility 
of antigen-specific memory T cells to tolerance Induction using an adoptive transfer 
model in which primed transgenic T cells were given to normal mice.
8.2 Experimental Protocol
BALB/c mice mice were primed systemically in the footpad with lOOpg OVA 
in 50pl CFA or with lOOpg OVA + 50|Xg LPS in 0.2ml saline subcutaneously at the 
base of the tail on dO and fed 25mg OVA at intervals thereafter. Control mice were fed 
saline after immunisation. 7 days after feeding, PLN were taken and Ag specific 
proliferation and cytokine production was assessed. 14 days after feeding mice were 
bled and semm assessed for antibody levels. On the same day mice were given HAO
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in the other rear footpad and 24 hours later OVA-specific DTH responses were 
measured.
To obtain primed OVA-specific transgenic T cells, BALB/c mice were 
adoptively transferred with DO 11.10 TCR transgenic T cells as described by Kearney 
etal{\A3) Mice were injected with 7.5 x 10^ KJ1-26+CD4+ cells intravenously and
two days later mice were immunised sc wdth OVA/CFA. Two weeks later, lymph 
node cells were prepared from these mice and the percentage of primed KJ1 -26+ cells 
present calculated by flow cytometry and 0.5 x 10° KJ1-26+CD4+ cells were then 
transferred into naive mice. These secondary recipient mice were fed either saline or 
200mg OVA 2 days after receiving the primed Tg T cells and assessed for tolerance 1, 
3 and 5 days after feeding by in vitro proliferation and cytokine production. Control 
groups of naive recipient mice received 0.5 x 10^ naive KJ1-26+CD4+ cells and 
tolerised.
8.3 Results
8.3.1 Effects of Feeding Antigen on Fullv Established Immune Responses.
In the first experiment, I set out to eliminate the possibility that the resistance of 
primed mice reflected the fact that in my experiments I was feeding mice relatively 
soon after priming when it might be anticipated that T cell expansion was proceeding. 
To examine this, mice were fed 25mg OVA 6 weeks after immunisation with 
OVA/CFA by which time the immune response would be fully established.
8.3.1.1 In vivo Responses
Saline fed control mice still had significant DTH and serum IgG responses 
when assessed 8 weeks later, However, mice fed 25mg OVA six weeks after 
immunisation had no significant tolerance of DTH (Figure 8.1), total OVA-specific
I
1 6 0
IgG antibody (Figure 8.2a), IgG I (Figure 8.2b) or IgG2a (Figure 8.2c) antibodies 
compared with controls.
8.3.1.2 In vitro Responses
Proliferation responses were low in saline fed mice by this time point (Figure 
8.3), although these mice still had significant IFNy and DL5 production (Figure 8.4). 
OVA-specific IFNy production was significantly decreased in mice fed OVA
6 weeks after immunisation, but proliferative activity was markedly and significantly 
enhanced in OVA fed animals. OVA-specif/& IL5 production was also significantly 
enhanced, but to a lower extent.
Thus feeding OVA to mice with a fully established immune response does not 
improve tolerance. Indeed, feeding OVA at this time appeared to stimulate a secondary 
response for some aspects of the systemic immune response.
8.3.2 Effects of Feeding OVA After Priming with OVA/LPS on Subsequent 
Effector Functions.
In all the experiments performed thus far, I used CFA as the adjuvant to induce 
systemic immunity. I considered it was possible that the long term resistance of these 
mice to oral tolerance might reflect the depot effect of this adjuvant, with persistently 
high levels of antigen being generated in the context of chronic inflammation and active 
costimulatory activity. To examine this possibility, I primed mice with OVA and LPS 
as a means of administering antigen in an adjuvant without long term depot effects.
8.3.2.1 In vivo Responses
I first examined the induction of tolerance using the protocols I had earned out 
with CFA, by feeding feeding mice 2 or 7 days after priming. Compared with CFA, 
immunisation with OVA and LPS induced lower levels of antigen-specific primary 
immune responses, especially those measured in vivo. DTH responses were
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S.3.2.2 In vitro Responses
OVA + LPS immunised mice had reasonable proliferative responses and IFNy
As oral tolerance was normal early after priming with OVA/LPS, I went on to
There was also no significant tolerance of OVA-specific proliferation (Figure 
,11), IFNy and IL5 production (Figure 8.12).
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reasonable, but antibody production was low. Nevertheless, as with mice primed with 
CFA mice fed 25mg OVA 2 or 7 days after immunisation with OVA + LPS had 
significant tolerance of DTH (Figure 8.5) compared with unfed controls. No significant 
tolerance of total OVA-specific IgG antibody (Figure 7.8a) and OVA-specific IgGl 
(Figure 8.6b) and IgG2a (Figure 8.6c) antibodies was found in any OVA fed mice.
/ IL5 production in vitro. Mice fed 25mg OVA 2 days after immunisation had 
significant tolerance of OVA-specific proliferation (Figure7.7), IFNy and IL5 
production (Figure7.8). However, OVA-specific proliferation was normal in mice fed 
7 days after immunisation, while IFNy production was significantly increased in these 
animals and IL5 production was decreased.
Thus feeding OVA early after immunisation with OVA/LPS results in a pattern 
of tolerance similar to that found when mice are primed using CFA as an adjuvant.
8.3.3 Effects of Feeding OVA Six Weeks After Priming with OVA/LPS on 
Subsequent Effector Functions
feed 25mg OVA 6 weeks after immunisation with OVA/LPS by which time the 
immune response would be fully established and I reasoned that there would be no
lingering effects of the adjuvant.
Under these conditions, OVA-specific DTH responses (Figure 8.9) were 
reduced compared with controls, but there was no significant tolerance of total IgG 
antibody (Figure 8.10a), IgGl (Figure 8.10b) and IgG2a (Figure 8.10c) antibodies.
Thus, as I found earlier when mice were primed with OVA/CFA, feeding 
OVA to mice with a fully established immune response does not improve tolerance. I 
therefore concluded that the difficulty in inducing oral tolerance six weeks after priming 
is not due to a depot of antigen or adjuvant, but rather the presence of an established 
immune response.
8.3.4 Effects of Feeding Antigen on Adoptively Transferred Antigen Experienced 
or Naive Transgenic T Cells
i
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As the results above suggested that the resistance of primed mice to oral 
tolerance was not simply due to persisting antigen, I decided to test the idea that 
activated/memory CD4 T cells were inherently resistant to tolerance induction after
■
initial exposure to a priming dose of antigen. To examine this possibility directly, I 
made use of an adoptive transfer system, in which naive or previously activated OVA- 
specific transgenic T cells were transfened into naive BALB/c mice which were then 
tolerised by feeding 200mg OVA.
8.3.4.1 In vivo and In vitro Responses
Antigen experienced 'memory' cells were obtained from recipients of naive 
DOl 1.10 Tg T cells which had been immunised with OVA/CFA 14 days earlier. This 
protocol for obtaining antigen experienced 'memory' cells is the same as that used by 
Pape, et al who showed that these Tg cells have a reduced expression of CD45RB 
(180).
As controls in this experiment, I adoptively transferred mice with naive 
DOl 1.10 Tg T cells and fed them a tolerogenic dose of OVA, Under these conditions, 
the expansion of Tg T cells was identical to that found in recipients of naive Tg T cells 
fed saline (Figure 8.13), with no evidence of the early expansion and subsequent 
reduction compared with saline fed controls, as has been reported in a previous study 
(179). Flowever, cells isolated 10 days after feeding OVA had reduced proliferative
1 6 3
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responses to OVA in vitro when compared with unfed mice transferred with naive 
cells, confirming the induction of functional tolerance (Figure 8.14d). It should be
noted here that the OVA-specific proliferation results in Figure 8,14c+d are calculated 
per individual Tg T cell present in the cultured population as previously calculated by 
Pape et al for 1L2 production (180). The proliferation results of the whole cultured 
populations follow a similar pattern to those proliferation results calculated per 
individual Tg T cell present in the cultured populations, however, in some cases 
apparent increases or decreases were only significant when calculated one way or the 
other. Thus, I used both methods for calculating OVA-specific proliferation. As 
expected, T cells from mice immunised with an immunogenic protocol of OVA/LPS 
sc after receiving naive cells expanded in peripheral lymphoid tissues and proliferated 
well when restimulated with OVA in vitro.
When antigen experienced 'memory' cells were transfeiTed into secondary 
recipients, only small numbers of these cells could be detected in the peripheral 
lymphoid tissues, especially in the group of secondary recipients examined 10 days 
after feeding. In addition, these cells showed reduced expansion in response to an 
immunogenic challenge with OVA/LPS sc compared with naive Tg cells (Figure 8.13) 
and also had reduced proliferative responses to further restimulation with OVA in vitro 
after in vivo priming with OVA/LPS (Figure 8.14). This poor clonal expansion was not 
surprising given that this was their third exposure to antigen and so confirms the 
'memory' nature of the transferred cells. When memory cells were isolated from saline 
fed secondary recipients at 4 and 10 days, these cells responded to  
restimulation with OVA in vitrons M  cells from recipients of naive Tg cells (Figure 
8.14). Although feeding OVA to the secondary recipients had no effect on the numbers 
or proportions of Tg cells in peripheral lymphoid tissues, there were reduced antigen- 
specific proliferative responses in OVA fed mice 4 days after feeding (Figure 8.14c) 
suggesting that activated/memory CD4 T cells are not inherently resistant to tolerance 
induction. By 10 days after feeding these responses were normal (Figure 8.14d).
I
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8.4 Conclusions
In this chapter I attempted to examine some of the possible reasons underlying
IIr
the resistance of the primed immune system to oral tolerance. In the first experiment, I 
found that feeding OVA to mice with a fully established immune response did not 
improve tolerance. Indeed, feeding OVA at this time appeared to stimulate a secondary 
response for some aspects of the systemic immune response. As I thought this long 
term resistance to oral tolerance might reflect the depot effect of this adjuvant, I decided 
to prime mice with OVA and LPS as a means of administering antigen in an adjuvant
without long term depot effects. I found that feeding OVA early after immunisation 
with OVA/LPS results in a pattern of tolerance similar to that found when mice aie 
primed using CFA as the adjuvant. Next, I went on to find that feeding OVA to mice 
with a fully established immune response to immunisation with OVA/LPS did not 
improve tolerance. Thus, I concluded that the difficulty in inducing oral tolerance six 
weeks after priming was not due to a depot of antigen or adjuvant, but rather the 
presence of an established immune response. Therefore, I decided to test the idea that 
activated/memory CD4 T cells were inherently resistant to tolerance induction after 
initial exposure to a priming dose of antigen. When OVA-specific memory Tg T cells 
were transfeired into secondary recipients, they expanded and proliferated less well 
than naive Tg cells in response to immunogenic challenge in vivo and in vitro. 
However, my experiments showed that the proliferation of these cells could be further 
reduced by feeding a tolerogenic dose of OVA. Thus, I conclude from the experiments 
presented in this chapter that activated/memory CD4 T cells are not inherently resistant 
to orally induced tolerance and that their resistance to tolerance is due to factors present 
in the microenvironment of the primed mouse such as the persistence of antigen or 
presence of costimulation.
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Figure 8.1 Effects of Feeding Antigen Six Weeks After Immunisation on 
Systemic Immunity.
Systemic DTH responses in mice given a single feed of 25mg OVA six weeks 
after subcutaneous immunisation with OVA/CFA, and in saline fed controls measured 
14 days after feeding. The results shown are mean specific increments in footpad 
thickness ± 1 SD for 5 mice per group.
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Figure 8.2 Effects of Feeding Antigen Six Weeks After Immunisation on 
Systemic Immunity.
(a) OVA-specific total serum IgG antibody responses in mice given a single 
feed of 25mg OVA six weeks after subcutaneous immunisation with OVA/CFA, and 
in saline fed controls measured 14 days after feeding. The results shown are mean % of 
purified IgG standard ± 1 SD for individual sera from 5 mice per group, (b) OVA- 
specific IgGl and (c) IgG2a antibody responses in control and OVA fed mice. The 
results shown are the reciprocal dilutions which give an OD equal to 5% of that given 
by a standard serum from hyperimmunised control mice for 5 mice per group.
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Figure 8.3 Effects of Feeding Antigen Six Weeks After Immunisation on 
Systemic Immunity.
OVA-specific proliferative responses in draining lymph nodes of mice given a 
single feed of 25mg OVA six weeks after subcutaneous immunisation with 
OVA/CFA, and in saline fed controls measured 7 days after feeding. The results 
shown are mean uptake of ^H-TdR ± 1 SD for quadruplicate cultures of lymph node 
cells pooled from 3 mice per group. (*p<0.002 versus Control, '*'^p<0.001 versus 
Control)
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Figure 8.4 Effects of Feeding Antigen Six Weeks After Immunisation on 
Systemic Immunity.
OVA-specific IFNy and IL5 production in draining lymph nodes of mice given 
a single feed of 25mg OVA six weeks after subcutaneous immunisation with 
OVA/CFA, and in saline fed controls measured 7 days after feeding. The results 
shown are mean cytokine levels (U/ml) ± 1 SD of triplicate samples from supernatants 
of cells pooled from 3 mice per group cultured in vitro for 2-4 days. (*p<0.05 versus 
Control, **p<0.001 versus Control)
1 7 0
$
:
0 .1 5 -1
T3(0a.
oou.
Ü
‘oa>a.in
■  Control 
m  OVAd+2 
H  O VA d+7
0.10  -
0.05
0.00
Group
Figure 8.5 Effects of Feeding Antigen After Immunisation with OVA/LPS on 
Systemic Immunity.
Systemic DTH responses in mice given a single feed of 25mg OVA 2 or 7 
days after subcutaneous immunisation with OVA/LPS, and in saline fed controls 
measured 21 days after immunisation. The results shown are mean specific increments 
in footpad thickness ± 1 SD for 5 mice per group. (*p<0.005 versus Control, 
*"^p<0.00l versus Control)
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Figure 8.6 Effects of Feeding Antigen After Immunisation with OVA/LPS on 
Systemic Immunity.
(a) OVA~specific total serum IgG antibody responses in mice given a single 
feed of 25mg OVA 2 or 7 days after subcutaneous immunisation with OVA/LPS, and 
in saline fed controls measured 21 days after immunisation. The results shown are 
mean % of purified IgG standard ± 1 SD for individual sera from 5 mice per group,
(b) OVA-specific IgGl and (c) IgG2a antibody responses in control and OVA fed 
mice. The results shown are the reciprocal dilutions which give an OD equal to 5% of 
that given by a standard serum from hyperimmunised control mice for 5 mice per 
group.
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Figure 8.7 Effects of Feeding Antigen After Immunisation with OVA/LPS on 
Systemic Immunity.
OVA-specific proliferative responses in draining lymph nodes of mice given a 
single feed of 25mg OVA 2 or 7 days after subcutaneous immunisation with 
OVA/LPS, and in saline fed controls measured 14 days after immunisation. The 
results shown are mean uptake of ^H-TdR ± 1 SD for quadmplicate cultures of lymph 
node cells pooled from 3 mice per group. (*p<0.002 versus Control, **p<0.001 versus 
Control)
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Figure 8.8 Effects of Feeding Antigen After Immunisation with OVA/LPS on 
Systemic Immunity.
OVA-specific IFNyand IL5 production in draining lymph nodes of mice given 
a single feed of 25mg OVA 2 or 7 days after subcutaneous immunisation with 
OV/VLPS, and in saline fed controls measured 14 days after immunisation. The 
results shown aie mean cytokine levels (U/ml) ± 1 SD of triplicate samples from 
supernatants of cells pooled from 3 mice per group cultured in vitro for 2-4 days. 
(*p<0.01 versus Control, **p<0.005 versus Control)
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Figure 8.9 Effects of Feeding Antigen Six Weeks After Immunisation with 
OVA/LPS on Systemic Immune Responses.
Systemic DTH responses in mice given a single feed of 25mg OVA six weeks 
after subcutaneous immunisation with OVA/LPS, and in saline fed controls measured 
14 days after feeding. The results shown are mean specific increments in footpad 
thickness ± 1 SD for 5 mice per group. C^p<0.05 versus Control)
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Figure 8.10 Effects of Feeding Antigen Six Weeks After Immunisation with 
OVA/LPS on Systemic Immune Responses.
(a) OVA-specific total serum IgG antibody responses in mice given a single 
feed of 25mg OVA six weeks after subcutaneous immunisation with OVA/LPS, and 
in saline fed controls measured 14 days after feeding. The results shown are mean % of 
purified IgG standard ± 1 SD for individual sera from 5 mice per group, (b) OVA- 
specific IgGl and (c) IgG2a antibody responses in control and OVA fed mice. The 
results shown are the reciprocal dilutions which give an OD equal to 5% of that given 
by a standard serum from hyperimmunised control mice for 5 mice per group.
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Figure 8.11 Effects of Feeding Antigen Six Weeks After Immunisation with 
OVA/LPS on Systemic Immune Responses.
OVA-specific proliferative responses in draining lymph nodes of mice given a 
single feed of 25mg OVA six weeks after subcutaneous immunisation with 
OVA/LPS, and in saline fed controls measured 7 days after feeding. The results shown 
are mean uptake of ^H-TdR ± 1 SD for quadruplicate cultures of lymph node cells 
pooled from 3 mice per group.
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Figure 8.12 Effects of Feeding Antigen Six Weeks After Immunisation with 
OVA/LPS on Systemic Immune Responses.
OVA-specific IFNy and IL5 production in draining lymph nodes of mice given 
a single feed of 25mg OVA six weeks after subcutaneous immunisation with 
OVA/LPS, and in saline fed controls measured 7 days after feeding. The results shown 
are mean cytokine levels (U/ml) ± 1 SD of triplicate samples from supernatants of cells 
pooled from 3 mice per group cultured in vitro for 2-4 days.
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Figure 8.13 Effects of Feeding Antigen to Mice Adoptively Transferred with 
Memory or Naive Tg T Cells,
Expansion of OVA-specific transgenic naive or memory T cells in response to 
tolerogenic or immunogenic challenge with OVA in vivo. Mice were transferred with 
0.5 X 10^ memory or naive KJ1-26+CD4’*" cells and 1 day later fed 200mg OVA or
0.2ml saline, or immunised with lOmg OVA + 50pg LPS subcutaneously. The results 
shown are (a) the mean percentage of KJ1-26+CD4+ cells or (b) the total number of 
KJ1-26+CD4+ cells in pooled lymph nodes from 2 individual mice per group ± 1 SD, 
4 and 10 days after feeding or sc immunisation. (*p<0.01 versus naive saline fed 
control, **p<0.005 versus mem saline fed control)
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Figure 8.14 Effects of Feeding Antigen to Mice Adoptively Transferred with 
Memory or Naive Tg T Ceils.
In vitro immune responsiveness of OVA-specific transgenic naive or memory 
T cells in response to tolerogenic or immunogenic challenge with OVA in vivo. Mice 
were transferred with 0.5 x 10^ memory or naive KJ1-26+004"^ cells and 1 day later 
fed 200mg OVA or 0.2ml saline, or immunised with lOmg OVA + 50pg LPS 
subcutaneously. The results shown are the mean OVA-specific proliferative responses 
in lymph nodes pooled from 2 mice/group shown as (a,b) mean uptake of ^H-TdR ± 
1 SD and (c,d) the uptake of ^H-TdR coirected for the numbers of Tg cells ± 1 SD 4 
(a,c) and 10 (b,d) days after feeding. (*p<0.05 versus memory saline fed control, 
**p<0.02 versus memory saline fed control, ***p<0.05 versus naive saline fed 
control)
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Chapter 9 Discussion
9.1 Introduction
The results presented in this thesis have confirmed and extended previous 
findings on the induction of oral tolerance by feeding antigen after priming. In addition, 
they have highlighted several important features of inducing oral tolerance in primed 
mice, many of which differ from the equivalent state in naive mice. My results have 
implications not only for the use of oral tolerance in the treatment of inflammatory 
diseases, but also for understanding the regulation of immune responses to protein 
antigens in vivo.
■M
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9.2 Effects of Feeding Regime on Oral Tolerance in Primed Mice
The usual result of feeding protein antigens to naive animals is the induction of
profound immunological unresponsiveness and this is cun'ently being exploited to treat
inflammatory disease. As the most useful therapeutic application of feeding antigen
would be to suppress established disease, the aim of this study was to compare the
immunological basis of oral tolerance induced by feeding a model antigen to naive and
primed animals. By applying recent insights into immunoregulation and oral tolerance
in naive animals, the experiments described in Chapter 3 were designed to establish a 
,model for inducing oral tolerance to OVA in mice with an established systemic
■ v::immune response. Thus I examined a variety of antigen doses administered at different 
times after priming with OVA/CFA and investigated the scope of responses influenced 
by the tolerance. The refufe ûtChapter 3 showed that feeding 2-200mg ovalbumin 
(OVA) 7 days after immunisation suppressed a wide range of specific immune 
responses in vivo and in vitro. The scope of this tolerance was similar to that found 
when antigen was fed before immunisation, encompassing DTH in vivo, as well as 
proliferation and the production of both T hI and Ty2 cytokines in vitro. However,
there was little or no effect on IgG antibody production and the extent of the tolerance 
in primed mice depended markedly on the dose of antigen fed. These results are similar
s;;::
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to the limited work that had been done previously, which also found that feeding OVA 
to systemically primed mice suppressed subsequent DTH responses better than 
humoral immunity (124,125).
The ability of systemic injection of antigen to induce effective antigen-specific
hyporesponsiveness in the treatment of established organ-specific autoimmune 
diseases has been reviewed recently (226). Passively induced EAE has been 
successfully treated with IV injections of MB? after the induction of disease, but before 
symptoms appeared. The presumed mechanism of protection was peripheral T-cell
apoptosis (227). Conversely ip injections of MBP peptide altered peptide ligand (APL) 
resulted in a shift in cytokine profile to IL4 and active suppression of the Th I mediated
disease (228). MBP or APL given iv has also been shown to suppress actively induced 
EAE after clinical signs of disease have appeared, but the mechanism of protection was
■
not determined (229). Peripheral T cell apoptosis has been proposed to be responsible 
for the protection from actively and passively induced neuritis induced by P2 myelin 
protein given iv after disease induction (230). It is interesting to note that parenterally 
induced protection from experimental autoimmune disease in these studies required 
multiple injections iv or ip of antigen early after the induction of disease. This contrasts
with the single feeds used in earlier oral tolerance work (124).
I:As I also found that tolerance was induced better by high doses of antigen given soon after immunisation (124,125), I decided to examine in more detail the effects of 
feeding a veiy high single dose of antigen and of using regimes of multiple feeding. 
Feeding a single dose of 400mg OVA 7 days after immunisation produced tolerance of 
DTH, proliferation and cytokine production, but also revealed some tolerance of total 
OVA-specific IgG production, which was not found using lower doses of fed antigen. 
However, IgG 1 and IgG2a antibody isotypes were still not tolerised by feeding 400mg 
OVA. In an attempt to enhance tolerance, I increased the frequency of feeding. 
However, multiple feeds of 5x5mg or 5x25mg OVA did not radically alter the scope 
of tolerance, with DTH, proliferation, and IL5 and IFNy production still being 
tolerised, but antibody responses remained generally resistant. Thus, in contrast to other
185
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studies (131), I found that multiple feeds of antigen did not extend significantly the 
scope of tolerance in primed mice, although those responses which were tolerised were 
often suppressed to a more significant degree under these conditions. My findings in 
primed mice also differ markedly from those obtained using naive mice which are 
easier to tolerise by feeding antigen. Even very high single doses of antigen or regimes 
of multiple feeding produced less tolerance in primed mice than in mice fed before 
priming and I would suggest that the most appropriate regime for inducing oral 
tolerance in primed mice might be multiple feeds of greater than 200mg OVA early 
after immunisation.
The resistance of all classes of the antibody responses to tolerance in primed 
mice contrasted with their susceptibility in naive mice in my own and other studies. 
However, it has often been reported that humoral immunity can be more difficult to 
tolerise by feeding antigen than T cell functions (54,64). The reasons for this 
dichotomy remain controversial, but one suggestion in naive mice is that preferential 
upregulation of Th 2 cell activity inhibits Th I activity. However I generally found 
efficient suppression of both Th I and Th 2 dependent cytokine production in both 
naive and primed mice. An alternative possibility to explain the poor tolerance of 
antibody responses is that in primed mice, only T cells and not B cells can be rendered 
tolerant by feeding antigen. This could occur if B cells in immunised mice have already 
been primed by antigen and been exposed to T cell derived cytokines and will therefore 
undergo further expansion when the appropriate antigen is fed. It has been reported that 
B cells are not readily tolerised by feeding antigen and indeed, one report on oral 
tolerance in humans concludes that feeding KLH induced B cell priming but systemic 
T cell tolerance (232). However, an older study has reported that B cells can be 
tolerised by feeding antigen, although this is more difficult than tolerising T cells by the 
same protocol (50).
An important finding of my study was that the effects of feeding after 
immunisation were highly time dependent. Thus DTH, proliferation and cytokine 
production were all suppressed more readily when antigen was fed in the first 2-4 days
1 8 6
after immunisation. This is consistent with previous reports, although the window of
3
susceptibility to induction of tolerance I found (around 7 days) was considerably 
narrower than the 14 days suggested in earlier studies (124,125). In further contrast 
with previous reports, I found only a slight improvement in the tolerance of antibody 
responses if antigen was fed 2 days rather than 8 days after immunisation. This may 
have been due to differences in the dose of antigen and feeding regime used in the
idifferent studies. ■
There could be a number of possibilities why tolerance is more difficult to 
induce in primed mice. One is that in primed animals, the relevant T and B cells have 
already localised in the microenvironment of the germinal centres where they may be 
inherently resistant to tolerance because of their advanced differentiation status, or 
because here they are inaccessible to the tolerogenic antigen derived from the gut. This 
idea is consistent with the fact that germinal centre foimation takes 7 days or more after 
primary immunisation (231), the time at which I found mice became resistant to the 
induction of tolerance. In addition, I found that the loss of tolerance coincided with the 
appearance of primary antibody, supporting previous evidence that semm antibody 
inhibits the induction of oral tolerance by reducing the levels of circulating antigen 
found after intestinal absoiption (123). Mopping up antigen in this way may result in 
very low overall amounts of antigen being available to the immune system, thus 
blunting the effects of feeding different amounts of antigen. This may also explain the 
fact that I did not find a clear dose response when antigen was fed after priming. This 
was surprising in view of the marked dose dependence of oral tolerance in naive 
animals (92,231), but is consistent with recent work on oral tolerance in established 
experimental acute encephalomyelitits (EAE), where the frequency of feeding, rather 
than the dose of antigen was the most important factor in determining the efficacy of 
the tolerising regime (131,132). In view of the impact this phenomenon could have on 
designing therapeutic regimes, it would be important to compare directly the amounts 
of antigen which gain access to the serum and lymphoid tissues of naive and primed 
mice fed different doses of protein.
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Further reasons underlying the less efficient oral tolerance in primed mice may 
be because primed mice may simply have more antigen-specific T cells to tolerise, or 
because systemically primed T cells are inherently more resistant to subsequent 
tolerance induction. Alternatively, the less profound tolerance may reflect the fact that in 
primed animals, only a few naive T cells remain to be tolerised and these may have a
I
relatively low affinity for antigen. Some of these issues were addressed later in my
. ' project.
3
9.3 Reasons for Relative Resistance of Oral Tolerance in Primed Mice
To investigate some of these reasons, I first explored the effects of persisting 
antigen after initial priming and examined the inherent susceptibility of Ag-specific 
memory T cells to tolerance induction.
I first examined whether my original protocol of systemic priming and 
tolerance induction was ineffective because I fed antigen at a time when one would
3'-'I''
assume that the systemic response was in its most active phase of development, with
'3
rapid clonal expansion of T and B cells, formation of germinal centres and migration of 
activated lymphocytes through the lymphoid tissues and to effector sites. Indeed, using 
the adoptive transfer system in which transgenic CD4"  ^ T cells aie transferred into 
normal syngeneic recipients and tracked by flow cytometry using the anti-clonotypic 
mAb (143), it has been shown that the peak of clonal expansion of T cells is around 5 
days after immunisation (225). Thus I hypothesised that the immune system might be 
too dynamic to be modified by tolerogenic antigen, or that the relevant T cells were 
sequestered in microenvironments that were inaccessible to fed antigen.
To address this possibility I fed antigen six weeks after systemic immunisation, 
at which time clonal expansion would have ceased and I considered that the primary 
systemic immune response would have stabilised fully. However, this did not extend 
the scope or degree of oral tolerance. Indeed, only IFNy production was suppressed at 
all in OVA fed mice, while OVA-specific proliferation and IL5 production were 
actually enhanced by feeding antigen. These results are consistent with previous studies
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showing that it is increasingly difficult to induce oral tolerance as time elapses after 
systemic priming (124,125), suggesting that the immune system of the fully primed
Î:
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animal is no longer susceptible to signals which are normally tolerogenic. One 
explanation I considered for this was that the priming inoculation of OVA in CFA
acted as a depot for antigen release in the context of continued inflammation induced by■
the adjuvant. In this way, there may be chronic upregulation of costimulatoiy 
molecules on antigen presenting cells so that antigen emenating from the gut will be 
presented in the periphery of a primed animal in an immunogenic, rather than a 
tolerogenic manner.
To address the depot effect of adjuvant on the induction of tolerance I primed 
mice with OVA in LPS, an immunomodulator which is only retained in significant 
quantities at the site of sc injection for a short time, with only 28% of the amount 
injected being found at the sc injection site 7 days after the injection of LPS (233). In 
contrast, OVA/CFA persists at the site of sc injection 6 months after the time of 
injection. Nevertheless, as I found when mice were primed with OVA/CFA, it was 
easier to induce tolerance by feeding OVA soon after immunisation with OVA/LPS, 
with more profound suppression 2 days, rather than 7 days after priming. In addition 
the pattern of tolerance was the same irrespective of the adjuvant used to prime 
systemically, with no tolerance of antibody responses in either case. There was also no 
tolerance when OVA/LPS primed mice were fed OVA 6 weeks after immunisation, 
suggesting that the depot effects of CFA did not influence the limited scope of oral 
tolerance in primed animals. Although these findings probably eliminate a possible role 
of adjuvant induced chronic inflammation in producing resistance to tolerance soon 
after systemic priming, I cannot exclude the possibility that persistence of antigen itself 
may be important in this respect. Staining sections of the draining lymph node or site 
of injection with monoclonal antibodies to peptide loaded MHC molecules would allow 
investigation of this possible persistence of antigen.
A further possibility is that the presence of memory cells was the cause of lack 
of tolerance at six weeks after priming with OVA/LPS. Memory cells are reputedly
1
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difficult to tolerise and to date no-one has shown that it is possible to tolerise an 
established immune response. The reason why memory cells might be more difficult 
to tolerise is probably because they are much more readily activated than naive T cells 
due to their expression of increased levels of adhesion molecules which allow them to 
interact effectively with an APC bearing much lower levels of antigen-MHC 
complexes. Memory T cells are also less dependent on certain costimulatory signals 
provided by APCs, meaning that presentation of fed antigen by APC lacking
costimulatory molecules may induce activation rather than the tolerance found with 
naive T cells (234-238).
To investigate further how the expansion and activation of antigen-specific T 
cells influenced the induction of oral tolerance in primed mice, I exploited a recently 
described adoptive transfer system (143) in which transgenic CD4'*' T cells are 
transfeiTed into normal syngeneic recipients. The first of these systems to be described 
was that using DO 11.10 transgenic T cells specific for the OVA323-339
immunodominant peptide and I-A^ which are recognised by KJl-26 antibody (143, 
180, 225). This model has now been widely used to study peripheral immune 
responses and also more recently oral tolerance in naive mice (114,179). The 
advantages of this system are the availability of the clonotypic antibody to track 
antigen-specific T cells directly and analyse their functions by intracellular cytokine 
production and apoptosis. In my experiments I transfeiTed naive OVA-TCR transgenic 
(Tg) cells into naive mice and 2 days later immunised sc with OVA/CFA. Then I fed 
antigen at various time-points after immunisation and followed the number and 
function of the transgenic T cells.
In the first experiments, I found that feeding soluble OVA after priming led to a 
small but significant reduction in the proportion and absolute numbers of transgenic T 
cells in the draining lymph nodes compared with saline fed controls. However, this 
alteration in the kinetics of T cell expansion only occuned if feeding was delayed until 
10 days after immunisation. This effect did not simply appear to be due to re-exposure 
of primed Ag-specific T cells to antigen, as there was no equivalent effect of feeding
1 9 0
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investigate why this might be the case, I fed a higher dose of OVA, as I thought the
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OVA in an immunogenic manner with CT. The inhibited expansion of T cells when 
antigen was fed 10 days after priming was accompanied by suppressed proliferative 
responses to OVA in vitro. Again these responses were not inhibited when antigen was
fed earlier after priming. These results contrasted with my earlier findings in normal (
mice, where tolerance could be induced early, but not late after priming. To try and
higher proportion of Ag-specific T cells found in adoptive transfer recipients compared 
with naive mice might complicate the consequences of feeding antigen. This approach 
confirmed that it was possible to induce tolerance late after priming, although the scope 
of this tolerance was somewhat variable, in that early after feeding antigen, proliferation 
was significantly reduced compared with controls whereas cytokine production was 
normal. In this experiment, feeding a high dose of antigen earlier (5 days) after priming 
also produced some evidence of tolerance, as shown by significantly decreased 
proliferation 7 days after feeding. However, T cell expansion and cytokine production 
were normal under these conditions. Feeding high doses of OVA in an immunogenic 
fonn with CT also had variable effects, as the transgenic T cells did not proliferate well 
compared with the controls when given this secondary immunogenic challenge 10 days 
after systemic priming. However, feeding a high dose of antigen with CT 5 days after 
priming adoptively transferred mice resulted in significantly increased proliferation 7 
days after feeding. It is surprising that OVA/CT did not always stimulate expansion of 
transgenic T cells and cytokine production as one would expect from a secondary 
response. This refractoiy state of antigen-experienced T cells has been reported in other 
systems and could reflect differences in TCR mediated signalling which render them 
unresponsive to antigen for a period of time after initial exposure (239).
It therefore remains unclear why I obtained different patterns of tolerance 
induction in intact mice compared with adoptively transfened primed mice, raising the 
question of the physiological relevance of the transfer model. It could be that transgenic 
T cells behave differently from normal T cells as they all have a highly specific TCR
.:-4
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for a single immunodominant epitope and are in a microenvironment surrounded by
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many sinndlar cells. This may alter the amount and nature of expansion T cells undergo 
under these conditions. To clarify these discrepancies it would be necessary to look 
more directly at the functions of individual transgenic T cells e.g. by using intracellulai' 
cytokine staining.
I next used the adoptive transfer model to examine the susceptibility of 
"memory" T cells themselves to tolerance induction. These "memory" cells were 
defined as having been previously exposed to antigen in adjuvant. In this experiment, I 
did find evidence that OVA-specific "memory" cells could be tolerised by feeding 
antigen, as there was a reduction in the Ag-specific proliferative response 4 days after 
feeding. However there was no reduction in the percentage or numbers of Tg cells in 
the lymph nodes after feeding. As the naive control T cell transfer that was fed OVA 
did reveal some evidence of oral tolerance in terms of Ag-specific proliferation 
responses, this suggests that it is fair to interpret from this experiment that memory 
cells are not inherently difficult to tolerise by feeding antigen. I conclude that their 
apparent resistance in the intact animal is more likely due to persistence of antigen and 
thus their Ag-specific T cells being exposed to antigen in the context of costimulation. 
Thus oral tolerance may only be induced effectively when memory cells are not in an 
environment where antigen is presented with costimulation. Interestingly, my results 
from mice transfened with "memory" cells and immunised with the immunogenic 
challenge of OVA/LPS showed that these cells could only respond poorly to antigen in 
vitro probably because this is the third occasion they have been presented with antigen 
further highlighting the refractory state of these cells to restimulation. Finally, one 
feature of these transfer experiments was tlrat very few "memory" T cells were found 
after adoptive cell transfer into normal recipients fed saline. This could reflect the 
absence of antigen under these conditions, as it is thought that persistence of antigen is 
required for antigen-specific memory cells to survive (237).
Together my findings show that oral tolerance is defective in primed mice 
unless used early after priming. This is not influenced by the stage of the developing 
systemic immune response but by factors present in the microenvironment of the
1 9 2
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primed mouse such as the persistence of antigen or presence of costimulation. These 
findings have implications for the use of oral tolerance in the therapy for autoimmune
at the very early stages of disease.
diseases as they suggest that oral tolerance would probably only be effective if applied s
9.4 Longevity of Oral Tolerance in Primed Mice
A further practical requirement of oral tolerance as a therapy is that the antigen 
specific suppressive effects will need to be long lasting. Previous studies in naive mice 
found that several parameters of the systemic immune responses remained tolerant for 
up to 17 months after feeding antigen (178) and so I investigated how long tolerance 
persisted after a single feed of 25mg OVA given 7 days after priming.
The results presented in chapter 4 indicated that the oral tolerance induced when 
antigen is fed after immunisation is not as long lasting as that reported in naive mice. In 
vivo tolerance was only found early after feeding, when antigen specific DTH 
responses were suppressed compared with controls. DTH responses were normal at 
later time points and antibody responses were not tolerised at any time after feeding, 
confirming my initial findings in Chapter 3. Some aspects of the in vitro response 
showed longer lasting tolerance however. Thus IFNy production remained tolerant in 
OVA fed mice for 12 months after feeding, although the interpretation of these 
findings is complicated by the fact this function was not inhibited at the earliest time 
after feeding in contrast to my other experiments. The reason for this discrepancy is 
unknown and time did not permit me to repeat the experiment. Similarly, the
I
experiments performed in chapter 4 indicated that IL5 production was primed early 
after feeding, whereas it had been unaffected or reduced in my first experiments. This 
underlines the possible resistance of Th 2 responses to feeding antigen, but it should be
noted that IL5 production was then tolerised at 6 months after feeding before returning 
to normal at 12 months. OVA-specific proliferation was found to be tolerised at the 
first time point but then returned to control levels by the 6 month time point.
'
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Surprisingly, the proliferative response was enhanced in the group fed OVA at the 12 
month time point.
Overall, these results suggest that only some aspects of the established immune 
response can be tolerised for any length of time by a single feed of antigen. It seems 
that as in other forms of oral tolerance (90-92), IFNy production is paiticularly 
sensitive to feeding in primed mice, although my results suggets that other aspects such 
as IL5 might also be tolerised at different times. Thus oral tolerance is a dynamic 
phenomenon, but there is suiprisingly little correlation between those aspects which can 
be tolerised at different times. Although this is consistent with previous results in the 
lab using naive mice (178), it emphasises the unpredictability of using oral tolerance as 
a blanket therapy strategy particularly in primed animals. Further, the fact that oral 
tolerance in primed mice was not long lasting suggests that the mechanisms of 
tolerance in primed mice are short lived. This could reflect the replacement of 
anergised/deleted T cells by responsive naive T cells exiting the thymus, an idea which 
could be tested by thymectomising mice after feeding antigen and investigating if the 
mice remain tolerant. Alternatively, it could reflect the recovery of anergic cells or their 
escape from active suppression to become fully responsive T cells. To address whether 
functionally impaired CD4+ T cells persist in vivo following the induction of oral 
tolerance, a small population of CD4+ OVA-specific TCR transgenic T cells could be 
tracked following the induction of oral tolerance by soluble OVA. Indeed this has been 
done following the induction of peripheral tolerance iv (180). Here they found that the 
unresponsive state was not associated with immune deviation or suppression. Instead, 
they found that the population of antigen-specific T cells were initially impaired in their 
ability to proliferate and produce cytokines in vivo and survived for several months, 
after which they recovered from their unresponsive state.
A possible technical issue which could complicate the interpretation of my 
experiments could be that I had to give the mice a secondary boost/immunisation of 
OVA/CFA in order to obtain a measurable response in the saline fed group at the later 
times. Thus, it may be that any mechanism of tolerance induced by the feed of antigen
1 9 4
.could not overcome this secondary immunisation with OVA/CFA. Although tolerance 
is not usually easy to break with repeated immunisations of this kind (123) in repeating
this experiment, it might be better to challenge with a less immunogenic protocol such 
as soluble OVA.
This experiment showed that oral tolerance induced in primed mice is not long 
lasting and this has implications for its use in clinical therapy in that it may not be a 
stable long lasting therapy. Repeated administration of oral antigen may therefore be 
required to induce long term therapeutic effects.
.M:
9.5 Role of IL4 and IL12 in Oral Tolerance in Primed Mice
The experiments in chapters 3 and 4 showed that feeding antigen after systemic 
priming results in in vivo and in vitro tolerance of several aspects of the systemic 
immune response. In these experiments it was impossible to tolerise antibody 
responses and in some cases, IL5 production was more difficult to tolerise than IFNy.
This contrasts with the findings in naive mice from our laboratory (57) and could 
suggest that Ty2 responses are unusually resistant to oral tolerance induction in primed
mice.
A number of mechanisms have been implicated in oral tolerance in naive 
animals including clonal anergy, clonal deletion or active suppression. Of particular 
note, cross regulation of T y l cells by activated Tp[2 cells is often believed to be
."V
responsible for models of tolerance in which there is a dichotomy of effects on 
humoral
and CMI responses (169,240). It is interesting to note here that in naive mice, the 
conditions for generating Th 2 lymphocyte tolerance may be different from those 
required to generate tolerance of Th I lymphocytes. These include extended continuous
exposure to high doses of antigen, rather than the single or intermittent feeding 
regimens which are usually sufficient to induce tolerance in Th I lymphocytes. Some 
workers have reported that Th 2 dependent responses may also be relatively preserved
4!
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in orally tolerised naive mice and have suggested that IL4 dependent Th 2 cells may act
as active suppressor cells under their conditions (77,91,92).
My results do not support the idea that IL4 dependent Th 2 cells may act as
active suppressor cells in mice tolerised by feeding after immunisation, as there was no 
preferential increase in the production of Th 2 cytokines in my mice with selective
tolerance of CMI responses. However as the tolerance of IL-5 production was 
occassionally less dramatic, I decided to investigate formally whether Ty2 cells were
necessaiy for oral tolerance in primed mice by examining the effects of feeding OVA 
to mice which had been immunised with OVA/CFA. The results presented in 
chapter 5 confirmed previous findings from the laboratory that feeding OVA to naive 
IL4“/" mice results in oral tolerance. I then extended these studies by showing that 
primed IL4"^“ mice fed 2-200mg OVA 7 days after immunisation developed a pattern 
of oral tolerance similar to that found in normal animals, with suppression of DTH in 
vivo and antigen-specific proliferation in vitro, as well as some suppression of IFNy 
and IL5 production in vitro, but no effects on serum antibodies. As in naive mice (57), 
these findings argue against a role for regulatory Th2 cells in oral tolerance in primed
mice. I propose that my results are more consistent with the hypothesis that the 
predominant mechanism of T cell tolerance after feeding high doses of antigen to 
primed mice is clonal anergy/deletion or an alternative active suppressor mechanism.
That anergy may be the critical mechanism for oral tolerance in primed mice is 
consistent with previous findings that this model of tolerance can not be prevented by 
2'-deoxyguanosine, an agent which inhibits the induction of oral tolerance in naive mice 
and which is believed to act by depleting regulatory T cells (125). The presence of 
anergy could be investigated further by adding IL2 to cultures of orally tolerised T cells 
to see if they regain their ability to proliferate in response to antigen in vitro.
One suppressor mechanism which I attempted to investigate was TGFp. As 
mentioned above, release of TGpp by a discrete subset of T cells has been implicated 
as a mechanism of oral tolerance in naive animals. This is proposed to operate 
primarily when oral tolerance has been induced using multiple low doses of antigen
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(190,200,205) and it has been suggested that TGpp and IFNy play opposing roles in
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Ithe regulation of mucosal immune responses (214,215). The idea that TGFp may play 
a role in oral tolerance is supported by the fact that IFNy-dependent gut inflammation 
caused by TNBS or by transfer of CD45RB^^CD4+ T cells to scid mice can be 
prevented by TGFp-secreting T cells (171,172). Further, anti-fL12 antibody enhances 
both TGFp production and high dose oral tolerance in OVA-specific TCR transgenic 
mice (214,215). Although the presence of bystander suppression and other
■mechanisms of active regulation have not yet been examined directly in oral tolerance 
in primed mice, it has been reported that TGF-p production is not enhanced in mice 
tolerised by feeding myelin basic protein after priming (131).
I decided to investigate if I could exploit this proposed regulatory axis to 
improve oral tolerance in primed mice, by feeding antigen to mice lacking IL12 (IL12“
/"). This has not been examined previously, but as these mice have deficient production 
of IFNy, I predicted this might allow the development of enhanced TGFP responses 
and so increase susceptibility to oral tolerance compared with wild type mice. I 
therefore examined oral tolerance in naive IL12"/" mice using protocols which might be 
likely to involve TGFP-dependent mechanisms, such as feeding 5x1 mg OVA starting 
10 days before immunisation. I also used my standard protocol of feeding 25mg OVA 
once 7 days after immunisation.
Certain aspects of tolerance were enhanced in IL12"^~ mice, namely IgGl 
antibody levels. However, other components of tolerance were normal or reduced, 
namely OVA-specific DTH levels, and no clear overall pattern emerged. Therefore, it 
is probably tme to conclude that the absence of IL12 has no overall effect on the 
induction of tolerance induced either before or after immunisation. In particular, the 
absence of H_,12 does not seem to reproducibly enhance tolerance in primed animals, 
although these experiments need to be repeated. It would now be useful to measure 
TGFp production directly in such animals. To examine directly the role of TGFp in 
oral tolerance in primed mice it would also be useful to deplete TGFp in vivo with 
monoclonal antibodies or to use TGFP"/" mice. Recently it has been shown using
i'?
TGpp"/" mice that active suppression mediated by TGFp is not the main mechanism 
of oral tolerance in naive mice, although there did appeal* to be some contribution from 
this cytokine (217). Taking the results of this report and my experiment in IL 12"/“ mice 
together, it seems unlikely that the main mechanism of oral tolerance in naive or 
primed mice is active suppression via TGFp.
Other possible regulatory mediators could be tested for their role in oral 
tolerance in primed animals. For example, ILIO"/" mice could be used to further 
investigate the role of Th 2 cells in oral tolerance in primed mice as these cytokines are 
also released by Th 2 cells but are not dependent on them. The role of ILIO is 
particularly important as it is known to suppress Th I cells (241) by acting on 
macrophages by blocking macrophage IL12 synthesis. This is because ÏL12 secretion 
by macrophages can activate natural killer (NK) cells to produce IFNy and naive CD4 
T cells activated in the presence of IL12 and IFNy are committed to differentiate into 
Th I ceils. Thus if ELIO production is enhanced as a result of feeding antigen then this 
may suppress the Th I cells that are causing the pathology in autoimmune diseases. 
Further, ELIO is a growth factor for a population of regulatoi*y T cells in the gut that 
release TGFp (171,172).
If it is confirmed that active suppression is not involved in oral tolerance in 
primed mice, my findings would suggest that it may be difficult to induce "bystander 
suppression" in primed mice. This phenomenon occurs when an orally tolerised animal 
is challenged both with the original antigen and an unrelated antigen and it is believed to 
be mediated by antigen-non-specific cytokines, such as TGF-P, released by regulatory 
T cells (173,174). Bystander suppression is therefore the basis for most therapeutic 
uses of oral tolerance, which employ antigens that are not normally the original antigen 
inducing the immunopathology. My results indicate that there could be a problem in 
inducing "bystander suppression" by oral tolerance to treat established disease.
i
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9.6 Attempts to Enhance Oral Tolerance in Primed Mice with Flt3L
As the oral tolerance in primed mice was not as profound or wide ranging as 
that found when equivalent amounts of antigen are fed to naive mice, I was interested 
in finding an alternative strategy for enhancing tolerance in primed animals.
The haemopoietic growth factor FltSligand (FLT3L) increases the numbers of 
dendritic cells (DCs) when it is given in vivo and recent work has shown that 
administration of FltSL to mice enhances the induction of oral tolerance in naive mice 
(114). This affected all aspects of the immune response and allowed normally non- 
tolerogenic doses of OVA to induce significant tolerance. The rationale for this appears 
to be that Flt3L expands the numbers of resting dendritic cells in the gut which then 
present fed antigen without costimulation to T cells, resulting in more profound 
tolerance. Thus, I decided to test the idea that expansion of DCs by FltSL might also 
extend the scope of oral tolerance in primed mice.
My results showed that expanding DC with FltSL did not interfere with the 
induction of oral tolerance in primed mice and enhanced the induction of tolerance in 
some instances, as well as allowing tolerance of some responses not normally 
susceptible to tolerance, such as antibody production. However, the effects of FltSL 
were quite variable and FltSL seemed to reveal eaiiy T cell priming after feeding OVA, 
perhaps due to the fact that FltSL was being administered around the time of systemic 
immunisation. It proved difficult to determine precisely the best time course and
'Mi
. . ;i ,protocol for examining the effects of FltSL on oral tolerance and I did not have time to 
extend these studies to obtain definitive results. This is most likely due to FltSL causing 
an increase in the kinetics of the response to the fed antigen. This is because in mice 
treated with FltSL there appeared to be an early increase in the response of PLN cells 
from mice fed OVA compared with mice fed saline. As this did not occur in saline 
treated mice it could be that FltSL was enhancing the numbers of DCs presenting fed 
antigen and so increasing the chance of T cells coming into contact with fed antigen 
compared with saline treated mice fed antigen. This would mean that T cells from mice 
treated with FltSL and fed antigen would come into contact with more DCs presenting
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antigen more quickly compared with saline treated mice fed antigen and hence showed 
greater initial responses.
Although the initial immune response of mice fed OVA and treated with FltSL 
is higher compared with saline fed controls, the outcome is slightly enhanced tolerance 
when compared with saline treated mice fed OVA. This has recently been confirmed in 
a TCR Tg adoptive ti'ansfer model (Williamson, E and Viney, JC, Personal 
Communication) and could possibly be explained by FltSL promoting greater 
activation induced cell death (AICD) in tolerised T cells. This needs to be studied 
directly, but is consistent with my earlier conclusions that direct inactivation of T cells 
may be a major mechanism of oral tolerance in primed mice. Therefore, as FltSL has 
been shown to enhance oral tolerance in mice, it could potentially be used to enhance 
the induction of oral tolerance in patients already presenting symptoms of disease.
9.7 Conclusions
In conclusion, the results presented in this thesis have confirmed and extended 
previous findings on the induction of oral tolerance by feeding antigen after priming. In 
addition, they have highlighted several differences between oral tolerance in naive and 
primed mice. These include the fact that antibody responses are not readily tolerised in 
primed mice and that higher doses of antigen have to be fed to obtain tolerance 
equivalent to that found after feeding antigen to naive mice. Although my study does 
not allow me to make firm conclusions whether similar mechanisms underly the oral 
tolerance induced by feeding antigen before or after systemic immunisation, I would 
propose that anergy and/or clonal deletion is the main mechanism of oral tolerance in 
primed mice. However this needs to be proven directly and the mechanisms remain 
unclear. There is also a need for cai'eful definition of the effects of different dose 
regimes and timing of feeding regimes, if this approach is to be used therapeutically. 
My results have implications not only for the use of oral tolerance in the treatment of 
inflammatoiy diseases, but also for understanding the regulation of immune responses
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techniques, the immunological consequences of feeding protein antigens to primed 
mice could be better understood. This would hopefully lead to tlie successful 
therapeutic use of oral tolerance to treat inflammatory diseases.
to protein antigens in vivo in that they highlight the differences in the response of a 
naive and a primed immune system to antigen given via a tolerogenic route.
A number of new techniques have been described for studying the immune 
system since the start of my studies. One new experimental system that could be used
.to understand the mechanisms of oral tolerance would be the use of antibody to peptide 
on MHC Class I or II antibodies allowing the fate of antigen to be followed directly. In 
addition, by combining this with adoptive transfer of Tg T cells or the use of peptide- 
class II MHC tetramers, it should be possible to assess where antigen is presented to 
Ag-specific T cells and their subsequent activation could be monitored in vivo. Together 
with labelling of APC, these strategies would allow the interactions between antigen, T 
cells and APCs to be tracked during the induction of oral tolerance. These studies 
would be useful as they may reveal the best specific APCs to target that would present 
antigen in a tolerogenic manner thus enhancing the tolerance induced by feeding
«'ft
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antigen. By employing these and other, new advances in immunological reseai'ch
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9.8 Prospects for Clinical Uses of Oral Tolerance
As I have noted, very little is known about the mechanisms of oral tolerance in 
primed mice and if treatment of humans is to become a therapeutic reality, it will be 
necessary to re-establish tolerance in a previously sensitized host. My studies showing 
that feeding antigen can suppress an ongoing immune response confirm that oral 
tolerance may be exploited for suppressing established immune responses in vivo. This 
confirms and extends results from experimental models of autoimmune disease. 
However, my studies have also highlighted several aspects which indicate that caution 
is necessary before clinical use can be considered routinely. Also, they may help 
explain the poor results from human trials. The main drawbacks are the limited scope
.of tolerance and that it is relatively transient. My results would suggest that feeding
I
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multiple high doses of antigen veiy soon after disease initiation will probably be 
required to induce a therapeutic level of systemic tolerance. Next, it may be necessary 
to use the exact antigen responsible for the disease, as my evidence supported a role for 
direct inactivation of T cells, rather than active suppression and therefore bystander 
effects. This has implications for the production of enough antigen to be fed in large
2 0 2
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doses which would be both difficult and expensive. It may also be necessary to explore
ways of modulating or enhancing tolerance which might allow oral tolerance to be 
reinduced in patients already presenting symptoms of disease. As described above, 
molecules such as FltSL which has been shown to enhance oral tolerance in mice could 
be employed. Cytokines such as TGFp and ILIO which are known to suppress 
haiTnful inflammatory T jjl responses may also be used to enhance the suppression
induced by feeding antigen. If these cytokines were given at the same time antigen was I
.ft;!
fed they might also allow the development of a population of antigen specific active 
suppressor cells which may provide a longer lasting therapy. Blocking antibody against 
inflammatory cytokines given while antigen was fed might also promote the 
development of antigen specific suppressor cells. Targetting the antigen to specific 
APCs that would present antigen in a tolerogenic manner would also be useful. Thus a 
combined approach may be necessary to achieve reproducible therapeutic tolerance by 
feeding antigen.
à
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